

DESCRIPTION

PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME,
MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

5

Technical Field

The present invention relates to pyrazole derivatives,
pharmaceutically acceptable salts thereof or prodrugs thereof
which are useful as medicaments, pharmaceutical compositions
10 comprising the same, pharmaceutical uses thereof and
intermediates for production thereof.

More particularly, the present invention relates to
pyrazole derivatives having an inhibitory activity in human SGLT1,
pharmaceutically acceptable salts thereof or prodrugs thereof
15 which are useful as agents for the prevention or treatment of
a disease associated with hyperglycemia such as diabetes,
impaired glucose tolerance, impaired fasting glycemia, diabetic
complications or obesity, pharmaceutical compositions
comprising the same, pharmaceutical uses thereof and
20 intermediates for production thereof.

Background Art

Diabetes is one of lifestyle-related diseases with the
background of change of eating habit and lack of exercise. Hence,
25 diet and exercise therapies are performed in patients with
diabetes. Furthermore, when its sufficient control and
continuous performance are difficult, drug treatment is
simultaneously performed. In addition, it has been confirmed

by large-scale clinical trial that it is necessary to practice a long-term control of blood sugar level strictly so as to prevent patients with diabetes from occurring and advancing diabetic complications by relieving treatment (see the following
5 References 1 and 2). Furthermore, many epidemiologic studies on impaired glucose tolerance and macroangiopathy show that impaired glucose tolerance as the boundary type is also a risk factor in macroangiopathy as well as diabetes. Thus, needs to improve postprandial hyperglycemia have been focused (see the
10 following Reference 3).

In recent years, development of various antidiabetic agents has been progressing with the background of a rapid increase of patients with diabetes. For example, α -glucosidase inhibitors, which delay carbohydrate digestion and absorption
15 at the small intestine, are used to improve postprandial hyperglycemia. It has been also reported that acarbose, one of α -glucosidase inhibitors, has an effect of preventing or delaying the incidence of diabetes by applying to patients with impaired glucose tolerance (see the following Reference 4).
20 However, since α -glucosidase inhibitors do not affect elevated glucose levels by ingesting a monosaccharide of glucose (see the following Reference 5), with recently changing compositions of sugars in meals, it has been desired to develop agents which exert a wider range of activities inhibiting carbohydrate
25 absorption.

In the meantime, it has been known that SGLT1, sodium-dependent glucose transporter 1, exists in the small

intestine which controls carbohydrate absorption. It has been also reported that insufficiency of glucose and galactose absorption arises in patients with dysfunction due to congenital abnormalities of human SGLT1 (see the following References 6-8).

5 In addition, it has been confirmed that SGLT1 is involved in glucose and galactose absorption (see the following References 9 and 10).

Furthermore, it is confirmed that mRNA and protein of SGLT1 increase and absorption of glucoses are accelerated in OLETF
10 rats and rats with streptozotocin-induced diabetic symptoms (see the following References 11 and 12). Generally in patients with diabetes, carbohydrate digestion and absorption are increased. For example, it is confirmed that mRNA and protein of SGLT1 are highly increased in the human small intestine (see the following
15 Reference 13).

Therefore, blocking a human SGLT1 activity inhibits absorption of carbohydrates such as glucose at the small intestine, subsequently can prevent increase of blood sugar level. Especially, it is considered that delaying glucose absorption
20 based on the above mentioned mechanism is effective to normalize postprandial hyperglycemia. In addition, since increase of SGLT1 in the small intestine is thought to contribute to increased carbohydrate absorption, fast development of agents, which have a potent inhibitory activity in human SGLT1, has been desired
25 for the prevention or treatment of diabetes.

Reference 1: The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med., 1993.9, Vol.329, No.14,

pp.977-986;

Reference 2: UK Prospective Diabetes Study Group, Lancet, 1998.9,
Vol.352, No.9131, pp.837-853;

Reference 3: Makoto, TOMINAGA, Endocrinology & Diabetology,
5 2001.11, Vol.13, No.5, pp.534-542;

Reference 4: Jean-Louis Chiasson and 5 persons, Lancet, 2002.6,
Vol.359, No.9323, pp.2072-2077;

Reference 5: Hiroyuki, ODAKA and 3 persons, Journal of Japanese
Society of Nutrition and Food Science, 1992, Vol.45, No.1,
10 pp.27-31;

Reference 6: Tadao, BABA and 1 person, Supplementary volume of
Nippon Rinsho, Ryoikibetsu Shokogun, 1998, No.19, pp.552-554;

Reference 7: Michihiro, KASAHARA and 2 persons, Saishin Igaku,
1996.1, Vol.51, No.1, pp.84-90;

15 Reference 8: Tomofusa, TSUCHIYA and 1 person, Nippon Rinsho,
1997.8, Vol.55, No.8, pp.2131-2139;

Reference 9: Yoshikatsu, KANAI, Kidney and Dialysis, 1998.12,
Vol.45, extra edition, pp.232-237;

Reference 10: E. Turk and 4 persons, Nature, 1991.3, Vol.350,
20 pp.354-356;

Reference 11: Y. Fujita and 5 persons, Diabetologia, 1998, Vol.41,
pp.1459-1466;

Reference 12: J. Dyer and 5 persons, Biochemical Society
Transactions, 1997, Vol.25, p.479S;

25 Reference 13: J. Dyer and 4 persons, American Journal of
Physiology, 2002.2, Vol.282, No.2, pp.G241-G248


Disclosure of the Invention

The present inventors have studied earnestly to find compounds having an inhibitory activity in human SGLT1. As a result, it was found that certain pyrazole derivatives represented by the following general formula (I) show an inhibitory activity in human SGLT1 at the small intestine and exert an excellent inhibitory activity in increase of blood glucose level as shown below, thereby forming the basis of the present invention.

The present invention is to provide novel pyrazole derivatives which exert an excellent inhibitory activity of blood glucose level increase by showing an inhibitory activity in human SGLT1 and inhibiting absorption of carbohydrate such as glucose at the small intestine, pharmaceutically acceptable salts thereof or prodrugs thereof, and to provide pharmaceutical compositions comprising the same, pharmaceutical uses thereof and intermediates for production thereof.

This is, the present invention relates to


[1] a pyrazole derivative represented by the general formula:




wherein

R^1 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group, an aryl group which may have the same or different 1 to 3 substituents
 5 selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group, or an aryl(C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C_{1-6} alkyl group and
 10 a C_{1-6} alkoxy group on the ring;

one of Q and T represents a group represented by the formula:



or a group represented by the formula:



15 while the other represents a C_{1-6} alkyl group, a halo(C_{1-6} alkyl) group, a C_{1-6} alkoxy-substituted (C_{1-6} alkyl) group or a C_{3-7} cycloalkyl group;

R^2 represents a hydrogen atom, a halogen atom, a hydroxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkylthio group, a halo(C_{1-6} alkyl) group, a halo(C_{1-6} alkoxy) group, a
 20 C_{1-6} alkoxy-substituted (C_{1-6} alkoxy) group, a C_{3-7} cycloalkyl-substituted (C_{2-6} alkoxy) group or a group of the general formula:

-A-R⁸ in which A represents a single bond, an oxygen atom, a methylene group, an ethylene group, -OCH₂- or -CH₂O-; and R⁸ represents a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3
 5 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₂₋₆ alkenyloxy group, a halo(C₁₋₆ alkyl) group, a hydroxy(C₁₋₆ alkyl) group, a carboxy group, a C₂₋₇ alkoxycarbonyl group, a cyano group and a nitro group, or a
 10 heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group;

X represents a single bond, an oxygen atom or a sulfur atom;

Y represents a single bond, a C₁₋₆ alkylene group or a
 15 C₂₋₆ alkenylene group with the proviso that X is a single bond when Y is a single bond;

Z represents a carbonyl group or a sulfonyl group;

R⁴ and R⁵ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same
 20 or different 1 to 3 groups selected from the following substituent group (i), or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group;

25 R³, R⁶ and R⁷ are the same or different, and each represents a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

substituent group (i) consists of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group, a group of the general formula: -CON(R⁹)R¹⁰ in which R⁹ and R¹⁰ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, and a C₁₋₄ aromatic cyclic amino group which may have a C₁₋₆ alkyl group as a substituent,

or a pharmaceutically acceptable salt thereof;

[2] a pyrazole derivative described in the above [1] wherein Y represents a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group; one of R⁴ and R⁵ represents a C₁₋₆ alkyl group which has
 5 the same or different 1 to 3 groups selected from the following substituent group (i), the other represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (i); and substituent group (i) consists of a hydroxy group, an amino group,
 10 a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group, a group of the general formula:
 15 -CON(R⁹)R¹⁰ in which R⁹ and R¹⁰ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆
 20 alkyl)]amino group, an ureido group, a mono or di(C₁₋₆ alkyl)-ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of
 25 a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected

from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group, a
 5 C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, and a C₁₋₄ aromatic cyclic amino group which may have a C₁₋₆ alkyl group as a substituent, or a pharmaceutically acceptable salt thereof;

10 [3] a pyrazole derivative described in the above [2] wherein one of R⁴ and R⁵ represents a C₁₋₆ alkyl group which has a group selected from the following substituent group (iA), the other represents a hydrogen atom; and substituent group (iA) is a group of the general formula: -CON(R^{9A})R^{10A} in which R^{9A}
 15 and R^{10A} bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, or a pharmaceutically acceptable salt thereof;


20 [4] a pyrazole derivative described in any one of the above [1]-[3] wherein X represents a single bond; and Y represents a trimethylene group or a 1-propenylene group, or a pharmaceutically acceptable salt thereof;

[5] a pyrazole derivative described in any one of the above
 25 [1]-[3] wherein X represents an oxygen atom; and Y represents an ethylene group or a trimethylene group, or a pharmaceutically acceptable salt thereof;

[6] a pyrazole derivative described in the above [1] wherein X represents a single bond; Y represents a single bond; one of R^4 and R^5 represents a C_{1-6} alkyl group which has the same or different 1 to 3 groups selected from the following substituent group (iB), the other represents a hydrogen atom or a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (iB); and substituent group (iB) consists of an ureido group, a sulfamide group, a mono or di(C_{1-6} alkyl)ureido group, a mono or di(C_{1-6} alkyl)sulfamide group, a C_{1-6} alkylsulfonylamino group, a group of the general formula: $-\text{CON}(\text{R}^{9\text{B}})\text{R}^{10\text{B}}$ in which one of $\text{R}^{9\text{B}}$ and $\text{R}^{10\text{B}}$ represents a C_{1-6} alkyl group which has the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C_{1-6} alkyl)amino group, a mono or di[hydroxy(C_{1-6} alkyl)]amino group, an ureido group, a mono or di(C_{1-6} alkyl)ureido group, a C_{2-7} acylamino group, a C_{1-6} alkylsulfonylamino group and a carbamoyl group, the other represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C_{1-6} alkyl)amino group, a mono or di[hydroxy(C_{1-6} alkyl)]amino group, an ureido group, a mono or di(C_{1-6} alkyl)-ureido group, a C_{2-7} acylamino group, a C_{1-6} alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C_{2-6} cyclic amino group which may have a substituent selected from the group consisting of a C_{1-6} alkyl group and a hydroxy(C_{1-6} alkyl) group, a C_{3-7}


cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a
 5 heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, and a C₁₋₄ aromatic cyclic amino group which may
 10 have a C₁₋₆ alkyl group as a substituent, or a pharmaceutically acceptable salt thereof;

[7] a pyrazole derivative described in any one of the above [1]-[6] wherein R¹ represents a hydrogen atom or a hydroxy(C₂₋₆ alkyl) group; T represents a group represented by the formula:



15


or a group represented by the formula:



Q represents a C₁₋₆ alkyl group or a halo(C₁₋₆ alkyl) group; and R³, R⁶ and R⁷ represent a hydrogen atom, or a pharmaceutically
 20 acceptable salt thereof;


[8] a pyrazole derivative described in any one of the above [1]-[6] wherein one of Q and T represents a group represented

by the formula:



the other represents a C₁₋₆ alkyl group, a halo(C₁₋₆ alkyl) group,
a C₁₋₆ alkoxy-substituted (C₁₋₆ alkyl) group or a C₃₋₇ cycloalkyl
5 group, or a pharmaceutically acceptable salt thereof;

[9] a pyrazole derivative described in the above [7] or
[8] wherein T represents a group represented by the formula:




or a pharmaceutically acceptable salt thereof;


10 [10] a pyrazole derivative described in the above [7] or
[9] wherein Q represents an isopropyl group, or a
pharmaceutically acceptable salt thereof;

[11] a prodrug of a pyrazole derivative described in any
one of the above [1]-[10] or a pharmaceutically acceptable salt
15 thereof;

[12] a prodrug described in the above [11] wherein T
represents a group represented by the formula:



or a group represented by the formula:



in which the hydroxy group at the 4-position is substituted by a glucopyranosyl group or a galactopyranosyl group, or the hydroxy group at the 6-position is substituted by a

5 glucopyranosyl group, a galactopyranosyl group, a C₂₋₇ acyl group, a C₁₋₆ alkoxy-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxycarbonyl group, an aryl(C₂₋₇ alkoxycarbonyl) group or a C₁₋₆ alkoxy-substituted (C₂₋₇ alkoxycarbonyl) group;

10 [13] a pyrazole derivative described in the above [1] which is a compound selected from the following group:

4-[(4-{3-[1-carbamoyl-1-(methyl)ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole;

15 3-(β-D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole;

3-(β-D-galactopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-[2-(dimethylamino)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-

20 propyl]phenyl)methyl]-1H-pyrazole;

4-[(4-{3-[1-(2-aminoethylcarbamoyl)-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-3-(β-D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole;

3-(β-D-galactopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-

25 [(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

propyl)phenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-
piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-
propyl}-2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;

5 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(4-
methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propyl)phenyl)methyl]-1*H*-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(4-
isopropylpiperazin-1-yl)carbonyl]-1-(methyl)ethyl-

10 carbamoyl]propyl)phenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{3-[(*S*)-2-hydroxy-1-
(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-5-isopropyl-
1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{(1*E*)-3-[(*S*)-2-hydroxy-1-
15 (methyl)ethylcarbamoyl]prop-1-enyl)phenyl)methyl]-5-
isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-
methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
ethoxy)-2-methylphenyl)methyl]-1*H*-pyrazole;

20 3-(β -D-glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di-
(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-
isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{2-[1-{[4-(2-hydroxyethyl)-
piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]ethoxy}-

25 2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

- ethoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;
- 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propyl)-2-methylphenyl)methyl}-1*H*-pyrazole;
- 5 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;
- 3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-
piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]propoxy)-
10 2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;
- 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-
[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethyl-
carbamoyl]propoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;
- 3-(β -D-galactopyranosyloxy)-1-(3-hydroxypropyl)-5-
15 isopropyl-4-{{4-(3-{1-[(piperazin-1-yl)carbonyl]-1-
(methyl)ethylcarbamoyl]propyl)phenyl)methyl}-1*H*-pyrazole;
- 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;
- 20 4-{{2-fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-
ethylcarbamoyl]propyl)phenyl)methyl}-3-(β -D-galacto-
pyranosyloxy)-5-isopropyl-1*H*-pyrazole;
- 4-{{2-chloro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-
ethylcarbamoyl]propyl)phenyl)methyl}-3-(β -D-glucopyranosyl-
25 oxy)-5-isopropyl-1*H*-pyrazole, and
- pharmaceutically acceptable salts thereof;

[14] a pyrazole derivative described in the above [13]

which is a compound selected from the following group:

3-(β -D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole;

5 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-1H-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-

10 propyl]-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-1H-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy)-2-methylphenyl)methyl]-1H-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{2-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole;

20 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy)-2-methylphenyl)methyl]-1H-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

25 propyl)-2-methylphenyl)methyl]-1H-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

propoxy)-2-methylphenyl)methyl}-1H-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-([4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propoxy)-2-methylphenyl)methyl}-1H-pyrazole;

5 4-([2-fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-
ethylcarbamoyl}propyl)phenyl)methyl)-3-(β -D-galacto-
pyranosyloxy)-5-isopropyl-1H-pyrazole, and
pharmaceutically acceptable salts thereof;

[15] a pharmaceutical composition comprising as an active
10 ingredient a pyrazole derivative described in any one of the
above [1]-[14], a pharmaceutically acceptable salt thereof or
a prodrug thereof;

[16] a human SGLT1 inhibitor comprising as an active
ingredient a pyrazole derivative described in any one of the
15 above [1]-[14], a pharmaceutically acceptable salt thereof or
a prodrug thereof;

[17] an agent for inhibiting postprandial hyperglycemia
comprising as an active ingredient a pyrazole derivative
described in any one of the above [1]-[14], a pharmaceutically
20 acceptable salt thereof or a prodrug thereof;

[18] an agent for the prevention or treatment of a disease
associated with hyperglycemia, which comprises as an active
ingredient a pyrazole derivative described in any one of the
above [1]-[14], a pharmaceutically acceptable salt thereof or
25 a prodrug thereof;

[19] an agent for the prevention or treatment described
in the above [18] wherein the disease associated with

hyperglycemia is a disease selected from the group consisting of diabetes, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hyper-cholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout;

[20] an agent for the inhibition of advancing impaired glucose tolerance or impaired fasting glycemia into diabetes in a subject, which comprises as an active ingredient a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof;

[21] an agent for the prevention or treatment of a disease associated with the increase of blood galactose level, which comprises as an active ingredient a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof;

[22] an agent for the prevention or treatment described in the above [21] wherein the disease associated with the increase of blood galactose level is galactosemia;

[23] a pharmaceutical composition described in the above [15] wherein the dosage form is sustained release formulation;

[24] an agent described in any one of the above [16]-[22] wherein the dosage form is sustained release formulation;

[25] a method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt

thereof or a prodrug thereof;

[26] a method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject, which comprises administering an effective amount of a pyrazole derivative
5 described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof;

[27] a use of a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a pharmaceutical
10 composition for the prevention or treatment of a disease associated with hyperglycemia;

[28] a use of a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a pharmaceutical
15 composition for the inhibition of advancing impaired glucose tolerance into diabetes in a subject;

[29] a pharmaceutical combination which comprises (A) a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof,
20 and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl
25 peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a

fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral

endopeptidase inhibitor, an angiotensin II receptor antagonist,
 an endothelin-converting enzyme inhibitor, an endothelin
 receptor antagonist, a diuretic agent, a calcium antagonist,
 a vasodilating antihypertensive agent, a sympathetic blocking
 5 agent, a centrally acting antihypertensive agent, an
 α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid
 synthesis inhibitor, a uricosuric agent and a urinary
 alkalinizer;

[30] a method for the prevention or treatment of a disease
 10 associated with hyperglycemia, which comprises administering
 an effective amount of (A) a pyrazole derivative described in
 any one of the above [1]-[14], a pharmaceutically acceptable
 salt thereof or a prodrug thereof, and (B) at least one member
 selected from the group consisting of an insulin sensitivity
 15 enhancer, a glucose absorption inhibitor, a biguanide, an insulin
 secretion enhancer, a SGLT2 inhibitor, an insulin or insulin
 analogue, a glucagon receptor antagonist, an insulin receptor
 kinase stimulant, a tripeptidyl peptidase II inhibitor, a
 dipeptidyl peptidase IV inhibitor, a protein tyrosine
 20 phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor,
 a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase
 inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic
 gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase
 kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like
 25 peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin,
 an amylin analogue, an amylin agonist, an aldose reductase
 inhibitor, an advanced glycation endproducts formation

inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor,

5 insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl

10 coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a

15 lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an

20 appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent,

25 a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a

uricosuric agent and a urinary alkalinizer;

[31] a method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject, which comprises administering an effective amount of (A) a pyrazole derivative
5 described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof, and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor,
10 an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-
15 bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose
20 reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-
25 dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor,

a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, 5 an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a 10 squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral 15 endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an 20 α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer;

[32] a use of (A) a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt 25 thereof or a prodrug thereof, and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion

enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B

5 inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3

10 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor,

15 a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin,

20 EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol

25 absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a


squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an
 5 angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking
 10 agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer, for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with
 15 hyperglycemia;

[33] a use of (A) a pyrazole derivative described in any one of the above [1]-[14], a pharmaceutically acceptable salt thereof or a prodrug thereof, and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer,
 20 a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B
 25 inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis

inhibitor, D-chiroinsitol, a glycogen synthase kinase-3
 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1
 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin
 analogue, an amylin agonist, an aldose reductase inhibitor, an
 5 advanced glycation endproducts formation inhibitor, a protein
 kinase C inhibitor, a γ -aminobutyric acid receptor antagonist,
 a sodium channel antagonist, a transcript factor NF- κ B inhibitor,
 a lipid peroxidase inhibitor, an N-acetylated- α -linked-acid-
 dipeptidase inhibitor, insulin-like growth factor-I,
 10 platelet-derived growth factor, a platelet-derived growth
 factor analogue, epidermal growth factor, nerve growth factor,
 a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin,
 EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics,
 cathartics, a hydroxymethylglutaryl coenzyme A reductase
 15 inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist,
 an acyl-coenzyme A cholesterol acyltransferase inhibitor,
 probcol, a thyroid hormone receptor agonist, a cholesterol
 absorption inhibitor, a lipase inhibitor, a microsomal
 triglyceride transfer protein inhibitor, a lipoxigenase
 20 inhibitor, a carnitine palmitoyl-transferase inhibitor, a
 squalene synthase inhibitor, a low-density lipoprotein receptor
 enhancer, a nicotinic acid derivative, a bile acid sequestrant,
 a sodium/bile acid cotransporter inhibitor, a cholesterol ester
 transfer protein inhibitor, an appetite suppressant, an
 25 angiotensin-converting enzyme inhibitor, a neutral
 endopeptidase inhibitor, an angiotensin II receptor antagonist,
 an endothelin-converting enzyme inhibitor, an endothelin

receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer,
 5 for the manufacture of a pharmaceutical composition for the inhibition of advancing impaired glucose tolerance into diabetes in a subject;

[34] a pyrazole derivative represented by the general
 10 formula:



wherein

R^{11} represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group which may have a
 15 protective group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective
 20 group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group, or an aryl(C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen

atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group on the ring;

one of Q² and T² represents a 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy group or a 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy group, while the other represents a C₁₋₆ alkyl group, a halo(C₁₋₆ alkyl) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkyl) group or a C₃₋₇ cycloalkyl group;

R¹² represents a hydrogen atom, a halogen atom, a hydroxy group which may have a protective group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a halo(C₁₋₆ alkyl) group, a halo(C₁₋₆ alkoxy) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkoxy) group, a C₃₋₇ cycloalkyl-substituted (C₂₋₆ alkoxy) group or a group of the general formula: -A-R¹⁸ in which A represents a single bond, an oxygen atom, a methylene group, an ethylene group, -OCH₂- or -CH₂O-; and R¹⁸ represents a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₂₋₆ alkenyloxy group, a halo(C₁₋₆ alkyl) group, a hydroxy(C₁₋₆ alkyl) group which may have a protective group, a carboxy group which may have a protective group, a C₂₋₇ alkoxycarbonyl group, a cyano group and a nitro group, or a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group;

X represents a single bond, an oxygen atom or a sulfur atom;

Y represents a single bond, a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group with the proviso that X is a single bond
5 when Y is a single bond;

Z represents a carbonyl group or a sulfonyl group;

R¹⁴ and R¹⁵ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent
10 group (ii), or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group which may have a protective group;

R³, R⁶ and R⁷ are the same or different, and each represents
15 a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

substituent group (ii) consists of a hydroxy group which may have a protective group, an amino group which may have a protective group, a mono or di(C₁₋₆ alkyl)amino group which may
20 have a protective group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group which may have a protective group, an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group, a group of the general formula:
25 -CON(R¹⁹)R²⁰ in which R¹⁹ and R²⁰ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from

the group consisting of a hydroxy group which may have a protective group, an amino group which may have a protective group, a mono or di(C₁₋₆ alkyl)amino group which may have a protective group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group which may have a protective group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group which may have a protective group, a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group which may have a protective group, and a C₁₋₄ aromatic cyclic amino group which may have a C₁₋₆ alkyl group as a substituent, or a salt thereof; and the like.

In the present invention, the term "C₁₋₆ alkyl group" means a straight-chained or branched alkyl group having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl

group, a *tert*-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a *tert*-pentyl group, a hexyl group or the like; the term "C₁₋₆ alkylene group" means a straight-chained or branched alkylene group having 1 to 6 carbon atoms such as

5 a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, a propylene group, a 1,1-dimethylethylene group or the like; the term "hydroxy(C₁₋₆ alkyl) group" means the above C₁₋₆ alkyl group substituted by a hydroxy group; the term "C₂₋₆ alkyl group" means a straight-chained or branched

10 alkyl group having 2 to 6 carbon atoms such as an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a *sec*-butyl group, a *tert*-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a *tert*-pentyl group, a hexyl group or the like; the term "hydroxy(C₂₋₆ alkyl) group"

15 means the above C₂₋₆ alkyl group substituted by a hydroxy group, such as a 2-hydroxyethyl group, a 3-hydroxypropyl group or the like; the term "C₁₋₆ alkoxy group" means a straight-chained or branched alkoxy group having 1 to 6 carbon atoms such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group,

20 a butoxy group, an isobutoxy group, a *sec*-butoxy group, a *tert*-butoxy group, a pentyloxy group, an isopentyloxy group, a neopentyloxy group, a *tert*-pentyloxy group, a hexyloxy group or the like; the term "C₁₋₆ alkoxy-substituted (C₁₋₆ alkyl) group" means the above C₁₋₆ alkyl group substituted by the above C₁₋₆

25 alkoxy group; the term "C₁₋₆ alkoxy-substituted (C₁₋₆ alkoxy) group" means the above C₁₋₆ alkoxy group substituted by the above C₁₋₆ alkoxy group, such as a methoxymethoxy group or the like;


the term "C₂₋₆ alkenyl group" means a straight-chained or branched alkenyl group having 2 to 6 carbon atoms such as a vinyl group, an allyl group, a 1-propenyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 2-methylallyl group or
5 the like; the term "C₂₋₆ alkenylene group" means a straight-chained or branched alkenylene group having 2 to 6 carbon atoms such as a vinylene group, a propenylene group or the like; the term "C₂₋₆ alkenyloxy group" means the above C₁₋₆ alkoxy group except for a methoxy group which has an unsaturated
10 bond, such as an allyloxy group or the like; the term "C₁₋₆ alkylthio group" means a straight-chained or branched alkylthio group having 1 to 6 carbon atoms such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, a *sec*-butylthio group,
15 a *tert*-butylthio group, a pentylthio group, an isopentylthio group, a neopentylthio group, a *tert*-pentylthio group, a hexylthio group or the like; the term "mono or di(C₁₋₆ alkyl) amino group" means an amino group mono-substituted by the above C₁₋₆ alkyl group or di-substituted by the same or different C₁₋₆ alkyl
20 groups as defined above; the term "mono or di[hydroxy(C₁₋₆ alkyl)] amino group" means an amino group mono-substituted by the above hydroxy(C₁₋₆ alkyl) group or di-substituted by the same or different hydroxy(C₁₋₆ alkyl) groups as defined above; the term "mono or di(C₁₋₆ alkyl) ureido group" means an ureido
25 group mono-substituted by the above C₁₋₆ alkyl group or di-substituted by the same or different C₁₋₆ alkyl groups as defined above; the term "mono or di(C₁₋₆ alkyl) sulfamide group"

means a sulfamide group mono-substituted by the above C₁₋₆ alkyl group or di-substituted by the same or different C₁₋₆ alkyl groups as defined above; the term "C₂₋₇ acylamino group" means an amino group substituted by a straight-chained or branched acyl group having 2 to 7 carbon atoms such as an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, a pivaloyl group, a hexanoyl group or the like; the term "C₁₋₆ alkylsulfonylamino group" means an amino group substituted by a straight-chained or branched alkylsulfonyl group having 1 to 6 carbon atoms, such as a methanesulfonyl group, an ethanesulfonyl group or the like; the term "C₃₋₇ cycloalkyl group" means a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group or a cycloheptyl group; the term "C₃₋₇ cycloalkyl-substituted (C₁₋₆ alkyl) group" means the above C₁₋₆ alkyl group substituted by the above C₃₋₇ cycloalkyl group; the term "C₃₋₇ cycloalkyl-substituted (C₂₋₆ alkoxy) group" means the above C₁₋₆ alkoxy group except for a methoxy group substituted by the above C₃₋₇ cycloalkyl group; the term "C₂₋₆ heterocycloalkyl group" means the above C₃₋₇ cycloalkyl group containing the same or different 1 or 2 hetero atoms other than the binding position selected from a nitrogen atom, an oxygen atom and a sulfur atom in the ring, which is derived from morpholine, thiomorpholine, tetrahydrofuran, tetrahydropyran, aziridine, azetidine, pyrrolidine, imidazolidine, oxazoline, piperidine, piperazine, pyrazolidine or the like; the term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom; the term "halo(C₁₋₆ alkyl) group" means the above


C₁₋₆ alkyl group substituted by the same or different 1 to 5
 halogen atoms as defined above, such as a trifluoromethyl group,
 a pentafluoroethyl group or the like; the term "halo(C₁₋₆ alkoxy)
 group" means the above C₁₋₆ alkoxy group substituted by the same
 5 or different 1 to 5 halogen atoms as defined above; the term
 "C₂₋₇ alkoxy carbonyl group" means a straight-chained or branched
 alkoxy carbonyl group having 2 to 7 carbon atoms such as a
 methoxy carbonyl group, an ethoxy carbonyl group, a propoxy-
 carbonyl group, an isopropoxy carbonyl group, a butoxy carbonyl
 10 group, an isobutyloxy carbonyl group, a sec-butoxy carbonyl group,
 a tert-butoxy carbonyl group, a pentyloxy carbonyl group, an
 isopentyloxy carbonyl group, a neopentyloxy carbonyl group, a
 tert-pentyloxy carbonyl group, a hexyloxy carbonyl group or the
 like; the term "aryl group" means mono to tricyclic aromatic
 15 hydrocarbon group such as a phenyl group, a naphthyl group, or
 the like; the term "aryl(C₁₋₆ alkyl) group" means the above C₁₋₆
 alkyl group substituted by the above aryl group; the term
 "heteroaryl group" means a 5 or 6-membered heteroaryl group
 containing the same or different 1 to 4 hetero atoms other than
 20 the binding position selected from a nitrogen atom, an oxygen
 atom and a sulfur atom in the ring, which is derived from thiazole,
 oxazole, isothiazole, isooxazole, pyridine, pyrimidine,
 pyrazine, pyridazine, pyrrole, thiophene, imidazole, pyrazole,
 oxadiazole, thiodiazole, tetrazole, furazan or the like; the
 25 term "C₂₋₆ cyclic amino group" means a 5 or 6-membered monocyclic
 amino group having 2 to 6 carbon atoms which may contain one
 hetero atom other than the nitrogen atom at the binding position

selected from a nitrogen atom, an oxygen atom and a sulfur atom in the ring, such as a morpholino group, a thiomorpholino group, a 1-aziridinyl group, a 1-azetidiny group, a 1-pyrrolidinyl group, a piperidino group, a 1-imidazolidinyl group, a 1-piperazinyl group, a pyrazolidinyl group or the like; the term "C₁₋₄ aromatic cyclic amino group" means a 5-membered aromatic monocyclic amino group having 1 to 4 carbon atoms which may contain 1 to 3 nitrogen atoms other than the nitrogen atom at the binding position, such as a 1-imidazolyl group, a 1-pyrrolyl group, a pyrazolyl group, a 1-tetrazolyl group or the like; the term "hydroxy-protective group" means a hydroxy-protective group used in general organic synthesis such as a benzyl group, a methoxymethyl group, an acetyl group, a pivaloyl group, a benzoyl group, a *tert*-butyldimethylsilyl group, a triisopropylsilyl group, an allyl group or the like; the term "amino-protective group" means an amino-protective group used in general organic synthesis such as a benzyloxycarbonyl group, a *tert*-butoxycarbonyl group, a benzyl group, a trifluoroacetyl group or the like; and the term "carboxy-protective group" means a carboxy-protective group used in general organic synthesis such as a benzyl group, a *tert*-butyldimethylsilyl group, an allyl group or the like.

In the present invention, for example, R¹ is preferably a hydrogen atom or a hydroxy(C₂₋₆ alkyl) group, and is more preferably a hydrogen atom; T is preferably a group of the formula:




or a group of the formula:




Q is preferably a C₁₋₆ alkyl group or a halo(C₁₋₆ alkyl) group,
 5 and is more preferably a C₁₋₆ alkyl group; the C₁₋₆ alkyl group
 in Q is preferably an ethyl group or an isopropyl group, and
 is more preferably an isopropyl group; X is preferably a single
 bond or an oxygen atom. Furthermore, when X is a single bond,
 Y is preferably a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group,
 10 and is more preferably a trimethylene group or a 1-propenylene
 group; and when X is an oxygen atom, Y is preferably a C₁₋₆ alkylene
 group, and is more preferably an ethylene group or a trimethylene
 group. Z is preferably a carbonyl group; R² is preferably a
 hydrogen atom, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy
 15 group, a C₁₋₆ alkoxy-substituted (C₂₋₆ alkoxy) group, a C₃₋₇
 cycloalkyl-substituted (C₂₋₆ alkoxy) group or a group of the
 general formula: -A-R⁸ in which A and R⁸ have the same meanings
 as defined above, and is more preferably a hydrogen atom, a
 chlorine atom, a fluorine atom or a methyl group; one of R⁴ and
 20 R⁵ is preferably a C₁₋₆ alkyl group which has 1 to 3 hydroxy
 groups or a group of the general formula: -CON(R⁹)R¹⁰ in which
 R⁹ and R¹⁰ are the same or different, and each represents a hydrogen

atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, 5 a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ 10 alkyl) group, while the other is preferably a hydrogen atom, and one of R⁴ and R⁵ is more preferably a C₁₋₆ alkyl group which has a group of the general formula: -CON(R^{9A})R^{10A} in which R^{9A} and R^{10A} bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent 15 selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, while the other is more preferably a hydrogen atom; and R³, R⁶ and R⁷ are preferably a hydrogen atom or a halogen atom, and all of them are more preferably a hydrogen atom.


20 As concrete compounds in the present invention, compounds described in Examples 1-116 are exemplified. Specifically, the following compounds or pharmaceutically acceptable salts thereof are preferable,




[Example 44]




[Example 48]




[Example 52]




[Example 56]




[Example 57]




[Example 59]




[Example 61]




[Example 62]




[Example 66]




[Example 73]




[Example 85]




[Example 87]




[Example 89]




[Example 99]




[Example 103]




[Example 105]




[Example 106]




[Example 107]




[Example 109]



[Example 112]



[Example 115]




[Example 116]

and 3-(β -D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole; 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}propyl)phenyl]-methyl}-1H-pyrazole; 3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl}propyl]-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole; 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}propyl)phenyl]methyl}-1H-pyrazole; 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}ethoxy)-2-methylphenyl]methyl}-1H-pyrazole; 3-(β -D-glucopyranosyloxy)-4-[(4-{2-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole; 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}ethoxy)-2-methylphenyl]methyl}-1H-pyrazole; 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

propyl)-2-methylphenyl)methyl}-1*H*-pyrazole; 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-([4-(3-{1-[(piperazin-1-yl)-carbonyl]-1-(methyl)ethylcarbamoyl}propoxy)-2-methylphenyl)methyl}-1*H*-pyrazole; 3-(β -D-galactopyranosyloxy)-
 5 5-isopropyl-4-([4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}propoxy)-2-methylphenyl)methyl}-1*H*-pyrazole; 4-([2-fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}propyl)phenyl)methyl)-3-(β -D-galactopyranosyloxy)-5-isopropyl-1*H*-pyrazole, or
 10 pharmaceutically acceptable salts thereof are more preferable.

For example, the compounds represented by the above general formula (I) of the present invention can be prepared according to the following procedure:



wherein L^1 represents a leaving group such as a halogen atom, a mesyloxy group, a tosyloxy group or the like; L^2 represents MgBr, MgCl, MgI, ZnI, ZnBr, ZnCl or a lithium atom; R represents

5 a C_{1-6} alkyl group, a halo(C_{1-6} alkyl) group, a C_{1-6} alkoxy-

substituted (C₁₋₆ alkyl) group or a C₃₋₇ cycloalkyl group; R⁰ represents a C₁₋₆ alkyl group; one of Q³ and T³ represents a hydroxy group, the other represents a C₁₋₆ alkyl group, a halo(C₁₋₆ alkyl) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkyl) group or
 5 a C₃₋₇ cycloalkyl group; and R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R¹¹, R¹², R¹⁴, R¹⁵, Q, Q², T, T², X, Y and Z have the same meanings as defined above.

Process 1-1

A compound represented by the above general formula (VI)
 10 can be prepared by condensing a benzyl derivative represented by the above general formula (IV) with a ketoacetate represented by the above general formula (V) in the presence of a base such as sodium hydride or potassium *tert*-butoxide in an inert solvent. As the inert solvent used in the reaction, for example,
 15 1,2-dimethoxyethane, tetrahydrofuran, *N,N*-dimethylformamide, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and
 20 reaction temperature.

Process 1-2

A benzylpyrazole derivative represented by the above general formula (III) can be prepared by condensing a compound represented by the above general formula (VI) with a hydrazine
 25 compound represented by the above general formula (VII) or a monohydrate thereof, or a salt thereof in the presence or absence of a base in an inert solvent, and introducing a hydrogen-

protective in usual way as occasion demands. As the inert solvent used in the condensing reaction, for example, toluene, tetrahydrofuran, chloroform, methanol, ethanol, a mixed solvent thereof and the like can be illustrated, and as the base, for example, triethylamine, *N,N*-diisopropylethylamine, pyridine, sodium methoxide, sodium ethoxide and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature. The obtained benzylpyrazole derivative represented by the above general formula (III) can be also used in the subsequent process after suitably converting into a salt thereof in usual way.

Process 1-3

15 A compound represented by the above general formula (X) can be prepared by condensing dithiocarbonate ester compound represented by the above general formula (VIII) with a ketone compound represented by the above general formula (IX) in the presence of a base such as sodium amide in an inert solvent. As the inert solvent used in the reaction, for example, toluene and the like can be illustrated. The reaction temperature is usually from -20°C to room temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature.

25 Process 1-4

A benzyloxypyrazole derivative represented by the above general formula (XI) can be prepared by condensing a compound

represented by the above general formula (X) with a hydrazine compound represented by the above general formula (VII) or a monohydrate thereof, or a salt thereof in the presence of a base such as triethylamine or *N,N*-diisopropylethylamine in an inert solvent, and introducing a hydrogen-protective in usual way as occasion demands. As the inert solvent used in the condensing reaction, for example, acetonitrile and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature.

Process 1-5

A pyrazole aldehyde derivative represented by the above general formula (XII) can be prepared by subjecting a compound represented by the above general formula (XI) to Vilsmeier reaction using phosphorus oxychloride and *N,N*-dimethylformamide in a various solvent. As the solvent used in the reaction, for example, *N,N*-dimethylformamide and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature.

Process 1-6

A compound represented by the above general formula (XIV) can be prepared by condensing a compound represented by the above general formula (XII) with a Grignard reagent, a Reformatsky reagent or a lithium reagent represented by the above general

formula (XIII) in an inert solvent. As the solvent used in the reaction, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from -78°C to room temperature, and the
5 reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature.

Process 1-7

A benzylpyrazole derivative represented by the above general formula (III) can be prepared by subjecting a compound
10 represented by the above general formula (XIV) to catalytic hydrogenation using a palladium catalyst such as palladium-carbon powder in the presence or absence of an acid such as hydrochloric acid in an inert solvent, and in a case of a compound having any sulfur atom represented by the above
15 general formula (XIV), subjecting the resulting compound to acid treatment in an aqueous solution of trifluoroacetic acid and dimethyl sulfide usually at 0°C to reflux temperature for 30 minutes to 1 day as occasion demands. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol,
20 tetrahydrofuran, ethyl acetate, acetic acid, isopropanol, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent
25 and reaction temperature. The obtained benzylpyrazole derivative represented by the above general formula (III) can be also used in the subsequent process after suitably converting

into a salt thereof in the usual way.

Process 1-8

[1] In case that one of Q^3 and T^3 is a C_{1-6} alkyl group, a C_{1-6} alkoxy-substituted (C_{1-6} alkyl) group or a C_{3-7} cycloalkyl group
5 in a benzylpyrazole derivative represented by the above general formula (III), a corresponding compound represented by the above general formula (II) of the present invention can be prepared by subjecting a corresponding benzylpyrazole derivative represented by the above general formula (III) to glycosidation
10 using acetobromo- α -D-glucose or acetobromo- α -D-galactose in the presence of a base such as silver carbonate, sodium hydride or the like in an inert solvent. As the inert solvent used in the reaction, for example, tetrahydrofuran, dimethoxyethane, *N,N*-dimethylformamide, a mixed solvent thereof and the like can
15 be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature.

[2] In case that one of Q^3 and T^3 is a halo(C_{1-6} alkyl) group
20 in a benzylpyrazole derivative represented by the above general formula (III), a corresponding compound represented by the above general formula (II) of the present invention can be prepared by subjecting a corresponding benzylpyrazole derivative represented by the above general formula (III) to glycosidation
25 using acetobromo- α -D-glucose or acetobromo- α -D-galactose in the presence of a base such as potassium carbonate or the like in an inert solvent. As the inert solvent used in the reaction,

for example, tetrahydrofuran, acetonitrile, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature.

[3] In case that one of Q^3 and T^3 is a C_{2-6} alkyl group, a C_{1-6} alkoxy-substituted (C_{1-6} alkyl) group or a C_{3-7} cycloalkyl group in a benzylpyrazole derivative represented by the above general formula (III), a corresponding compound represented by the above general formula (II) of the present invention can be also prepared by subjecting a corresponding benzylpyrazole derivative represented by the above general formula (III) to glycosidation using acetobromo- α -D-glucose or acetobromo- α -D-galactose in the presence of a base such as sodium hydroxide, potassium hydroxide, potassium carbonate or the like and a phase transfer catalyst such as benzyltri(*n*-butyl)ammonium chloride, benzyltri(*n*-butyl)ammonium bromide, tetra(*n*-butyl)ammonium hydrogen sulfate or the like in an inert solvent containing water. As the inert solvent used in the reaction, dichloromethane, toluene, benzotrifluoride, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature.

The obtained glycosidated benzylpyrazole derivative represented by the above general formula (II) can be also used

in the subsequent process after suitably converting into a salt thereof and separating in the usual way.


Process 1-9

A pyrazole derivative represented by the above general
5 formula (I) of the present invention can be prepared by subjecting a compound represented by the above general formula (II) to alkaline hydrolysis, and removing a protective group or
subjecting a nitro group of the resulting compound to reduction as occasion demands. As the solvent used in the hydrolysis
10 reaction, for example, methanol, ethanol, tetrahydrofuran, water, a mixed solvent thereof and the like can be illustrated. As the base, for example, sodium hydroxide, sodium methoxide, sodium ethoxide and the like can be illustrated. The reaction
temperature is usually from 0°C to reflux temperature, and the
15 reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature. As mentioned above, in case of compounds having a protective
group in R^{11} , R^{12} , R^{14} and/or R^{15} after the hydrolysis, the protective group can be suitably removed in the usual way.
20 Furthermore, after the completion of the above reaction, compounds having a nitro group in R^2 represented by the above general formula (I) can be also derived into a corresponding
compound having an amino group by catalytic reduction using a platinum catalyst such as platinum oxide in an inert solvent
25 such as ethyl acetate at usually room temperature to reflux temperature for usually 30 minutes to 1 day in the usual way.

Among the compounds represented by the above general

formula (III) as starting materials, there can be the following three tautomers in compounds wherein R^{11} is a hydrogen atom, varying based on difference in the reaction conditions, and the compounds represented by the above general formula (III) include

5 all the compounds:




wherein R, R³, R⁶, R⁷, R¹², R¹⁴, R¹⁵, X, Y and Z have the same meanings as defined above.

Of the compounds represented by the above general formula

10 (I) of the present invention, a compound wherein R^1 represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a hydroxy(C₂₋₆ alkyl) group, a C₃₋₇ cycloalkyl group, a C₃₋₇ cycloalkyl-substituted (C₁₋₆ alkyl) group or an aryl-substituted (C₁₋₆ alkyl) group which may have the same or different 1 to 3 substituents selected

15 from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, for example, can be prepared according to the following procedure:




wherein L^3 represents a leaving group such as a halogen atom, a mesyloxy group, a tosyloxy group or the like; R^{21} represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group which may have a protective group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group or an aryl-substituted (C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group; R^{31} represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group or an aryl-substituted (C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group; and R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{12} , R^{14} , R^{15} , Q , Q^2 , T , T^2 , X , Y and Z have the same meanings as defined above.

20 Process 2

A pyrazole derivative represented by the above general formula (Ia) of the present invention can be prepared by subjecting a compound represented by the above general formula

(IIa) to hydrolysis according to a similar method to that described in the above process 1-9 and *N*-alkylation using an *N*-alkylating agent represented by the above general formula (XV) in the presence of a base such as cesium carbonate or potassium carbonate in an inert solvent, and in case of compounds having a protective group, suitably removing the protective group in the usual way as occasion demands. As the inert solvent used in the *N*-alkylation, for example, acetonitrile, ethanol, 1,2-dimethoxyethane, tetrahydrofuran, *N,N*-dimethylformamide, dimethyl sulfoxide, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 10 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature.

Of the compounds represented by the above general formula (I) of the present invention, a compound wherein R^1 represents a hydrogen atom, for example, can be also prepared according to the following procedure:



wherein $R^2, R^3, R^4, R^5, R^6, R^7, R^{12}, R^{14}, R^{15}, Q, Q^2, T, T^2, X, Y$ and Z have the same meanings as defined above.

Process 3-1

A compound represented by the above general formula (XVII) can be prepared by subjecting a compound represented by the above general formula (XVI) to catalytic hydrogenation using a
5 palladium catalyst such as palladium-carbon powder in an inert solvent to remove the benzyl group. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol, tetrahydrofuran, ethyl acetate, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually
10 from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.

Process 3-2


A compound represented by the above general formula (IIa)
15 of the present invention can be prepared by condensing a compound represented by the above general formula (XVII) with an amine derivative represented by the above general formula (XVIII) in the presence of a condensing agent such as 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide hydrochloride or dicyclohexyl-
20 carbodiimide and in the presence or absence of a base such as triethylamine or *N,N*-diisopropylethylamine in an inert solvent after suitably adding 1-hydroxybenzotriazole as occasion demands. As the solvent used in the condensing reaction, for example, *N,N*-dimethylformamide, dichloromethane, tetra-
25 hydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour

to 2 days, varying based on a used starting material, solvent and reaction temperature.

Process 3-3

A pyrazole derivative represented by the above general
5 formula (Ib) of the present invention can be prepared by
subjecting a compound represented by the above general formula
(IIa) to alkaline hydrolysis, and removing the protective group
in the usual way as occasion demands. As the solvent used in
the hydrolysis reaction, for example, methanol, ethanol,
10 tetrahydrofuran, water, a mixed solvent thereof and the like
can be illustrated. As the base, for example, sodium hydroxide,
sodium methoxide, sodium ethoxide and the like can be illustrated.
The reaction temperature is usually from 0°C to reflux temperature,
and the reaction time is usually from 30 minutes to 1 day, varying
15 based on a used starting material, solvent and reaction
temperature. In case of compounds having a protective group
in R¹², R¹⁴ and/or R¹⁵ after the hydrolysis, the protective group
can be suitably removed in the usual way as the process 1-9.

Of the compounds represented by the above general formula
20 (I) of the present invention, a compound wherein R¹ represents
a hydrogen atom; X represents a single bond; and Y represents
a C₂₋₆ alkylene group or a C₂₋₆ alkenylene group, for example,
can be prepared according to the following procedures:



wherein L^4 represents a leaving group such as a chlorine atom, a bromine atom, an iodine atom, a trifluoromethanesulfonyloxy group or the like; Y^1 represents a single bond or a C_{1-4} alkylene group; and R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{12} , R^{14} , R^{15} , Q , Q^2 , T , T^2 and Z have the same meanings as defined above.

Process 4-1

A pyrazole derivative represented by the above general formula (XXI) can be prepared by subjecting a pyrazole derivative represented by the above general formula (XIX) to Heck reaction with an olefine derivative represented by the above general formula (XX) using a palladium catalyst such as palladium-carbon powder, palladium acetate, tetrakis(triphenylphosphine)-palladium, dibenzylideneacetonepalladium or bis(triphenylphosphine)palladium dichloride in the presence or absence of a phosphine ligand such as tris(2-methylphenyl)phosphine or triphenylphosphine and in the presence of a base such as triethylamine, sodium *tert*-butoxide, potassium *tert*-butoxide or cesium fluoride in an inert solvent. As the solvent used in the reaction, for example, acetonitrile, toluene,

tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent
5 and reaction temperature.

Process 4-2

A compound represented by the above general formula (XXII) can be prepared by subjecting a compound represented by the above general formula (XXI) to catalytic hydrogenation using a
10 palladium catalyst such as palladium-carbon powder in an inert solvent. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol, tetrahydrofuran, ethyl acetate, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature,
15 and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.


Process 4-3

A compound represented by the above general formula (IIb)
20 of the present invention can be prepared by condensing a compound represented by the above general formula (XXII) with an amine derivative represented by the above general formula (XVIII) in the presence of a condensing agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or dicyclohexyl-
25 carbodiimide and a base such as triethylamine or *N,N*-diisopropylethylamine in an inert solvent after suitably adding 1-hydroxybenzotriazole as occasion demands, and suitably removing the

protective group in the usual way as occasion demands. As the solvent used in the condensing reaction, for example, *N,N*-dimethylformamide, dichloromethane, tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.

Process 4-4

10 A pyrazole derivative represented by the above general formula (Ic) of the present invention can be prepared by subjecting a compound represented by the above general formula (IIb) to alkaline hydrolysis, and suitably removing the protective group in the usual way as occasion demands. As the solvent used in the hydrolysis reaction, for example, methanol, ethanol, tetrahydrofuran, water, a mixed solvent thereof and the like can be illustrated. As the base, for example, sodium hydroxide, sodium methoxide, sodium ethoxide and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature. In case of compounds having a protective group in R¹², R¹⁴ and/or R¹⁵ after the hydrolysis, the protective group can be suitably removed in the usual way as the process 1-9.



In the formula, L^4 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{12} , R^{14} , R^{15} , Q , Q^2 , T , T^2 , Y^1 and Z have the same meanings as defined above.

Process 5-1

- 5 A compound represented by the above general formula (IIc) of the present invention can be prepared by condensing a compound represented by the above general formula (XXI) with an amine

derivative represented by the above general formula (XVIII) in the presence of a condensing agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or dicyclohexylcarbodiimide and a base such as triethylamine or *N,N*-diisopropylethylamine in an inert solvent after suitably adding 1-hydroxybenzotriazole as occasion demands, and suitably removing the protective group in the usual way as occasion demands. As the solvent used in the condensing reaction, for example, *N,N*-dimethylformamide, dichloromethane, tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.

15 Process 5-2

A pyrazole derivative represented by the above general formula (IIc) of the present invention can be prepared by subjecting a pyrazole derivative represented by the above general formula (XIX) to Heck reaction with an olefine derivative represented by the above general formula (XXIII) using a palladium catalyst such as palladium-carbon powder, palladium acetate, tetrakis(triphenylphosphine)palladium, dibenzylideneacetonepalladium or bis(triphenylphosphine)palladium dichloride in the presence or absence of a phosphine ligand such as tris(2-methylphenyl)phosphine or triphenylphosphine and in the presence of a base such as triethylamine, sodium *tert*-butoxide, potassium *tert*-butoxide or cesium

fluoride in an inert solvent. As the solvent used in the reaction, for example, acetonitrile, toluene, tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the
5 reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.

Process 5-3

A pyrazole derivative represented by the above general formula (Id) of the present invention can be prepared by
10 subjecting a compound represented by the above general formula (IIc) to alkaline hydrolysis, and suitably removing the protective group in the usual way as occasion demands. As the solvent used in the hydrolysis reaction, for example, methanol, ethanol, tetrahydrofuran, water, a mixed solvent thereof and
15 the like can be illustrated. As the base, for example, sodium hydroxide, sodium methoxide, sodium ethoxide and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material,
20 solvent and reaction temperature. In case of compounds having a protective group in R¹², R¹⁴ and/or R¹⁵ after the hydrolysis, the protective group can be suitably removed in the usual way as the process 1-9.

Process 5-4

25 A compound represented by the above general formula (IIb) can be prepared by subjecting a compound represented by the above general formula (IIc) to catalytic hydrogenation using a

palladium catalyst such as palladium-carbon powder in an inert solvent. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol, tetrahydrofuran, ethyl acetate, a mixed solvent thereof and the like can be illustrated. The
5 reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material, solvent and reaction temperature.

Process 5-5

10 A compound represented by the above general formula (Ic) of the present invention can be prepared by subjecting a compound represented by the above general formula (Id) to catalytic hydrogenation using a palladium catalyst such as palladium-carbon powder in an inert solvent. As the solvent used in the
15 catalytic hydrogenation, for example, methanol, ethanol, tetrahydrofuran, ethyl acetate, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, varying based on a used starting material,
20 solvent and reaction temperature.

Process 5-6

A pyrazole derivative represented by the above general formula (Ic) of the present invention can be prepared by
subjecting a compound represented by the above general formula
25 (IIb) to alkaline hydrolysis, and suitably removing the protective group in the usual way as occasion demands. As the solvent used in the hydrolysis reaction, for example, methanol,

ethanol, tetrahydrofuran, water, a mixed solvent thereof and the like can be illustrated. As the base, for example, sodium hydroxide, sodium methoxide, sodium ethoxide and the like can be illustrated. The reaction temperature is usually from 0°C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, varying based on a used starting material, solvent and reaction temperature. In case of compounds having a protective group in R^{12} , R^{14} and/or R^{15} after the hydrolysis, the protective group can be suitably removed in the usual way as the process 1-9.

The compounds represented by the above general formula (I) of the present invention obtained by the above production processes can be isolated and purified by conventional separation means such as fractional recrystallization, purification using chromatography, solvent extraction and solid phase extraction.

The pyrazole derivatives represented by the above general formula (I) of the present invention can be converted into their pharmaceutically acceptable salts in the usual way. Examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, acid addition salts with organic acids such as formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, *p*-toluenesulfonic acid, propionic acid, citric acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid and the like, salts with

inorganic bases such as a sodium salt, a potassium salt and the like, and salts with organic bases such as *N*-methyl-D-glucamine, *N,N'*-dibenzylethylenediamine, 2-aminoethanol, tris(hydroxymethyl)aminomethane, arginine, lysine and the like.

5 The compounds represented by the above general formula (I) of the present invention include their solvates with pharmaceutically acceptable solvents such as ethanol and water.

Of the pyrazole derivatives represented by the above general formula (I) of the present invention and the prodrugs
10 thereof, there are two geometrical isomers in each compound having an unsaturated bond. In the present invention, either of *cis*(*Z*)-isomer or *trans*(*E*)-isomer can be employed.

Of the pyrazole derivatives represented by the above general formula (I) of the present invention and the prodrugs
15 thereof, there are two optical isomers, *R*-isomer and *S*-isomer, in each compound having an asymmetric carbon atom excluding the glucopyranosyloxymoiety or the galactopyranosyloxymoiety. In the present invention, either of the isomers can be employed, and a mixture of both isomers can be also employed.

20 A prodrug of a compound represented by the above general formula (I) of the present invention can be prepared by introducing an appropriate group forming a prodrug into any one or more groups selected from a hydroxy group in the glucopyranosyl moiety or the galactopyranosyl moiety, or optionally in R^1 , R^2 ,
25 R^4 or R^5 , a cyclic amino group in case that R^1 is a hydrogen atom, and an amino group in case that R^1 , R^2 , R^4 or R^5 is a substituent having an amino group of the compound represented

by the above general formula (I) using a corresponding reagent to produce a prodrug such as a halide compound or the like in the usual way, and then by suitably isolating and purifying in the usual way as occasion demands. As a group forming a prodrug

5 used in a hydroxy group or an amino group, for example, a C₂₋₇ acyl group, a C₁₋₆ alkoxy-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl group, an aryl-substituted (C₂₋₇ alkoxy-carbonyl) group, a C₁₋₆ alkoxy-substituted (C₂₋₇ alkoxy-carbonyl) group

10 or the like can be illustrated. As a group forming a prodrug used in a cyclic amino group, for example, a C₂₋₇ acyl group, a C₁₋₆ alkoxy-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl group, a C₁₋₆ alkoxy-substituted (C₂₋₇

15 alkoxy-carbonyl) group, a (C₂₋₇ acyloxy)methyl group, a 1-(C₂₋₇ acyloxy)ethyl group, a (C₂₋₇ alkoxy-carbonyl)oxymethyl group, a 1-[(C₂₋₇ alkoxy-carbonyl)oxy]ethyl group, a (C₃₋₇ cycloalkyl)oxycarbonyloxymethyl group, a 1-[(C₃₋₇ cycloalkyl)-oxycarbonyloxy]ethyl group or the like can be illustrated. The

20 term "C₂₋₇ acyl group" means a straight-chained or branched acyl group having 2 to 7 carbon atoms such as an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, a pivaloyl group, a hexanoyl group or the like; and the

25 term "C₁₋₆ alkoxy-substituted (C₂₋₇ acyl) group" means the above C₂₋₇ acyl group substituted by the above C₁₋₆ alkoxy group; the term "C₂₋₇ alkoxy-carbonyl-substituted (C₂₋₇ acyl) group" means the above C₂₋₇ acyl group substituted by the above C₂₋₇

alkoxycarbonyl group; the term "aryl-substituted (C₂₋₇ alkoxy carbonyl) group" means the above C₂₋₇ alkoxy carbonyl group substituted by the above aryl group, such as a benzyloxy carbonyl group; the term "C₁₋₆ alkoxy-substituted (C₂₋₇ alkoxy carbonyl) group" means the above C₂₋₇ alkoxy carbonyl group substituted by the above C₁₋₆ alkoxy group; the term "(C₂₋₇ acyloxy)methyl group" means a hydroxymethyl group O-substituted by the above C₂₋₇ acyl group; the term "1-(C₂₋₇ acyloxy)ethyl group" means a 1-hydroxyethyl group O-substituted by the above C₂₋₇ acyl group; the term "(C₂₋₇ alkoxy carbonyl)oxymethyl group" means a hydroxymethyl group substituted by the above C₂₋₇ alkoxy carbonyl group; and the term "1-[(C₂₋₇ alkoxy carbonyl)oxy]ethyl group" means a 1-hydroxyethyl group O-substituted by the above C₂₋₇ alkoxy carbonyl group. In addition, the term "(C₃₋₇ cycloalkyl)oxycarbonyl group" means a cyclic alkoxy carbonyl group having the above C₃₋₇ cycloalkyl group; the term "(C₃₋₇ cycloalkyl)oxycarbonyloxymethyl group" means a hydroxymethyl group O-substituted by the above (C₃₋₇ cycloalkyl)oxycarbonyl group; and the term "1-[(C₃₋₇ cycloalkyl)oxycarbonyloxy]ethyl group" means a 1-hydroxyethyl group O-substituted by the above (C₃₋₇ cycloalkyl)oxycarbonyl group. Furthermore, as a group forming a prodrug, a glucopyranosyl group or a galactopyranosyl group can be illustrated. For example, these groups are preferably introduced into the hydroxy group at the 4 or 6 position of the glucopyranosyl group or the galactopyranosyl group, and are more preferably introduced into the hydroxy group at the 4 or 6 position of the glucopyranosyl group.

The pyrazole derivatives represented by the above general formula (I) of the present invention, for example, showed a potent inhibitory activity in human SGLT1 in a human SGLT1 inhibitory activity confirmatory test as described below, and exerted an excellent inhibitory activity of blood glucose level increase in a confirmatory test of the inhibitory activity of blood glucose level increase in rat. Thus, the pyrazole derivatives represented by the above general formula (I) of the present invention exhibit an excellent SGLT1 inhibitory activity at the small intestine, and can remarkably inhibit blood glucose level increase and/or decrease blood galactose level by inhibiting or delaying glucose and galactose absorption. Therefore, a pharmaceutical composition comprising as an active ingredient a pyrazole derivative represented by the above general formula (I) of the present invention, a pharmaceutically acceptable salt and a prodrug thereof is extremely useful as an agent for inhibiting postprandial hypreglycemia, an agent for the inhibition of advancing impaired glucose tolerance (IGT) or impaired fasting glycemia (IFG) into diabetes in a subject, and an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications (e.g., retinopathy, neuropathy, nephropathy, ulcer, macroangiopathy), obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia, gout or the like, which relates

to SGLT1 activity at the small intestine, and an agent for the prevention or treatment of a disease associated with increasing blood galactose level such as galactosemia.

Furthermore, the compounds of the present invention can
5 be suitably used in combination with at least one member selected from drugs other than SGLT2 inhibitors. Examples of the drugs which can be used in combination with the compounds of the present invention include an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer,
10 a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase
15 inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue,
20 an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an N-acetylated- α -linked-acid-
25 dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor (PDGF), a platelet-derived growth factor (PDGF) analogue (e.g., PDGF-AA, PDGF-BB, PDGF-AB),

epidermal growth factor (EGF), nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyltransferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

In case of uses of the compound of the present invention in combination with the above one or more drugs, the present invention includes either dosage forms of simultaneous administration as a single preparation or separated preparations in way of the same or different administration route, and

administration at different dosage intervals as separated preparations in way of the same or different administration route. A pharmaceutical combination comprising the compound of the present invention and the above drug(s) includes both dosage forms as a single preparation and separated preparations for combination as mentioned above.

The compounds of the present invention can obtain more advantageous effects than additive effects in the prevention or treatment of the above diseases when using suitably in combination with the above one or more drugs. Also, the administration dose can be decreased in comparison with administration of either drug alone, or adverse effects of coadministered drugs other than SGLT1 inhibitors can be avoided or declined.

Concrete compounds as the drugs used for combination and preferable diseases to be treated are exemplified as follows. However, the present invention is not limited thereto, and the concrete compounds include their free compounds, and their or other pharmaceutically acceptable salts.

As insulin sensitivity enhancers, peroxisome proliferator-activated receptor- γ agonists such as troglitazone, pioglitazone hydrochloride, rosiglitazone maleate, sodium darglitazone, GI-262570, isaglitazone, LG-100641, NC-2100, T-174, DRF-2189, CLX-0921, CS-011, GW-1929, ciglitazone, sodium englitazone and NIP-221, peroxisome proliferator-activated receptor- α agonists such as GW-9578 and BM-170744, peroxisome proliferator-activated

receptor- α/γ agonists such as GW-409544, KRP-297, NN-622, CLX-0940, LR-90, SB-219994, DRF-4158 and DRF-MDX8, retinoid X receptor agonists such as ALRT-268, AGN-4204, MX-6054, AGN-194204, LG-100754 and bexarotene, and other insulin sensitivity enhancers such as reglixane, ONO-5816, MBX-102, CRE-1625, FK-614, CLX-0901, CRE-1633, NN-2344, BM-13125, BM-501050, HQL-975, CLX-0900, MBX-668, MBX-675, S-15261, GW-544, AZ-242, LY-510929, AR-H049020 and GW-501516 are illustrated. Insulin sensitivity enhancers are used preferably for diabetes, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder or atherosclerosis, and more preferably for diabetes, impaired glucose tolerance or hyperinsulinemia because of improving the disturbance of insulin signal transduction in peripheral tissues and enhancing glucose uptake into the tissues from the blood, leading to lowering of blood glucose level.

As glucose absorption inhibitors, compounds other than SGLT1 inhibitors, for example, α -glucosidase inhibitors such as acarbose, voglibose, miglitol, CKD-711, emiglitate, MDL-25,637, camiglibose and MDL-73,945, and α -amylase inhibitors such as AZM-127 are illustrated. Glucose absorption inhibitors are used preferably for diabetes, impaired glucose tolerance, diabetic complications, obesity or hyperinsulinemia, and more preferably for impaired glucose tolerance because of inhibiting the gastrointestinal enzymatic digestion of carbohydrates contained in foods, and inhibiting

or delaying the absorption of glucose into the body.

As biguanides, phenformin, buformin hydrochloride, metformin hydrochloride or the like are illustrated.

Biguanides are used preferably for diabetes, impaired glucose
5 tolerance, diabetic complications or hyperinsulinemia, and more
preferably for diabetes, impaired glucose tolerance or
hyperinsulinemia because of lowering blood glucose level by
inhibitory effects on hepatic gluconeogenesis, accelerating
effects on anaerobic glycolysis in tissues or improving effects
10 on insulin resistance in peripheral tissues.

As insulin secretion enhancers, tolbutamide,
chlorpropamide, tolazamide, acetohexamide, glyclopyramide,
glyburide (glibenclamide), gliclazide, 1-butyl-3-metanilyl-
urea, carbutamide, glibornuride, glipizide, gliquidone,
15 glisoxapide, glybuthiazol, glybuzole, glyhexamide, sodium
glymidine, glypinamide, phenbutamide, tolcyclamide,
glimepiride, nateglinide, mitiglinide calcium hydrate,
repaglinide or the like are illustrated. In addition, the
insulin secretion enhancers include glucokinase activators such
20 as RO-28-1675. Insulin secretion enhancers are used preferably
for diabetes, impaired glucose tolerance or diabetic
complications, and more preferably for diabetes or impaired
glucose tolerance because of lowering blood glucose level by
acting on pancreatic β -cells and enhancing the insulin secretion.

25 As SGLT2 inhibitors, T-1095 and compounds described in
Japanese patent publications Nos. Hei10-237089 and 2001-288178,
and International Publications Nos. WO01/16147, WO01/27128,

WO01/68660, WO01/74834, WO01/74835, WO02/28872, WO02/36602, WO02/44192, WO02/53573 etc. are illustrated. SGLT2 inhibitors are used preferably for diabetes, impaired glucose tolerance, diabetic complications, obesity or hyperinsulinemia, and more
5 preferably for diabetes, impaired glucose tolerance, obesity or hyperinsulinemia because of lowering blood glucose level by inhibiting the reabsorption of glucose at the kidney's proximal tubule.

As insulin or insulin analogues, human insulin, animal-
10 derived insulin, human or animal-derived insulin analogues or the like are illustrated. These preparations are used preferably for diabetes, impaired glucose tolerance or diabetic complications, and more preferably for diabetes or impaired glucose tolerance.

15 As glucagon receptor antagonists, BAY-27-9955, NNC-92-1687 or the like are illustrated; as insulin receptor kinase stimulants, TER-17411, L-783281, KRX-613 or the like are illustrated; as tripeptidyl peptidase II inhibitors, UCL-1397 or the like are illustrated; as dipeptidyl peptidase IV
20 inhibitors, NVP-DPP728A, TSL-225, P-32/98 or the like are illustrated; as protein tyrosine phosphatase 1B inhibitors, PTP-112, OC-86839, PNU-177496 or the like are illustrated; as glycogen phosphorylase inhibitors, NN-4201, CP-368296 or the like are illustrated; as fructose-bisphosphatase inhibitors,
25 R-132917 or the like are illustrated; as pyruvate dehydrogenase inhibitors, AZD-7545 or the like are illustrated; as hepatic gluconeogenesis inhibitors, FR-225659 or the like are

illustrated; as glucagon-like peptide-1 analogues, exendin-4, CJC-1131 or the like are illustrated; as glucagon-like peptide 1 agonists; AZM-134, LY-315902 or the like are illustrated; and as amylin, amylin analogues or amylin agonists, pramlintide acetate or the like are illustrated. These drugs, glucose-6-phosphatase inhibitors, D-chiroinsitol, glycogen synthase kinase-3 inhibitors and glucagon-like peptide-1 are used preferably for diabetes, impaired glucose tolerance, diabetic complications or hyperinsulinemia, and more preferably for diabetes or impaired glucose tolerance.

As aldose reductase inhibitors, ascorbyl gamolenate, tolrestat, epalrestat, ADN-138, BAL-ARI8, ZD-5522, ADN-311, GP-1447, IDD-598, fidarestat, sorbinil, ponalrestat, risarestat, zenarestat, minalrestat, methosorbinil, AL-1567, imirestat, M-16209, TAT, AD-5467, zopolrestat, AS-3201, NZ-314, SG-210, JTT-811, lindolrestat or the like are illustrated. Aldose reductase inhibitors are preferably used for diabetic complications because of inhibiting aldose reductase and lowering excessive intracellular accumulation of sorbitol in accelated polyol pathway which are in continuous hyperglycemic condition in the tissues in diabetic complications.

As advanced glycation endproducts formation inhibitors, pyridoxamine, OPB-9195, ALT-946, ALT-711, pimagedine hydrochloride or the like are illustrated. Advanced glycation endproducts formation inhibitors are preferably used for diabetic complications because of inhibiting formation of advanced glycation endproducts which are accelated in continuous

hyperglycemic condition in diabetes and declining of cellular damage.

As protein kinase C inhibitors, LY-333531, midostaurin or the like are illustrated. Protein kinase C inhibitors are
 5 preferably used for diabetic complications because of inhibiting of protein kinase C activity which is accelerated in continuous hyperglycemic condition in diabetes.

As γ -aminobutyric acid receptor antagonists, topiramate or the like are illustrated; as sodium channel antagonists,
 10 mexiletine hydrochloride, oxcarbazepine or the like are illustrated; as transcrit factor NF- κ B inhibitors, dexlipotam or the like are illustrated; as lipid peroxidase inhibitors, tirilazad mesylate or the like are illustrated; as
 N-acetylated- α -linked-acid-dipeptidase inhibitors, GPI-5693
 15 or the like are illustrated; and as carnitine derivatives, carnitine, levacecarnine hydrochloride, levocarnitine chloride, levocarnitine, ST-261 or the like are illustrated. These drugs, insulin-like growth factor-I, platelet-derived growth factor, platelet derived growth factor analogues, epidermal growth
 20 factor, nerve growth factor, uridine, 5-hydroxy-1-methyl-hidantoin, EGB-761, bimoclomol, sulodexide and Y-128 are preferably used for diabetic complications.

As antidiarrhoics or cathartics, polycarbophil calcium, albumin tannate, bismuth subnitrate or the like are illustrated.
 25 These drugs are preferably used for diarrhea, constipation or the like accompanying diabetes or the like.

As hydroxymethylglutaryl coenzyme A reductase inhibitors,

sodium cerivastatin, sodium pravastatin, lovastatin, simvastatin, sodium fluvastatin, atorvastatin calcium hydrate, SC-45355, SQ-33600, CP-83101, BB-476, L-669262, S-2468, DMP-565, U-20685, BAY-x-2678, BAY-10-2987, calcium pitavastatin,

5 calcium rosuvastatin, colestolone, dalvastatin, acitemate, mevastatin, crilvastatin, BMS-180431, BMV-21950, glenvastatin, carvastatin, BMV-22089, bervastatin or the like are illustrated. Hydroxymethylglutaryl coenzyme A reductase inhibitors are used preferably for hyperlipidemia, hypercholesterolemia,

10 hypertriglyceridemia, lipid metabolism disorder or atherosclerosis, and more preferably for hyperlipidemia, hypercholesterolemia or atherosclerosis because of lowering blood cholesterol level by inhibiting hydroxymethylglutaryl coenzyme A reductase.

15 As fibric acid derivatives, bezafibrate, beclobate, binifibrate, ciprofibrate, clinofibrate, clofibrate, aluminum clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicofibrate, pirifibrate, ronifibrate, simfibrate, theofibrate, AHL-157 or the like are illustrated. Fibric acid

20 derivatives are used preferably for hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder or atherosclerosis, and more preferably for hyperlipidemia, hypertriglyceridemia or atherosclerosis because of activating hepatic lipoprotein

25 lipase and enhancing fatty acid oxidation, leading to lowering of blood triglyceride level.

As β_3 -adrenoceptor agonists, BRL-28410, SR-58611A,

ICI-198157, ZD-2079, BMS-194449, BRL-37344, CP-331679,
 CP-114271, L-750355, BMS-187413, SR-59062A, BMS-210285,
 LY-377604, SWR-0342SA, AZ-40140, SB-226552, D-7114, BRL-35135,
 FR-149175, BRL-26830A, CL-316243, AJ-9677, GW-427353, N-5984,
 5 GW-2696, YM178 or the like are illustrated. β_3 -Adrenoceptor
 agonists are used preferably for obesity, hyperinsulinemia,
 hyperlipidemia, hypercholesterolemia, hypertriglyceridemia or
 lipid metabolism disorder, and more preferably for obesity or
 hyperinsulinemia because of stimulating β_3 -adrenoceptor in
 10 adipose tissue and enhancing the fatty acid oxidation, leading
 to induction of energy expenditure.

As acyl-coenzyme A cholesterol acyltransferase
 inhibitors, NTE-122, MCC-147, PD-132301-2, DUP-129, U-73482,
 U-76807, RP-70676, P-06139, CP-113818, RP-73163, FR-129169,
 15 FY-038, EAB-309, KY-455, LS-3115, FR-145237, T-2591, J-104127,
 R-755, FCE-28654, YIC-C8-434, avasimibe, CI-976, RP-64477,
 F-1394, eldacimibe, CS-505, CL-283546, YM-17E, lecimibide,
 447C88, YM-750, E-5324, KW-3033, HL-004, eflucimibe or the like
 are illustrated. Acyl-coenzyme A cholesterol acyltransferase
 20 inhibitors are used preferably for hyperlipidemia, hyper-
 cholesterolemia, hypertriglyceridemia or lipid metabolism
 disorder, and more preferably for hyperlipidemia or hyper-
 cholesterolemia because of lowering blood cholesterol level by
 inhibiting acyl-coenzyme A cholesterol acyltransferase.

25 As thyroid hormone receptor agonists, sodium liothyronine,
 sodium levothyroxine, KB-2611 or the like are illustrated; as
 cholesterol absorption inhibitors, ezetimibe, SCH-48461 or the

like are illustrated; as lipase inhibitors, orlistat, ATL-962, AZM-131, RED-103004 or the like are illustrated; as carnitine palmitoyltransferase inhibitors, etomoxir or the like are illustrated; as squalene synthase inhibitors, SDZ-268-198, 5 BMS-188494, A-87049, RPR-101821, ZD-9720, RPR-107393, ER-27856 or the like are illustrated; as nicotinic acid derivatives, nicotinic acid, nicotinamide, nicomol, niceritrol, acipimox, nicorandil or the like are illustrated; as bile acid sequestrants, colestyramine, colestilan, colesevelam hydrochloride, 10 GT-102-279 or the like are illustrated; as sodium/bile acid cotransporter inhibitors, 264W94, S-8921, SD-5613 or the like are illustrated; and as cholesterol ester transfer protein inhibitors, PNU-107368E, SC-795, JTT-705, CP-529414 or the like are illustrated. These drugs, probcol, microsomal triglyceride 15 transfer protein inhibitors, lipoxygenase inhibitors and low-density lipoprotein receptor enhancers are preferably used for hyperlipidemia, hypercholesterolemia, hypertriglyceridemia or lipid metabolism disorder.

As appetite suppressants, monoamine reuptake inhibitors, 20 serotonin reuptake inhibitors, serotonin releasing stimulants, serotonin agonists (especially 5HT_{2C}-agonists), noradrenaline reuptake inhibitors, noradrenaline releasing stimulants, α_1 -adrenoceptor agonists, β_2 -adrenoceptor agonists, dopamine agonists, cannabinoid receptor antagonists, γ -aminobutyric acid 25 receptor antagonists, H₃-histamine antagonists, L-histidine, leptin, leptin analogues, leptin receptor agonists, melanocortin receptor agonists (especially, MC3-R agonists,

MC4-R agonists), α -melanocyte stimulating hormone, cocaine-and amphetamine-regulated transcript, mahogany protein, enterostatin agonists, calcitonin, calcitonin-gene-related peptide, bombesin, cholecystokinin agonists (especially CCK-A agonists), corticotropin-releasing hormone, corticotrophin-releasing hormone analogues, corticotropin-releasing hormone agonists, urocortin, somatostatin, somatostatin analogues, somatostatin receptor agonists, pituitary adenylate cyclase-activating peptide, brain-derived neurotrophic factor, ciliary neurotrophic factor, thyrotropin-releasing hormone, neurotensin, sauvagine, neuropeptide Y antagonists, opioid peptide antagonists, galanin antagonists, melanin-concentrating hormone antagonists, agouti-related protein inhibitors and orexin receptor antagonists are illustrated.

Concretely, as monoamine reuptake inhibitors, mazindol or the like are illustrated; as serotonin reuptake inhibitors, dexfenfluramine hydrochloride, fenfluramine, sibutramine hydrochloride, fluvoxamine maleate, sertraline hydrochloride or the like are illustrated; as serotonin agonists, inotriptan, (+)-norfenfluramine or the like are illustrated; as noradrenaline reuptake inhibitors, bupropion, GW-320659 or the like are illustrated; as noradrenaline releasing stimulants, rolipram, YM-992 or the like are illustrated; as β_2 -adrenoceptor agonists, amphetamine, dextroamphetamine, phentermine, benzphetamine, methamphetamine, phendimetrazine, phenmetrazine, diethylpropion, phenylpropanolamine, clobenzorex or the like are illustrated; as dopamine agonists,

ER-230, doprexin, bromocriptine mesylate or the like are illustrated; as cannabinoid receptor antagonists, rimonabant or the like are illustrated; as γ -aminobutyric acid receptor antagonists, topiramate or the like are illustrated; as

5 H₃-histamine antagonists, GT-2394 or the like are illustrated; as leptin, leptin analogues or leptin receptor agonists, LY-355101 or the like are illustrated; as cholecystokinin agonists (especially CCK-A agonists), SR-146131, SSR-125180, BP-3.200, A-71623, FPL-15849, GI-248573, GW-7178, GI-181771,

10 GW-7854, A-71378 or the like are illustrated; and as neuropeptide Y antagonists, SR-120819-A, PD-160170, NGD-95-1, BIBP-3226, 1229-U-91, CGP-71683, BIBO-3304, CP-671906-01, J-115814 or the like are illustrated. Appetite suppressants are used preferably for diabetes, impaired glucose tolerance, diabetic

15 complications, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia or gout, and more preferably for obesity because of stimulating or inhibiting the activities of intracerebral

20 monoamines or bioactive peptides in central appetite regulatory system and suppressing the appetite, leading to reduction of energy intake.

As angiotensin-converting enzyme inhibitors, captopril, enalapril maleate, alacepril, delapril hydrochloride, ramipril,

25 lisinopril, imidapril hydrochloride, benazepril hydrochloride, ceronapril monohydrate, cilazapril, sodium fosinopril, perindopril erbumine, calcium moveltipril, quinapril hydro-

chloride, spirapril hydrochloride, temocapril hydrochloride, trandolapril, calcium zofenopril, moexipril hydrochloride, rentiapril or the like are illustrated. Angiotensin-converting enzyme inhibitors are preferably used for diabetic complications or hypertension.

As neutral endopeptidase inhibitors, omapatrilat, MDL-100240, fasidotril, sampatrilat, GW-660511X, mixanpril, SA-7060, E-4030, SLV-306, ecadotril or the like are illustrated. Neutral endopeptidase inhibitors are preferably used for diabetic complications or hypertension.

As angiotensin II receptor antagonists, candesartan cilexetil, candesartan cilexetil/hydrochlorothiazide, potassium losartan, eprosartan mesylate, valsartan, telmisartan, irbesartan, EXP-3174, L-158809, EXP-3312, olmesartan, tasosartan, KT-3-671, GA-0113, RU-64276, EMD-90423, BR-9701 or the like are illustrated. Angiotensin II receptor antagonists are preferably used for diabetic complications or hypertension.

As endothelin-converting enzyme inhibitors, CGS-31447, CGS-35066, SM-19712 or the like are illustrated; as endothelin receptor antagonists, L-749805, TBC-3214, BMS-182874, BQ-610, TA-0201, SB-215355, PD-180988, sodium sitaxsentan, BMS-193884, darusentan, TBC-3711, bosentan, sodium tezosentan, J-104132, YM-598, S-0139, SB-234551, RPR-118031A, ATZ-1993, RO-61-1790, ABT-546, enlasentan, BMS-207940 or the like are illustrated. These drugs are preferably used for diabetic complications or hypertension, and more preferably for hypertension.

As diuretic agents, chlorthalidone, metolazone, cyclopenthiiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, indapamide, tripamide, mefruside, azosemide, 5 etacrynic acid, torasemide, piretanide, furosemide, bumetanide, meticrane, potassium canrenoate, spironolactone, triamterene, aminophylline, cicletanine hydrochloride, LLU- α , PNU-80873A, isosorbide, D-mannitol, D-sorbitol, fructose, glycerin, acetazolamide, methazolamide, FR-179544, OPC-31260, lixivaptan, 10 conivaptan hydrochloride or the like are illustrated. Diuretic drugs are preferably used for diabetic complications, hypertension, congestive heart failure or edema, and more preferably for hypertension, congestive heart failure or edema because of reducing blood pressure or improving edema by 15 increasing urinary excretion.

As calcium antagonists, aranidipine, efonidipine hydrochloride, nicardipine hydrochloride, barnidipine hydrochloride, benidipine hydrochloride, manidipine hydrochloride, cilnidipine, nisoldipine, nitrendipine, 20 nifedipine, nilvadipine, felodipine, amlodipine besilate, pranidipine, lercanidipine hydrochloride, isradipine, elgodipine, azelnidipine, lacidipine, vatanidipine hydrochloride, lemildipine, diltiazem hydrochloride, clentiazem maleate, verapamil hydrochloride, S-verapamil, 25 fasudil hydrochloride, bepridil hydrochloride, gallopamil hydrochloride or the like are illustrated; as vasodilating antihypertensive agents, indapamide, todralazine hydrochloride,

hydralazine hydrochloride, cadralazine, budralazine or the like are illustrated; as sympathetic blocking agents, amosulalol hydrochloride, terazosin hydrochloride, bunazosin hydrochloride, prazosin hydrochloride, doxazosin mesylate, 5 propranolol hydrochloride, atenolol, metoprolol tartrate, carvedilol, nipradilol, celiprolol hydrochloride, nebivolol, betaxolol hydrochloride, pindolol, tertatolol hydrochloride, bevantolol hydrochloride, timolol maleate, carteolol hydrochloride, bisoprolol hemifumarate, bopindolol malonate, 10 nipradilol, penbutolol sulfate, acebutolol hydrochloride, tilisolol hydrochloride, nadolol, urapidil, indoramin or the like are illustrated; as centrally acting antihypertensive agents, reserpine or the like are illustrated; and as α_2 -adrenoceptor agonists, clonidine hydrochloride, 15 methyldopa, CHF-1035, guanabenz acetate, guanfacine hydrochloride, moxonidine, lofexidine, talipexole hydrochloride or the like are illustrated. These drugs are preferably used for hypertension.

As antiplatelets agents, ticlopidine hydrochloride, 20 dipyridamole, cilostazol, ethyl icosapentate, sarpogrelate hydrochloride, dilazep dihydrochloride, trapidil, beraprost sodium, aspirin or the like are illustrated. Antiplatelets agents are preferably used for atherosclerosis or congestive heart failure.

25 As uric acid synthesis inhibitors, allopurinol, oxypurinol or the like are illustrated; as uricosuric agents, benzbromarone, probenecid or the like are illustrated; and as

urinary alkalinizers, sodium hydrogen carbonate, potassium citrate, sodium citrate or the like are illustrated. These drugs are preferably used for hyperuricemia or gout.

In case of uses in combination with drugs other than SGLT2 inhibitors, for example, in the use for diabetes, the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitors, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist and an appetite suppressant is preferable; the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitors, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase

inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue and an amylin agonist is more preferable; and the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor and an insulin or insulin analogue is most preferable. Similarly, in the use for diabetic complications, the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, glycogen synthase kinase-3 inhibitors, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an N-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth

factor-I, platelet-derived growth factor, a platelet derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an
5 angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist and a diuretic agent is preferable; and the combination with at least one member of the group consisting
10 of an aldose reductase inhibitor, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor and an angiotensin II receptor antagonist is more preferable.
Furthermore, in the use for obesity, the combination with at least one member of the group consisting of an insulin sensitivity
15 enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine
20 phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like
25 peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, a β_3 -adrenoceptor agonist and an appetite suppressant is preferable; and the combination

with at least one member of the group consisting of a SGLT2 inhibitor, a β_3 -adrenoceptor agonist and an appetite suppressant is more preferable.

When the pharmaceutical compositions of the present invention are employed in the practical treatment, various dosage forms are used depending on their uses. As examples of the dosage forms, powders, granules, fine granules, dry sirups, tablets, capsules, injections, solutions, ointments, suppositories, poultices and the like are illustrated, which are orally or parenterally administered. The pharmaceutical compositions of the present invention also include sustained release formulation including gastrointestinal mucoadhesive formulation (e.g., International publications Nos. WO99/10010, WO99/26606, and Japanese patent publication No. 2001-2567).

These pharmaceutical compositions can be prepared by admixing with or by diluting and dissolving with an appropriate pharmaceutical additive such as excipients, disintegrators, binders, lubricants, diluents, buffers, isotonicities, antiseptics, moistening agents, emulsifiers, dispersing agents, stabilizing agents, dissolving aids and the like, and formulating the mixture in accordance with conventional methods. In case of the uses of the compound of the present invention in combination with the drug(s) other than SGLT1 inhibitors, they can be prepared by formulating each active ingredient together or individually.

When the pharmaceutical compositions of the present invention are employed in the practical treatment, the dosage of a compound represented by the above general formula (I), a

pharmaceutically acceptable salt thereof or a prodrug thereof as the active ingredient is appropriately decided depending on the age, sex, body weight and degree of symptoms and treatment of each patient, which is approximately within the range of from 5 0.1 to 1,000mg per day per adult human in the case of oral administration and approximately within the range of from 0.01 to 300mg per day per adult human in the case of parenteral administration, and the daily dose can be divided into one to several doses per day and administered suitably. Also, in case 10 of the uses of the compound of the present invention in combination with the drug(s) other than SGLT1 inhibitors, the dosage of the compound of the present invention can be decreased, depending on the dosage of the drug(s) other than SGLT1 inhibitors.

15 Examples

The present invention is further illustrated in more detail by way of the following Reference Examples, Examples and Test Examples. However, the present invention is not limited thereto.

20

Reference Example 1

2-Amino-2-methylpropionamide

To a solution of 2-benzyloxycarbonylamino-2-methylpropionic acid (1 g) in *N,N*-dimethylformamide (10 mL) were added 25 1-hydroxybenzotriazole (0.63 g), 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (1.21 g), triethylamine (1.76 mL) and 28% aqueous ammonia solution (2 mL), and the mixture

was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with 0.5 mol/L hydrochloric acid, water, 1 mol/L aqueous sodium hydroxide solution, water and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give 2-benzyloxycarbonylamino-2-methylpropionamide (0.26 g). This material was dissolved in methanol (5 mL). To the solution was added 10% palladium-carbon powder (30 mg), and the mixture was stirred under a hydrogen atmosphere for 3 hours. The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure to give the title compound (0.11 g).

^1H -NMR (DMSO- d_6) δ ppm:

1.15 (6H, s), 1.9 (2H, brs), 6.83 (1H, brs), 7.26 (1H, brs)

Reference Example 2

4-[(4-Bromophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

To a suspension of sodium hydride (60%, 3.85 g) in tetrahydrofuran (250 mL) was added ethyl 4-methyl-3-oxopentanoate (15.2 g), and the mixture was stirred at 0°C for 10 minutes. To the reaction mixture was added a solution of 4-bromobenzyl bromide (20 g) in tetrahydrofuran (100 mL), and the mixture was stirred at room temperature overnight. To the reaction mixture was added water, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over

anhydrous sodium sulfate, and the solvent was removed under reduced pressure. To a solution of the residue in toluene (10 mL) was added hydrazine monohydrate (8.01 g), and the mixture was stirred at 100°C overnight. After cooling the reaction mixture to room temperature, the solvent was removed under reduced pressure. To the residue was added ethyl acetate (20 mL), and the mixture was stirred at room temperature for 2 hours. The precipitated crystals were collected by filtration. The collected crystals were washed with water and *n*-hexane successively, and dried at 40°C under reduced pressure to give the title compound (11.5 g).

¹H-NMR (DMSO-d₆) δ ppm:

1.07 (6H, d, J=7.1Hz), 2.75-2.9 (1H, m), 3.55 (2H, s), 7.05-7.15 (2H, m), 7.35-7.45 (2H, m)

Reference Example 3

3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole

To a suspension of 4-[(4-bromophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one (5.0 g) in dichloromethane (50 mL) were added acetobromo-α-D-glucose (7.0 g), benzyltri(*n*-butyl)ammonium chloride (5.3 g) and 5 mol/L aqueous sodium hydroxide solution (8.5 mL), and the mixture was stirred at room temperature overnight. The organic layer was separated, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/1) to give the title compound (4.12

g).

^1H -NMR (CDCl_3) δ ppm:

1.1-1.25 (6H, m), 1.86 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06
(3H, s), 2.85-2.95 (1H, m), 3.58 (1H, d, $J=16.2\text{Hz}$), 3.64 (1H,
5 d, $J=16.2\text{Hz}$), 3.8-3.95 (1H, m), 4.15 (1H, dd, $J=12.4\text{Hz}$, 2.2Hz),
4.32 (1H, dd, $J=12.4\text{Hz}$, 3.9Hz), 5.15-5.35 (3H, m), 5.53 (1H,
d, $J=7.5\text{Hz}$), 6.95-7.05 (2H, m), 7.3-7.4 (2H, m)

Reference Example 4

10 3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-((4-
[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-
pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-
15 pyrazole (3.0 g) and 3-butenic acid (1.0 g) in acetonitrile (15 mL) were added triethylamine (2.4 g), palladium acetate (II) (0.11 g) and tris(2-methylphenyl)phosphine (0.29 g), and the mixture was refluxed overnight under shading the light. The solvent was removed under reduced pressure, and the residue was
20 purified by column chromatography on silica gel (eluent: ethyl acetate - dichloromethane/methanol = 10/1) to give the title compound (1.74 g).

^1H -NMR (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.84 (3H, s), 2.01 (3H, s), 2.02 (3H, s), 2.05
25 (3H, s), 2.8-2.95 (1H, m), 3.2-3.3 (2H, m), 3.59 (1H, d, $J=16.0\text{Hz}$),
3.66 (1H, d, $J=16.0\text{Hz}$), 3.8-3.9 (1H, m), 4.18 (1H, dd, $J=12.3\text{Hz}$,
1.8Hz), 4.33 (1H, dd, $J=12.3\text{Hz}$, 3.8Hz), 5.15-5.35 (3H, m),

5.4-5.5 (1H, m), 6.2-6.3 (1H, m), 6.4-6.5 (1H, m), 7.0-7.1 (2H, m), 7.2-7.3 (2H, m)

Reference Example 5

5 3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-2-carboxyvinyl]phenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using acrylic acid instead of 3-butenic acid.

10 ^1H -NMR (CDCl_3) δ ppm:

1.19 (6H, d, $J=7.3\text{Hz}$), 1.84 (3H, s), 2.01 (3H, s), 2.04 (3H, s), 2.05 (3H, s), 2.85-3.0 (1H, m), 3.66 (1H, d, $J=16.2\text{Hz}$), 3.73 (1H, d, $J=16.2\text{Hz}$), 3.85-3.95 (1H, m), 4.2 (1H, dd, $J=12.6\text{Hz}$, 2.2Hz), 4.34 (1H, dd, $J=12.6\text{Hz}$, 4.1Hz), 5.15-5.35 (3H, m), 5.5
15 (1H, d, $J=7.7\text{Hz}$), 6.4 (1H, d, $J=15.7\text{Hz}$), 7.15-7.2 (2H, m), 7.4-7.5 (2H, m), 7.71 (1H, d, $J=15.7\text{Hz}$)

Example 1

20 4-({4-[3-(Carbamoylmethylcarbamoyl)propyl]phenyl)methyl}-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl}-methyl)-5-isopropyl-1H-pyrazole (0.34 g) in *N,N*-dimethylformamide (1 mL) were added glycineamide hydrochloride (0.12 g),
25 1-hydroxybenzotriazole (0.09 g), 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (0.15 g) and triethylamine (0.27 g), and the mixture was stirred at room temperature

overnight. The insoluble material was removed by filtration. To the filtrate was added 5 mol/L aqueous sodium hydroxide solution (0.5 mL), and the mixture was stirred at room temperature for 1 hour. The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ m, 120 Å, 20 x 50 mm, flow rate 30 mL/minute linear gradient, water/ acetonitrile = 90/10 - 10/90) to give 4-({4-[(1E)-3-(carbamoyl-methylcarbamoyl)prop-1-enyl]phenyl)methyl}-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole (0.03 g). This material was dissolved in methanol (1 mL). To the solution was added 10% palladium-carbon powder (0.01 g), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (0.02 g).

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.85-1.95 (2H, m), 2.25 (2H, t, J=7.6Hz), 2.6 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.25-3.4 (4H, m), 3.6-3.9 (6H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 2

4-([4-(3-Carbamoylpropyl)phenyl]methyl)-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using ammonium chloride instead of glycinamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.8-1.95 (2H, m), 2.19 (2H, t, J=7.6Hz), 2.58
(2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.3-3.45 (4H, m), 3.6-3.8
(3H, m), 3.8-3.9 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

5

Example 3

4-({4-[3-(2-Carbamoylethylcarbamoyl)propyl]phenyl}methyl)-
3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
10 that described in Example 1 using 3-aminopropionamide instead
of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.8-1.95 (2H, m), 2.15 (2H, t, J=7.3Hz), 2.4
(2H, t, J=6.7Hz), 2.56 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m),
15 3.25-3.45 (6H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15
(4H, m)

Example 4

4-({4-[3-(2-Aminoethylcarbamoyl)propyl]phenyl}methyl)-3-(β-
20 D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
that described in Example 1 using N-benzyloxycarbonyl-1,2-
diaminoethane hydrochloride instead of glycineamide hydro-
chloride.

25 ¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.85-1.95 (2H, m), 2.19 (2H, t, J=7.6Hz), 2.58
(2H, t, J=7.5Hz), 2.8 (2H, t, J=6.1Hz), 2.85-2.95 (1H, m), 3.2-3.4

(6H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 5

4-({4-[3-(3-Aminopropylcarbamoyl)propyl]phenyl}methyl)-3-
 5 (β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N*-benzyloxycarbonyl-1,3-diaminopropane hydrochloride instead of glycine hydrochloride.

10 $^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.6-1.7 (2H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, $J=7.7\text{Hz}$), 2.57 (2H, t, $J=7.5\text{Hz}$), 2.68 (2H, t, $J=7.1\text{Hz}$), 2.85-2.95 (1H, m), 3.22 (2H, t, $J=6.7\text{Hz}$), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

15

Example 6

4-({4-[3-(4-Aminobutylcarbamoyl)propyl]phenyl}methyl)-3-(β -
D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N*-benzyloxycarbonyl-1,4-diaminobutane hydrochloride instead of glycine hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.45-1.65 (4H, m), 1.8-1.95 (2H, m), 2.16 (2H, t, $J=7.5\text{Hz}$), 2.57 (2H, t, $J=7.7\text{Hz}$), 2.83 (2H, t, $J=7.0\text{Hz}$), 2.85-3.0 (1H, m), 3.17 (2H, t, $J=6.6\text{Hz}$), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

25

Example 7

4-[(4-{3-[(S)-1-Carbamoyl-2-(4-hydroxyphenyl)ethyl-
 carbamoyl]propyl}phenyl)methyl]-3-(β-D-glucopyranosyloxy)-
 5 5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using L-tyrosine amide hydrochloride instead of glycine amide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

10 1.1-1.2 (6H, m), 1.7-1.8 (2H, m), 2.1-2.2 (2H, m), 2.44 (2H, t, J=7.5Hz), 2.76 (1H, dd, J=13.9Hz, 9.3Hz), 2.85-2.95 (1H, m), 3.04 (1H, dd, J=13.9Hz, 5.5Hz), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 4.57 (1H, dd, J=9.3Hz, 5.5Hz), 5.0-5.1 (1H, m), 6.65-6.75 (2H, m), 6.95-7.15 (6H, m)

15

Example 8

4-[[4-(3-Benzylcarbamoylpropyl)phenyl]methyl]-3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

20 The title compound was prepared in a similar manner to that described in Example 1 using benzylamine instead of glycine amide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.85-1.95 (2H, m), 2.22 (2H, t, J=7.5Hz), 2.57 (2H, t, J=7.5Hz), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 4.33 (2H, s), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m), 7.15-7.45 (5H, m)

25

Example 9

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-([4-(3-phenethyl-carbamoylpropyl)phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using phenethylamine instead of glycineamide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.75-1.9 (2H, m), 2.12 (2H, t, $J=7.5\text{Hz}$), 2.51 (2H, t, $J=7.7\text{Hz}$), 2.77 (2H, t, $J=7.5\text{Hz}$), 2.8-2.95 (1H, m), 3.25-3.45 (6H, m), 3.6-3.9 (4H, m), 5.0-5.15 (1H, m), 6.95-7.05 (2H, m), 7.05-7.3 (7H, m)

Example 10

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-([4-[3-(3-pyridyl-methylcarbamoyl)propyl]phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-picolylamine instead of glycineamide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.85-1.95 (2H, m), 2.22 (2H, t, $J=7.6\text{Hz}$), 2.56 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 4.37 (2H, s), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m), 7.35-7.45 (1H, m), 7.7-7.8 (1H, m), 8.4-8.45 (1H, m), 8.45-8.5 (1H, m)

25 Example 11

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-([4-{3-[2-(2-pyridyl)ethylcarbamoyl]propyl}phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 2-(2-aminoethyl)pyridine instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

5 1.1-1.15 (6H, m), 1.75-1.9 (2H, m), 2.11 (2H, t, J=7.5Hz), 2.51 (2H, t, J=7.6Hz), 2.85-3.0 (3H, m), 3.25-3.45 (4H, m), 3.52 (2H, t, J=6.9Hz), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 6.95-7.15 (4H, m), 7.2-7.35 (2H, m), 7.7-7.8 (1H, m), 8.4-8.5 (1H, m)

10 Example 12

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-[(4-{3-[2-(dimethylamino)ethylcarbamoyl]propyl}phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N,N*-dimethylethylenediamine instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.6Hz), 2.25 (6H, s), 2.42 (2H, t, J=6.9Hz), 2.57 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.25-3.4 (6H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 13

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-[(4-{3-[2-(morpholin-4-yl)ethylcarbamoyl]propyl}phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Example 1 using 4-(2-aminoethyl)morpholine instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.6Hz),
 5 2.4-2.55 (6H, m), 2.58 (2H, t, J=7.6Hz), 2.85-2.95 (1H, m),
 3.25-3.45 (6H, m), 3.6-3.9 (8H, m), 5.0-5.1 (1H, m), 7.0-7.15
 (4H, m)

Example 14

10 3-(β-D-Glucopyranosyloxy)-4-([4-(3-{2-[bis(2-hydroxyethyl)-
 amino]ethylcarbamoyl}propyl)phenyl]methyl)-5-isopropyl-1H-
 pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N,N*-bis(2-hydroxyethyl)-
 15 ethylenediamine instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.8-1.95 (2H, m), 2.18 (2H, t, J=7.5Hz), 2.5-2.7
 (8H, m), 2.85-2.95 (1H, m), 3.25 (2H, t, J=6.4Hz), 3.3-3.4 (4H,
 m), 3.5-3.9 (8H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

20

Example 15

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-([4-(3-{3-[bis(2-
 hydroxyethyl)amino]propylcarbamoyl}propyl)phenyl]methyl)-
 1H-pyrazole

25 The title compound was prepared in a similar manner to that described in Example 1 using *N,N*-bis(2-hydroxyethyl)-1,3-diaminopropane instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.6-1.75 (2H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.5Hz), 2.5-2.75 (8H, m), 2.8-2.95 (1H, m), 3.21 (2H, t, J=6.7Hz), 3.25-3.45 (4H, m), 3.5-3.9 (8H, m), 5.0-5.15 (1H, m),
5 7.0-7.2 (4H, m)

Example 16

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-[(4-{3-[3-(dimethylamino)propylcarbamoyl]propyl}phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N,N*-dimethyl-1,3-diaminopropane instead of glycine hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

15 1.1-1.15 (6H, m), 1.6-1.75 (2H, m), 1.8-1.95 (2H, m), 2.16 (2H, t, J=7.5Hz), 2.22 (6H, s), 2.3-2.35 (2H, m), 2.57 (2H, t, J=7.6Hz), 2.85-2.95 (1H, m), 3.17 (2H, t, J=6.9Hz), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

20 Example 17

3-(β-D-Glucopyranosyloxy)-4-[(4-{3-[2-(imidazol-1-yl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 1-(2-aminoethyl)imidazole
25 instead of glycine hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.8-2.0 (4H, m), 2.17 (2H, t, J=7.6Hz), 2.57

(2H, t, J=7.7Hz), 2.85-2.95 (1H, m), 3.14 (2H, t, J=6.8Hz),
 3.3-3.45 (4H, m), 3.6-3.9 (4H, m), 4.03 (2H, t, J=7.0Hz), 5.0-5.1
 (1H, m), 6.9-7.0 (1H, m), 7.0-7.15 (5H, m), 7.6-7.7 (1H, m)

5 Example 18

3-(β-D-Glucopyranosyloxy)-4-({4-[3-(2-hydroxyethyl)-
carbamoylpropyl]phenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Example 1 using 2-aminoethanol instead of
 10 glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.8-1.95 (2H, m), 2.18 (2H, t, J=7.5Hz), 2.57
 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.27 (2H, t, J=5.8Hz),
 3.3-3.5 (4H, m), 3.57 (2H, t, J=5.9Hz), 3.6-3.9 (4H, m), 5.0-5.1
 15 (1H, m), 7.0-7.15 (4H, m)

Example 19

3-(β-D-Glucopyranosyloxy)-4-[(4-{3-[2-hydroxy-1-(hydroxy-
methyl)ethyl]carbamoylpropyl}phenyl)methyl]-5-isopropyl-1H-
 20 pyrazole

The title compound was prepared in a similar manner to
 that described in Example 1 using 2-amino-1,3-propanediol
 instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

25 1.05-1.2 (6H, m), 1.8-1.95 (2H, m), 2.21 (2H, t, J=7.6Hz), 2.58
 (2H, t, J=7.6Hz), 2.85-2.95 (1H, m), 3.3-3.45 (4H, m), 3.55-3.95
 (9H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 20

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[2-hydroxy-1-hydroxy-
methyl-1-(methyl)ethyl]carbamoylpropyl}phenyl)methyl]-5-
5 isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 2-amino-2-methyl-1,3-propanediol instead of glycineamide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

10 1.1-1.15 (6H, m), 1.22 (3H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, $J=7.7\text{Hz}$), 2.58 (2H, t, $J=7.5\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.55-3.9 (8H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 21

15 3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[2-hydroxy-1,1-bis-(hydroxymethyl)ethyl]carbamoyl}propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using tris(hydroxymethyl)amino-
20 methane instead of glycineamide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.8-1.95 (2H, m), 2.23 (2H, t, $J=7.5\text{Hz}$), 2.59 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (10H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

25

Example 22

4-[(4-{3-[(S)-1-(Carbamoyl)ethyl]carbamoyl}propyl}phenyl)-

methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using L-alanine amide hydrochloride instead of glycine amide hydrochloride.

5 $^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.32 (3H, d, $J=7.2\text{Hz}$), 1.8-1.95 (2H, m),
2.15-2.25 (2H, m), 2.58 (2H, t, $J=7.5\text{Hz}$), 2.85-2.95 (1H, m),
3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 4.32 (1H, q, $J=7.2\text{Hz}$), 5.0-5.1
(1H, m), 7.0-7.15 (4H, m)

10

Example 23

4-[(4-{3-[(S)-1-Carbamoyl-2-hydroxyethylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

15 The title compound was prepared in a similar manner to that described in Example 1 using L-serine amide hydrochloride instead of glycine amide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.85-1.95 (2H, m), 2.2-2.3 (2H, m), 2.59 (2H,
20 t, $J=7.4\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (6H,
m), 4.4 (1H, t, $J=5.2\text{Hz}$), 5.0-5.1 (1H, m), 7.05-7.15 (4H, m)

Example 24

4-[(4-{3-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Example 1 using 2-amino-2-methylpropionamide instead of glycineamide hydrochloride.

^1H -NMR (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.44 (6H, s), 1.8-1.95 (2H, m), 2.18 (2H, t, $J=7.5\text{Hz}$), 2.58 (2H, t, $J=7.4\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 25

4-[(4-{3-[2-(Acetylamino)ethylcarbamoyl]propyl}phenyl)-methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using *N*-acetyleneethylenediamine instead of glycineamide hydrochloride.

^1H -NMR (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.8-1.95 (5H, m), 2.16 (2H, t, $J=7.6\text{Hz}$), 2.57 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.2-3.45 (8H, m), 3.6-3.9 (4H, m), 5.0-5.15 (1H, m), 7.0-7.15 (4H, m)

Example 26

4-[(4-{(1E)-3-Carbamoylprop-1-enyl}phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{(1E)-3-carboxyprop-1-enyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole (32 mg) in *N,N*-dimethylformamide (1 mL) were added ammonium chloride (8 mg), 1-hydroxybenzotriazole (9 mg), 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (15 mg) and triethylamine (21

mg), and the mixture was stirred at room temperature overnight. The insoluble material was removed by filtration, 5 mol/L aqueous sodium hydroxide solution (0.5 mL) was added to the filtrate, and the resulting mixture was stirred at room temperature for 1 hour. The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ m, 120 Å, 20 x 50mm, flow rate 30 mL/minute linear gradient, water/ acetonitrile = 90/10 - 10/90) to give the title compound (7 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 2.8-2.95 (1H, m), 3.05-3.15 (2H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.15 (1H, m), 6.15-6.35 (1H, m), 6.48 (1H, d, J=15.6Hz), 7.1-7.2 (2H, m), 7.2-7.3 (2H, m)

Example 27

3-(β -D-Glucopyranosyloxy)-4-[(4-[(1E)-2-[2-hydroxy-1-hydroxymethyl-1-(methyl)ethylcarbamoyl]vinyl]phenyl)-methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 26 using 2-amino-2-methyl-1,3-propanediol and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-[(1E)-2-carboxyvinyl]phenyl)methyl]-5-isopropyl-1H-pyrazole instead of ammonium chloride and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl]-5-isopropyl-1H-pyrazole, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.3 (3H, s), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (8H, m), 5.05-5.15 (1H, m), 6.64 (1H, d, J=15.9Hz), 7.2-7.3 (2H, m), 7.4-7.5 (3H, m)

5 Example 28

3-(β -D-Glucopyranosyloxy)-4-[(4-((1E)-2-[2-hydroxy-1,1-bis-(hydroxymethyl)ethylcarbamoyl]vinyl)phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 26 using tris(hydroxymethyl)-aminomethane and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-((4-[(1E)-2-carboxyvinyl]phenyl)methyl)-5-isopropyl-1H-pyrazole instead of ammonium chloride and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-((4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.67 (1H, dd, J=12.1Hz, 5.3Hz), 3.7-3.9 (9H, m), 5.05-5.15 (1H, m), 6.69 (1H, d, J=15.7Hz), 7.24 (2H, d, J=8.3Hz), 7.45 (2H, d, J=8.3Hz), 7.48 (1H, d, J=15.7Hz)

Example 29

4-[(4-((1E)-2-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]vinyl)phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Example 26 using 2-amino-2-methylpropionamide and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-((4-[(1E)-2-carboxyvinyl]phenyl)methyl)-5-isopropyl-1H-pyrazole instead of ammonium chloride and 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-((4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.52 (6H, s), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.67 (1H, dd, $J=11.9\text{Hz}$, 5.1Hz), 3.7-3.9 (3H, m), 5.0-5.15 (1H, m), 6.6 (1H, d, $J=15.8\text{Hz}$), 7.24 (2H, d, $J=8.4\text{Hz}$), 7.4-7.5 (3H, m)

Example 30

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[1-(2-hydroxyethyl)-carbamoyl]-1-(methyl)ethylcarbamoyl}propyl)phenyl)methyl]-5-isopropyl-1H-pyrazole

To a solution of 2-benzyloxycarbonylamino-2-methylpropionic acid (0.5 g) in dichloromethane (5 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.61 g), 1-hydroxybenzotriazole (0.43 g) and 2-aminoethanol (1.16 g), and the mixture was stirred at room temperature overnight. To the reaction mixture was added water, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was dissolved in methanol (5 mL). To

the solution was added 10% palladium-carbon powder (0.10 g), and the mixture was stirred at room temperature under a hydrogen atmosphere for 4 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under
5 reduced pressure to give 2-(2-amino-2-methylpropionyl-amino)ethanol (0.11 g). To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole (70 mg) in *N,N*-dimethylformamide (0.5 mL) were added 1-ethyl-3-(3-di-
10 methylaminopropyl)carbodiimide hydrochloride (32 mg), 1-hydroxybenzotriazole (23 mg) and 2-(2-amino-2-methylpropionylamino)ethanol (0.11 g), and the mixture was stirred at room temperature overnight. The insoluble material was removed by filtration, 5 mol/L aqueous sodium hydroxide solution
15 (0.25 mL) was added to the filtrate, and the resulting mixture was stirred at room temperature for 1 hour. To the mixture was added acetic acid (0.09 mL), and the mixture was diluted with water (1 mL). The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column
20 chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å, 20 x 50mm, flow rate 30 mL/minute linear gradient, water/methanol = 90/10 - 10/90) to give 3-(β -D-glucopyranosyloxy)-4-(4-{(1E)-3-[1-(2-hydroxyethylcarbamoyl)-1-methylethylcarbamoyl]prop-1-enyl}phenyl)methyl)-5-isopropyl-1H-pyrazole (14 mg). This
25 material was dissolved in methanol (0.5 mL). To the solution was added 10% palladium-carbon powder (7 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for

2 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (11 mg).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

5 1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, $J=7.6\text{Hz}$), 2.58 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (6H, m), 3.56 (2H, t, $J=5.8\text{Hz}$), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

10 Example 31

4-[(4-{3-[1-Carbamoylmethylcarbamoyl-1-(methyl)ethyl-carbamoyl]propyl}phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 30 using glycineamide hydrochloride and triethylamine instead of 2-aminoethanol.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

15 1.1-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.22 (2H, t, $J=7.5\text{Hz}$), 2.58 (2H, t, $J=7.7\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (6H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Reference Example 6

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole

25 The title compound was prepared in a similar manner to that described in Reference Example 3 using acetobromo- α -D-galactose instead of acetobromo- α -D-glucose.

^1H -NMR (CDCl_3) δ ppm:

1.17 (6H, d, $J=7.3\text{Hz}$), 1.88 (3H, s), 1.99 (3H, s), 2.02 (3H, s), 2.17 (3H, s), 2.8-2.95 (1H, m), 3.59 (1H, d, $J=16.0\text{Hz}$), 3.66 (1H, d, $J=16.0\text{Hz}$), 4.05-4.25 (3H, m), 5.1 (1H, dd, $J=10.4\text{Hz}$, 3.5Hz), 5.35-5.45 (2H, m), 5.57 (1H, d, $J=8.2\text{Hz}$), 6.95-7.05 (2H, m), 7.3-7.4 (2H, m)

Reference Example 7

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-
10 [(1E)-3-carboxyprop-1-enyl]phenyl)methyl}-5-isopropyl-1H-
pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-bromophenyl)-
15 methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole.

^1H -NMR (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.83 (3H, s), 1.99 (3H, s), 2.00 (3H, s), 2.17
20 (3H, s), 2.8-2.95 (1H, m), 3.26 (2H, d, $J=6.9\text{Hz}$), 3.6 (1H, d, $J=16.2\text{Hz}$), 3.69 (1H, d, $J=16.2\text{Hz}$), 4.05-4.3 (3H, m), 5.1 (1H, dd, $J=10.1\text{Hz}$, 3.5Hz), 5.3-5.5 (3H, m), 6.2-6.3 (1H, m), 6.45 (1H, d, $J=15.9\text{Hz}$), 7.0-7.1 (2H, m), 7.2-7.3 (2H, m), 10.0-12.0 (1H, br)

25

Example 32

3-(β -D-Galactopyranosyloxy)-4-[(4-{3-[2-hydroxy-1-hydroxy-

methyl-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-
isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methyl-1,3-propanediol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide hydrochloride, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.22 (3H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, J=7.4Hz), 2.58 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.52 (1H, dd, J=9.8Hz, 3.6Hz), 3.55-3.8 (10H, m), 3.85-3.9 (1H, m), 5.05-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 33

4-[(4-{3-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-
pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide

hydrochloride, respectively.

^1H -NMR (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.44 (6H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, $J=7.6\text{Hz}$), 2.57 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.52 (1H, dd, $J=9.7\text{Hz}$, 3.4Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.85-3.9 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 34

4-({4-[3-(2-Aminoethylsulfamoyl)propyl]phenyl)methyl}-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

A suspension of sodium allylsulfonate (2.0 g) in thionyl chloride (10.4 mL) was heated at 70°C and stirred for 1.5 days. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure. The obtained residue was dissolved in dry tetrahydrofuran (10 mL), and the solvent was removed under reduced pressure. The obtained residue was again dissolved in dry tetrahydrofuran (10 mL), and the solvent was removed under reduced pressure to give allylsulfonyl chloride (1.26 g). To a suspension of *N*-benzyloxycarbonyl-1,2-diaminoethane hydrochloride (0.82 g) and triethylamine (0.63 g) in dichloromethane (5 mL) was added allylsulfonyl chloride (0.25 g) at room temperature, and the mixture was stirred overnight. The reaction was quenched by addition of water, and the organic layer of the resulting mixture was separated. The organic layer was washed with 1 mol/L hydrochloric acid, a saturated aqueous sodium hydrogen carbonate solution and brine successively, and dried over anhydrous sodium

sulfate. The solvent was removed under reduced pressure to give *N*-(2-benzyloxycarbonylaminoethyl)allylsulfonamide (82 mg). This material was dissolved in acetonitrile (0.25 mL). To the solution were added 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1*H*-pyrazole (70 mg), triethylamine (57 mg), palladium acetate (II) (3 mg) and tris(2-methylphenyl)phosphine (7 mg), and the mixture was refluxed overnight under shading the light. The solvent was removed under reduced pressure, and the residue was dissolved in methanol (0.5 mL). To this solution was added 5 mol/L aqueous sodium hydroxide solution (0.25 mL), and the mixture was stirred at room temperature for 1 hour. The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å, 20 x 50 mm, flow rate 30 mL/minute linear gradient, water/methanol = 90/10 - 10/90) to give 4-({4-[(1*E*)-3-(2-benzyloxycarbonylaminoethylsulfamoyl)-prop-1-enyl]phenyl)methyl}-3-(β -D-glucopyranosyloxy)-5-isopropyl-1*H*-pyrazole (14 mg). This material was dissolved in methanol (0.5 mL). To the solution was added 10% palladium-carbon powder (5 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (10 mg).

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 2.0-2.1 (2H, m), 2.65-2.75 (4H, m), 2.85-2.95

(1H, m), 2.95-3.05 (4H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m),
5.0-5.1 (1H, m), 7.05-7.2 (4H, m)

Example 35

5 4-[(4-{3-[1-Carbamoyl-1-(methyl)ethylsulfamoyl]propyl}-phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a suspension of benzyl 2-amino-2-methylpropionate *p*-toluenesulfonic acid salt (Tetrahedron, 1991, Vol.47, No.2,
10 pp.259-270; 3.9 g) and triethylamine (2.7 g) in dichloromethane (15 mL) was added allylsulfonyl chloride (0.75 g) at room temperature, and the mixture was stirred overnight. The reaction was quenched by addition of water, and the organic layer of the resulting mixture was separated. The organic layer was
15 washed with 1 mol/L hydrochloric acid, a saturated aqueous sodium hydrogen carbonate solution and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give *N*-[1-benzyloxycarbonyl-1-(methyl)-ethyl] allylsulfonamide (0.48 g). To a solution of 3-(2,3,4,6-
20 tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)-methyl]-5-isopropyl-1H-pyrazole (0.40 g), *N*-[1-benzyloxycarbonyl-1-(methyl)ethyl] allylsulfonamide (0.48 g) in acetonitrile (1 mL) were added triethylamine (0.32 g), palladium acetate (II) (14 mg) and tris(2-methylphenyl)phosphine (39 mg),
25 and the mixture was refluxed overnight under shading the light. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent:

n-hexane/ethyl acetate = 1/1 - ethyl acetate) to give
3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-
{(1*E*)-3-[1-benzyloxycarbonyl-1-(methyl)ethylsulfamoyl]prop-
1-enyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole (0.11 g).

- 5 This material was dissolved in methanol (1 mL). To the solution
was added 10% palladium-carbon powder (50 mg), and the mixture
was stirred at room temperature under a hydrogen atmosphere for
2 hours. The insoluble material was removed by filtration, and
the solvent of the filtrate was removed under reduced pressure
10 to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-
[(4-{3-[1-carboxy-1-(methyl)ethylsulfamoyl]propyl}phenyl)-
methyl]-5-isopropyl-1*H*-pyrazole (95 mg). To a solution of
3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-
[1-carboxy-1-(methyl)ethylsulfamoyl]propyl}phenyl)methyl]-
15 5-isopropyl-1*H*-pyrazole (50 mg) in *N,N*-dimethylformamide (0.5
mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (19 mg) and 1-hydroxybenzotriazole (13 mg). An
ammonia gas was bubbled into the mixture for about 2 minutes,
and the resulting mixture was stirred at room temperature
20 overnight. The insoluble material was removed by filtration.
To the filtrate was added 5 mol/L aqueous sodium hydroxide
solution (0.25 mL), and the mixture was stirred at room
temperature for 1 hour. To the reaction mixture was added acetic
acid (0.09 mL), and the mixture was diluted with water (1 mL).
25 The insoluble material was removed by filtration, and the
filtrate was purified by preparative reverse phase column
chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å,

20 x 50mm, flow rate 30 mL/minute linear gradient, water/methanol= 90/10 - 10/90) to give the title compound (14 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.43 (6H, s), 2.0-2.15 (2H, m), 2.7 (2H, t, J=7.4Hz), 2.8-2.95 (1H, m), 2.95-3.1 (2H, m), 3.25-3.45 (4H, m), 3.6-3.9 (4H, m), 5.0-5.15 (1H, m), 7.05-7.2 (4H, m)

Reference Example 8

Benzyl hydroxypivalate

10 To a suspension of hydroxypivalic acid (3 g) and potassium carbonate (3.9 g) in *N,N*-dimethylformamide (25 mL) was added benzyl bromide (2.9 mL), and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with diethyl ether.

15 The organic layer was washed with water twice and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure to give the title compound (4.7 g).

¹H-NMR (CDCl₃) δ ppm:

1.22 (6H, s), 2.33 (1H, t, J=6.7Hz), 3.58 (2H, d, J=6.7Hz), 5.15 (2H, s), 7.3-7.4 (5H, m)

Reference Example 9

4-(2-Benzoyloxycarbonyl-2-methylpropoxy)benzaldehyde

25 To a solution of 4-hydroxybenzaldehyde (2.7 g), benzyl hydroxypivalate (4.7 g) and triphenylphosphine (6.4 g) in tetrahydrofuran (22 mL) was added diethyl azodicarboxylate (40% toluene solution, 11 mL), and the mixture was stirred at room

temperature for 2 days. The reaction mixture was poured into water, and the resulting mixture was extracted with diethyl ether. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was removed under reduced
 5 pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 6/1 - 4/1) to give the title compound (0.97 g).

¹H-NMR (CDCl₃) δ ppm:

1.36 (6H, s), 4.07 (2H, s), 5.15 (2H, s), 6.9-7.0 (2H, m), 7.2-7.35
 10 (5H, m), 7.75-7.85 (2H, m), 9.89 (1H, s)

Reference Example 10

[4-(2-Benzoyloxycarbonyl-2-methylpropoxy)phenyl]methanol

To a solution of 4-(2-benzoyloxycarbonyl-2-methyl-
 15 propoxy)benzaldehyde (0.97 g) in tetrahydrofuran (20 mL) was added sodium borohydride (59 mg), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into 0.5 mol/L hydrochloric acid, and the resulting mixture was extracted with diethyl ether. The organic layer was washed with
 20 water and brine successively, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 6/1 - 3/2) to give the title compound (0.95 g).

25 ¹H-NMR (CDCl₃) δ ppm:

1.34 (6H, s), 1.51 (1H, t, J=5.9Hz), 3.99 (2H, s), 4.62 (2H, d, J=5.9Hz), 5.15 (2H, s), 6.8-6.9 (2H, m), 7.25-7.35 (7H, m)

Reference Example 11

4-[[4-(2-Benzylloxycarbonyl-2-methylpropoxy)phenyl]methyl]-
1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

5 To a solution of [4-(2-benzylloxycarbonyl-2-methyl-
propoxy)phenyl]methanol (0.95 g) in tetrahydrofuran (8 mL) were
added triethylamine (0.48 mL) and methanesulfonyl chloride (0.26
mL) under ice-cooling, and the mixture was stirred for 1 hour.
The insoluble material was removed by filtration. The obtained
10 solution of [4-(2-benzylloxycarbonyl-2-methylpropoxy)-
phenyl]methyl mesylate in tetrahydrofuran was added to a
suspension of sodium hydride (60%, 139 mg) and ethyl
4-methyl-3-oxopentanoate (0.52g) in tetrahydrofuran (15 mL),
and the mixture was heated for reflux for 15 hours. To the
15 reaction mixture was added 1 mol/L hydrochloric acid, and the
resulting mixture was extracted with diethyl ether. The organic
layer was washed with water and dried over anhydrous magnesium
sulfate. The solvent was removed under reduced pressure. To
a solution of the residue in ethanol (10 mL) was added hydrazine
20 monohydrate (0.16 mL), and the mixture was stirred at room
temperature for 2 days. The reaction mixture was concentrated
under reduced pressure, and the residue was purified by column
chromatography on silica gel (eluent: dichloromethane/methanol
= 30/1 - 20/1) to give the title compound (0.25 g).

25 $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.15 (6H, d, $J=6.9\text{Hz}$), 1.32 (6H, s), 2.85-2.95 (1H, m), 3.66
(2H, s), 3.94 (2H, s), 5.13 (2H, s), 6.7-6.8 (2H, m), 7.05-7.15

(2H, m), 7.2-7.35 (5H, m)

Reference Example 12

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methyl}-5-isopropyl-1H-pyrazole

To a solution of 4-{[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one (0.25 g), acetobromo- α -D-glucose (0.48 g) and benzyltri(n-butyl)ammonium chloride (0.18 g) in dichloromethane (5 mL) was added 5 mol/L aqueous sodium hydroxide solution (0.35 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was purified by column chromatography on aminopropylated silica gel (eluent: n-hexane/ethyl acetate = 1/1 - 1/3) to give the title compound (0.28 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.16 (6H, d, $J=7.1\text{Hz}$), 1.32 (6H, s), 1.86 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.85-2.95 (1H, m), 3.56 (1H, d, $J=16.0\text{Hz}$), 3.62 (1H, d, $J=16.0\text{Hz}$), 3.8-3.9 (1H, m), 3.92 (1H, d, $J=8.7\text{Hz}$), 3.94 (1H, d, $J=8.7\text{Hz}$), 4.15 (1H, dd, $J=12.5\text{Hz}$, 2.4Hz), 4.31 (1H, dd, $J=12.5\text{Hz}$, 4.2Hz), 5.13 (2H, s), 5.15-5.3 (3H, m), 5.55-5.65 (1H, m), 6.7-6.75 (2H, m), 6.95-7.05 (2H, m), 7.25-7.35 (5H, m)

Reference Example 13

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-carboxy-2-methylpropoxy)phenyl]methyl}-5-isopropyl-1H-

pyrazole

3-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-
 {[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methyl}-5-
 isopropyl-1*H*-pyrazole (0.28 g) was dissolved in methanol (6 mL).

5 To the solution was added 10% palladium-carbon powder (54 mg),
 and the mixture was stirred at room temperature under a hydrogen
 atmosphere overnight. The insoluble material was removed by
 filtration, and the solvent of the filtrate was removed under
 reduced pressure to give the title compound (0.25 g).

10 $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.16 (6H, d, $J=6.7\text{Hz}$), 1.33 (6H, s), 1.88 (3H, s), 2.01 (3H,
 s), 2.03 (3H, s), 2.05 (3H, s), 2.85-3.0 (1H, m), 3.54 (1H, d,
 $J=15.8\text{Hz}$), 3.6 (1H, d, $J=15.8\text{Hz}$), 3.8-3.9 (1H, m), 3.91 (1H,
 d, $J=8.8\text{Hz}$), 3.93 (1H, d, $J=8.8\text{Hz}$), 4.15 (1H, dd, $J=12.5\text{Hz}$, 2.0Hz),
 15 4.32 (1H, dd, $J=12.5\text{H}$, 4.0Hz), 5.15-5.3 (3H, m), 5.4-5.45 (1H,
 m), 6.7-6.8 (2H, m), 6.95-7.05 (2H, m)

Example 36

3-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-
 20 [(*S*)-1-(carbamoyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)-
 methyl]-5-isopropyl-1*H*-pyrazole

To a solution of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-gluco-
 pyranosyloxy)-4-[[4-(2-carboxy-2-methylpropoxy)phenyl]-
 methyl]-5-isopropyl-1*H*-pyrazole (0.13 g) in *N,N*-dimethyl-
 25 formamide (2 mL) were added L-alanine amide hydrochloride (46
 mg), triethylamine (0.08 mL), 1-hydroxybenzotriazole (38 mg)
 and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

hydrochloride (0.11 g), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate solution, water and brine successively, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 20/1 - 10/1) to give the title compound (0.14 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.29 (3H, s), 1.32 (3H, s), 1.38 (3H, d, $J=7.5\text{Hz}$), 1.89 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.85-2.95 (1H, m), 3.57 (1H, d, $J=16.0\text{Hz}$), 3.62 (1H, d, $J=16.0\text{Hz}$), 3.8-3.9 (2H, m), 3.94 (1H, d, $J=9.1\text{Hz}$), 4.14 (1H, dd, $J=12.5\text{Hz}$, 2.4Hz), 4.3 (1H, dd, $J=12.5\text{Hz}$, 4.1Hz), 4.4-4.55 (1H, m), 5.15-5.4 (4H, m), 5.58 (1H, d, $J=8.0\text{Hz}$), 6.2-6.35 (1H, br), 6.67 (1H, d, $J=7.3\text{Hz}$), 6.7-6.8 (2H, m), 7.0-7.1 (2H, m)

Example 37

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di(methyl)ethylcarbamoyl]-2-methylpropoxy}-phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 36 using 2-amino-2-methyl-1-propanol instead of L-alanine amide hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.25 (6H, s), 1.27 (6H, s), 1.89 (3H, s), 1.97 (3H, s), 2.01 (3H, s), 2.02 (3H, s), 2.85-3.0 (1H, m), 3.5 (2H, s), 3.6 (2H, s), 3.89 (2H, s), 3.9-4.0 (1H, m), 4.11 (1H, dd, J=12.3Hz, 2.2Hz), 4.3 (1H, dd, J=12.3Hz, 4.0Hz), 5.05-5.15 (2H, m), 5.25-5.35 (1H, m), 5.48 (1H, d, J=7.9Hz), 6.75-6.9 (3H, m), 7.0-7.1 (2H, m)

Example 38

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carbamoyl-1-(methyl)ethylcarbamoyl]-2-methylpropoxy}-phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 36 using 2-amino-2-methylpropionamide instead of L-alanine amide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.27 (6H, s), 1.49 (6H, s), 1.89 (3H, s), 1.97 (3H, s), 2.01 (3H, s), 2.02 (3H, s), 2.85-3.0 (1H, m), 3.6 (2H, s), 3.9-4.0 (3H, m), 4.11 (1H, dd, J=12.3Hz, 2.4Hz), 4.3 (1H, dd, J=12.3Hz, 4.0Hz), 5.05-5.15 (2H, m), 5.25-5.35 (1H, m), 5.48 (1H, d, J=8.4Hz), 6.75-6.85 (2H, m), 7.0-7.1 (2H, m)

Example 39

4-[(4-{2-[(S)-1-(Carbamoyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(carbamoyl)ethylcarbamoyl]-2-

methylpropoxy}phenyl)methyl]-5-isopropyl-1*H*-pyrazole (0.14 g) in methanol (4 mL) was added sodium methoxide (28% methanol solution, 0.04 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: methanol) to give the title compound (94 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.29 (3H, s), 1.3 (3H, s), 1.35 (3H, d, J=7.5Hz),
 10 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.8 (3H, m), 3.8-3.9 (1H, m), 3.94 (2H, s), 4.3-4.45 (1H, m), 5.0-5.1 (1H, m), 6.75-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 40

15 3-(β-D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di-(methyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-5-isopropyl-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Example 39 using 3-(2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-(dimethyl)-ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-5-isopropyl-1*H*-pyrazole instead of 3-(2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[(*S*)-1-(carbamoyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-5-isopropyl-1*H*-pyrazole.

25 ¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.25 (6H, s), 1.27 (6H, s), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.5 (2H, s), 3.6-3.7 (2H, m), 3.74 (1H,

d, $J=16.0\text{Hz}$), 3.8-3.95 (3H, m), 5.0-5.15 (1H, m), 6.75-6.9 (2H, m), 7.05-7.15 (2H, m)

Example 41

5 4-[(4-{2-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 39 using 3-(2,3,4,6-tetra-O-acetyl-
10 β -D-glucopyranosyloxy)-4-[(4-{2-[1-carbamoyl-1-(methyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(carbamoyl)ethylcarbamoyl]-2-methylpropoxy}phenyl)methyl]-5-isopropyl-1H-pyrazole.

15 $^1\text{H-NMR}$ (CD_3OD) δ ppm:
1.05-1.15 (6H, m), 1.27 (6H, s), 1.49 (6H, s), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.8 (3H, m), 3.8-3.9 (1H, m), 3.93 (2H, s), 5.0-5.1 (1H, m), 6.75-6.85 (2H, m), 7.05-7.15 (2H, m)

20 Example 42

3-(β -D-Glucopyranosyloxy)-4-[[4-(3-{1-[2-hydroxy-1-(hydroxymethyl)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 30 using 2-amino-1,3-propanediol
25 instead of 2-aminoethanol.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.43 (6H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.5-3.95 (9H, m), 5.0-5.15 (1H, m), 7.0-7.2 (4H, m)

5 Example 43

3-(β -D-Glucopyranosyloxy)-4-{[4-(3-{1-[2-hydroxy-1,1-bis-(hydroxymethyl)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl)phenyl]methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 30 using tris(hydroxymethyl)-aminomethane instead of 2-aminoethanol.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.18 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.5Hz), 2.85-3.0 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (10H, m), 5.0-5.15 (1H, m), 7.0-7.2 (4H, m)

Reference Example 14

4-Bromo-2-methylbenzyl alcohol

To a solution of 4-bromo-2-methylbenzoic acid (10 g) in tetrahydrofuran (60 mL) was added borane-dimethylsulfide complex (7.07 g) under ice-cooling. The reaction mixture was stirred at room temperature for 5 minutes, and stirred at 75°C for 2 days. The reaction mixture was cooled to room temperature. A saturated aqueous potassium carbonate solution was added to the reaction mixture, and the organic layer was separated. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under

reduced pressure to give the title compound (9.0 g).

^1H -NMR (CDCl_3) δ ppm:

1.55-1.65 (1H, m), 2.36 (3H, s), 4.64 (2H, d, $J=5.4\text{Hz}$), 7.2-7.25 (1H, m), 7.3-7.35 (2H, m)

5

Reference Example 15

4-[(4-Bromo-2-methylphenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

To a solution of 4-bromo-2-methylbenzyl alcohol (9.0 g) in dichloromethane (50 mL) was added thionyl chloride (3.8 mL) under ice-cooling, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give 4-bromo-2-methylbenzyl chloride (9.8 g). To a suspension of sodium hydride (60%, 2.1 g) in tetrahydrofuran (90 mL) was added ethyl 4-methyl-3-oxo-pentanoate (7.5 g) under ice-cooling, and the reaction mixture was stirred at room temperature for 1 hour. 4-Bromo-2-methylbenzyl chloride (9.8 g) was added to the reaction mixture, and the resulting mixture was stirred at 70°C for 3 days. The reaction mixture was poured into a saturated aqueous ammonium chloride solution, and the mixture was extracted with diethyl ether. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure. To a solution of the residue in toluene (20 mL) was added hydrazine monohydrate (5.4 mL), and the mixture was stirred at 90°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was treated

with *n*-hexane-diethyl ether (10/1) to crystallize. The crystals were collected by filtration and washed with *n*-hexane, water and *n*-hexane successively, and dried under reduced pressure to give the title compound (12.4 g).

5 ^1H -NMR (DMSO- d_6) δ ppm:

1.05 (6H, d, $J=6.8\text{Hz}$), 2.28 (3H, s), 2.65-2.8 (1H, m), 3.45 (2H, s), 6.82 (1H, d, $J=8.2\text{Hz}$), 7.24 (1H, dd, $J=8.2\text{Hz}$, 1.8Hz), 7.33 (1H, d, $J=1.8\text{Hz}$), 8.5-12.0 (2H, br)

10 Reference Example 16

3-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromo-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 3 using 4-[(4-bromo-2-methylphenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one instead of 4-[(4-bromophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one.

^1H -NMR (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.81 (3H, s), 1.99 (3H, s), 2.02 (3H, s), 2.06 (3H, s), 2.28 (3H, s), 2.75-2.9 (1H, m), 3.49 (1H, d, $J=16.7\text{Hz}$), 3.59 (1H, d, $J=16.7\text{Hz}$), 3.8-3.9 (1H, m), 4.05-4.2 (1H, m), 4.3 (1H, dd, $J=12.4\text{Hz}$, 4.0Hz), 5.1-5.3 (3H, m), 5.5-5.6 (1H, m), 6.76 (1H, d, $J=8.2\text{Hz}$), 7.1-7.2 (1H, m), 7.25-7.3 (1H, m)

25 Reference Example 17

3-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-[(1*E*)-3-carboxyprop-1-enyl]-2-methylphenyl)methyl]-5-

isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromo-2-methylphenyl)-methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.78 (3H, s), 1.99 (3H, s), 2.02 (3H, s), 2.06 (3H, s), 2.29 (3H, s), 2.75-2.9 (1H, m), 3.13 (2H, d, $J=7.3\text{Hz}$), 3.54 (1H, d, $J=16.8\text{Hz}$), 3.64 (1H, d, $J=16.8\text{Hz}$), 3.8-3.9 (1H, m), 4.05-4.15 (1H, m), 4.25-4.35 (1H, m), 5.1-5.3 (3H, m), 5.5-5.6 (1H, m), 6.15-6.25 (1H, m), 6.46 (1H, d, $J=16.1\text{Hz}$), 6.85 (1H, d, $J=7.9\text{Hz}$), 7.05 (1H, d, $J=7.9\text{Hz}$), 7.15 (1H, s)

Reference Example 18

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-2-carboxyvinyl]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromo-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and acrylic acid instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole and 3-butenic acid, respectively.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.73 (3H, s), 1.99 (3H, s), 2.04 (3H, s), 2.06
 (3H, s), 2.35 (3H, s), 2.8-2.9 (1H, m), 3.58 (1H, d, J=17.2Hz),
 3.69 (1H, d, J=17.2Hz), 3.85-3.95 (1H, m), 4.21 (1H, dd, J=12.4Hz,
 2.2Hz), 4.35 (1H, dd, J=12.4Hz, 3.9Hz), 5.15-5.3 (3H, m), 5.45
 5 (1H, d, J=7.8Hz), 6.4 (1H, d, J=15.8Hz), 6.93 (1H, d, J=7.8Hz),
 7.2-7.3 (1H, m), 7.3-7.4 (1H, m), 7.69 (1H, d, J=15.8Hz)

Example 44

4-[(4-{3-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]propyl}-2-
 10 methylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-
1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl-
 β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-2-
 15 methylphenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-
 methylpropionamide instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-
 β -glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-
 phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide
 hydrochloride, respectively.

20 ^1H -NMR (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.44 (6H, s), 1.8-1.9 (2H, m), 2.2 (2H, t, J=7.6Hz),
 2.3 (3H, s), 2.55 (2H, t, J=7.6Hz), 2.75-2.9 (1H, m), 3.2-3.4
 (4H, m), 3.6-3.9 (4H, m), 4.95-5.1 (1H, m), 6.8-6.9 (2H, m),
 6.9-7.0 (1H, m)

25

Example 45

4-[(4-[(1E)-2-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]vinyl]-

2-methylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 26 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-2-carboxyvinyl]-2-methylphenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and ammonium chloride, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.52 (6H, s), 2.36 (3H, s), 2.75-2.9 (1H, m), 3.2-3.4 (4H, m), 3.6-3.85 (4H, m), 5.0-5.1 (1H, m), 6.58 (1H, d, $J=15.8\text{Hz}$), 7.0 (1H, d, $J=7.9\text{Hz}$), 7.2-7.3 (1H, m), 7.33 (1H, s), 7.43 (1H, d, $J=15.8\text{Hz}$)

Example 46

3-(β -D-Glucopyranosyloxy)-4-[(4-[(1E)-2-[2-hydroxy-1-hydroxymethyl-1-(methyl)ethylcarbamoyl]vinyl]-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 26 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-2-carboxyvinyl]-2-methylphenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methyl-1,3-propanediol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and ammonium chloride,

respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05 -1.15 (6H, m), 1.3 (3H, s), 2.36 (3H, s), 2.75-2.9 (1H, m), 3.25-3.45 (4H, m), 3.6-3.85 (8H, m), 5.04 (1H, d, J=6.1Hz),
 5 6.62 (1H, d, J=15.5Hz), 6.99 (1H, d, J=7.6Hz), 7.26 (1H, d, J=7.6Hz), 7.32 (1H, s), 7.42 (1H, d, J=15.5Hz)

Example 47

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-[(4-[(1E)-2-[2-
 10 (sulfamoylamino)ethylcarbamoyl]vinyl]-2-methylphenyl)-
methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 26 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-[(1E)-2-carboxyvinyl]-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and
 15 N-sulfamoylethylenediamine instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl]-5-isopropyl-1H-pyrazole and ammonium chloride, respectively.

20 ¹H-NMR (CD₃OD) δ ppm:

1.05 -1.2 (6H, m), 2.36 (3H, s), 2.75-2.9 (1H, m), 3.19 (2H, t, J=6.3Hz), 3.25-3.4 (4H, m), 3.47 (2H, t, J=6.3Hz), 3.6-3.7 (1H, m), 3.7-3.9 (3H, m), 5.04 (1H, d, J=7.3Hz), 6.54 (1H, d, J=15.7Hz), 7.0 (1H, d, J=7.9Hz), 7.27 (1H, d, J=7.9Hz), 7.33
 25 (1H, s), 7.47 (1H, d, J=15.7Hz)

Reference Example 19

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{(1E)-3-carboxyprop-1-enyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole (0.4 g) in *N,N*-dimethylformamide (2 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (0.18 g), 1-hydroxybenzotriazole (0.13 g), benzyl 2-amino-2-methylpropionate *p*-toluenesulfonic acid salt (1.16 g) and triethylamine (0.64 g) at room temperature, and the mixture was stirred overnight. To the reaction mixture was added water, and the resulting mixture was extracted with dichloromethane. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/1 - ethyl acetate) to give 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{(1E)-3-[1-benzyloxy-carbonyl-1-(methyl)ethylcarbamoyl]prop-1-enyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole (0.18 g). This material was dissolved in methanol (2 mL). To the solution was added 10% palladium-carbon powder (50 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 4 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (0.15 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.05-1.2 (6H, m), 1.57 (3H, s), 1.59 (3H, s), 1.85 (3H, s),
 1.85-1.95 (2H, m), 1.99 (3H, s), 2.02 (3H, s), 2.1-2.2 (5H, m),
 2.6 (2H, t, J=7.4Hz), 2.8-2.95 (1H, m), 3.59 (1H, d, J=16.1Hz),
 3.68 (1H, d, J=16.1Hz), 4.0-4.1 (1H, m), 4.14 (1H, dd, J=11.0Hz,
 8.2Hz), 4.27 (1H, dd, J=11.0Hz, 5.6Hz), 5.08 (1H, dd, J=10.3Hz,
 3.5Hz), 5.37 (1H, d, J=8.1Hz), 5.4-5.5 (2H, m), 6.19 (1H, s),
 6.95-7.1 (4H, m)

Reference Example 20

10 3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-
 [1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-
 5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Reference Example 19 using 3-(2,3,4,6-tetra-
 15 O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-
 1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole instead of
 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-
 [(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-
 pyrazole.

20 $^1\text{H-NMR}$ (CDCl_3) δ ppm:
 1.05-1.2 (6H, m), 1.57 (3H, s), 1.58 (3H, s), 1.85 (3H, s),
 1.85-1.95 (2H, m), 2.0 (3H, s), 2.03 (3H, s), 2.05 (3H, s), 2.15
 (2H, t, J=7.6Hz), 2.6 (2H, t, J=7.5Hz), 2.8-2.95 (1H, m), 3.58
 (1H, d, J=15.7Hz), 3.66 (1H, d, J=15.7Hz), 3.8-3.9 (1H, m), 4.17
 25 (1H, dd, J=11.9Hz, 2.2Hz), 4.34 (1H, dd, J=11.9Hz, 3.4Hz),
 5.15-5.3 (3H, m), 5.35-5.45 (1H, m), 6.18 (1H, s), 6.95-7.1 (4H,
 m)

Reference Example 21

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-
 [1-carboxy-1-(methyl)ethylcarbamoyl]propyl}-2-methyl-
 5 phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 19 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

10 instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl}-5-isopropyl-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.05-1.15 (6H, m), 1.57 (3H, s), 1.58 (3H, s), 1.76 (3H, s),
 15 1.85-1.95 (2H, m), 1.99 (3H, s), 2.02 (3H, s), 2.05 (3H, s),
 2.1-2.2 (2H, m), 2.25 (3H, s), 2.5-2.6 (2H, m), 2.7-2.85 (1H, m),
 3.51 (1H, d, $J=16.8\text{Hz}$), 3.61 (1H, d, $J=16.8\text{Hz}$), 3.8-3.9 (1H, m),
 4.1-4.2 (1H, m), 4.32 (1H, dd, $J=12.2\text{Hz}$, 3.4Hz), 5.15-5.3 (3H, m),
 5.38 (1H, d, $J=8.1\text{Hz}$), 6.23 (1H, s), 6.77 (1H, d, $J=7.8\text{Hz}$),
 20 6.85 (1H, d, $J=7.8\text{Hz}$), 6.93 (1H, s)

Example 48

3-(β -D-Galactopyranosyloxy)-4-[(4-{3-[1-[[4-(2-hydroxy-ethyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]-
 25 propyl]phenyl)methyl]-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-

carbamoyl]propyl]phenyl)methyl]-5-isopropyl-1H-pyrazole (30 mg) in *N,N*-dimethylformamide (0.5 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (12 mg), 1-hydroxybenzotriazole (9 mg) and 1-(2-hydroxyethyl)piperazine (54 mg), and the mixture was stirred at room temperature overnight. To the reaction mixture was added 5 mol/L aqueous sodium hydroxide solution (0.25 mL), and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added acetic acid (0.1 mL), and the mixture was diluted with water (1 mL). The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å, 20 x 50mm, flow rate 30 mL/minute linear gradient, water/acetonitrile = 90/10 - 10/60) to give the title compound (4 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.7Hz), 2.35-2.55 (6H, m), 2.58 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.52 (1H, dd, J=9.7Hz, 3.4Hz), 3.55-3.8 (12H, m), 3.87 (1H, d, J=3.4Hz), 5.08 (1H, d, J=8.0Hz), 7.0-7.15 (4H, m)

20

Example 49

3-(β -D-Glucopyranosyloxy)-4-[[4-(3-{1-[2-hydroxy-1-(hydroxymethyl)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl)methyl]-5-isopropyl-1H-pyrazole

25

The title compound was prepared in a similar manner to that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-

carbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole and 2-amino-1,3-propanediol instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole and 1-(2-hydroxyethyl)piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.43 (6H, s), 1.8-1.95 (2H, m), 2.19 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.5-3.95 (9H, m), 5.0-5.15 (1H, m), 7.0-7.2 (4H, m)

Example 50

3-(β -D-Glucopyranosyloxy)-4-{[4-(3-{1-[2-hydroxy-1,1-bis-(hydroxymethyl)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl}-propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Example 48 using 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole and tris(hydroxymethyl)aminomethane instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole and 1-(2-hydroxyethyl)piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.18 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.5Hz), 2.85-3.0 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (10H, m), 5.0-5.15 (1H, m), 7.0-7.2 (4H, m)

Example 51

3-(β -D-Galactopyranosyloxy)-4-[(4-{3-[1-(2-hydroxyethyl-carbamoyl)-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

5 The title compound was prepared in a similar manner to that described in Example 48 using 2-aminoethanol instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.42 (6H, s), 1.8-1.9 (2H, m), 2.19 (2H, t, J=7.6Hz), 2.57 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.28 (2H, t, J=5.8Hz), 3.45-3.65 (4H, m), 3.65-3.8 (5H, m), 3.86 (1H, d, J=2.7Hz), 5.08 (1H, d, J=7.9Hz), 7.0-7.15 (4H, m)

Example 52

15 3-(β -D-Galactopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-[2-(dimethylamino)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-1H-pyrazole

20 The title compound was prepared in a similar manner to that described in Example 48 using *N,N*-dimethylethylenediamine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.41 (6H, s), 1.8-1.9 (2H, m), 2.19 (2H, t, J=7.7Hz), 2.24 (6H, s), 2.42 (2H, t, J=6.8Hz), 2.58 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.28 (2H, t, J=6.8Hz), 3.52 (1H, dd, J=9.7Hz, 3.3Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, J=7.4Hz), 7.0-7.15 (4H, m)

Example 53

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-[2-(dimethylamino)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-1H-pyrazole

- 5 The title compound was prepared in a similar manner to that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and *N,N*-dimethylethylenediamine instead of 3-(2,3,4,6-tetra-O-
- 10 acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(2-hydroxyethyl)piperazine, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

- 1.05-1.15 (6H, m), 1.41 (6H, s), 1.8-1.9 (2H, m), 2.18 (2H, t, $J=7.5\text{Hz}$), 2.23 (6H, s), 2.41 (2H, t, $J=6.8\text{Hz}$), 2.57 (2H, t, $J=7.6\text{Hz}$), 2.8-2.95 (1H, m), 3.2-3.45 (6H, m), 3.6-3.9 (4H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)
- 15

Example 54

- 20 3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-[3-(dimethylamino)propylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-1H-pyrazole

- The title compound was prepared in a similar manner to that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl-
- 25 β -D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and *N,N*-dimethyl-1,3-propanediamine instead of 3-(2,3,4,6-tetra-

O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(2-hydroxyethyl)piperazine, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

5 1.1-1.15 (6H, m), 1.41 (6H, s), 1.6-1.7 (2H, m), 1.8-1.9 (2H, m), 2.19 (2H, t, $J=7.7\text{Hz}$), 2.22 (6H, s), 2.35 (2H, t, $J=7.6\text{Hz}$), 2.57 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 3.18 (2H, t, $J=6.6\text{Hz}$), 3.3-3.45 (4H, m), 3.6-3.8 (3H, m), 3.8-3.9 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

10

Example 55

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-5-isopropyl-1H-pyrazole

15 The title compound was prepared in a similar manner to that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-5-isopropyl-1H-pyrazole.

20

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.16 (2H, t, $J=7.5\text{Hz}$), 2.35-2.55 (6H, m), 2.58 (2H, t, $J=7.3\text{Hz}$), 2.85-3.0 (1H, m), 3.25-3.45 (4H, m), 3.55-3.9 (10H, m), 5.0-5.15 (1H, m), 7.0-7.15 (4H, m)

25

Example 56

4-[(4-{3-[1-(2-Aminoethylcarbamoyl)-1-(methyl)ethyl-carbamoyl]propyl}phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

- 5 The title compound was prepared in a similar manner to that described in Example 48 using ethylenediamine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

- 1.1-1.2 (6H, m), 1.41 (6H, s), 1.8-1.9 (2H, m), 2.19 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.6Hz), 2.7 (2H, t, J=5.9Hz), 2.85-2.95 (1H, m), 3.24 (2H, t, J=5.9Hz), 3.51 (1H, dd, J=9.8Hz, 3.2Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.86 (1H, d, J=3.2Hz), 5.07 (1H, d, J=7.9Hz), 7.0-7.15 (4H, m)

15 Example 57

3-(β -D-Galactopyranosyloxy)-5-isopropyl-4-[[4-(3-[1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propyl)phenyl)methyl]-1H-pyrazole

- 20 The title compound was prepared in a similar manner to that described in Example 48 using piperazine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

- 1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.1-2.2 (2H, m), 2.58 (2H, t, J=7.4Hz), 2.65-2.8 (4H, m), 2.85-2.95 (1H, m), 3.45-3.8 (11H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, J=8.0Hz), 7.0-7.15 (4H, m)

Example 58

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-([4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propyl)phenyl)methyl}-1H-pyrazole

- 5 The title compound was prepared in a similar manner to
that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl- β -
D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-
carbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and
piperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-
10 galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-
carbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and
1-(2-hydroxyethyl)piperazine, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

- 1.1-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.17 (2H, t,
15 J=7.6Hz), 2.5-2.85 (6H, m), 2.85-3.0 (1H, m), 3.25-3.45 (4H,
m), 3.5-3.9 (8H, m), 5.0-5.15 (1H, m), 7.0-7.15 (4H, m)

Example 59

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-
20 piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]propyl}-
2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

- The title compound was prepared in a similar manner to
that described in Example 48 using 3-(2,3,4,6-tetra-O-acetyl- β -
D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-
25 carbamoyl]propyl}-2-methylphenyl)methyl]-5-isopropyl-1H-
pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-galacto-
pyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-

carbamoyl]propyl]phenyl)methyl]-5-isopropyl-1H-pyrazole.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.8-1.9 (2H, m), 2.1-2.2 (2H, m), 2.3 (3H, s), 2.35-2.6 (8H, m), 2.75-2.9 (1H, m), 3.25-3.4
5 (4H, m), 3.45-3.75 (9H, m), 3.8 (1H, d, J=11.1Hz), 4.95-5.05 (1H, m), 6.8-7.0 (3H, m)

Example 60

3-(β-D-Galactopyranosyloxy)-4-([4-(3-{1-[2-hydroxy-1,1-bis-
10 (hydroxymethyl)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl]methyl})-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 48 using tris(hydroxymethyl)-aminomethane instead of 1-(2-hydroxyethyl)piperazine.

15 ¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.18 (2H, t, J=7.5Hz), 2.58 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.52 (1H, dd, J=9.7Hz, 3.4Hz), 3.55-3.9 (13H, m), 5.07 (1H, d, J=7.5Hz),
20 7.0-7.15 (4H, m)

Example 61

3-(β-D-Galactopyranosyloxy)-5-isopropyl-4-([4-(3-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl]methyl})-1H-pyrazole

25 The title compound was prepared in a similar manner to that described in Example 48 using 1-methylpiperazine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.42 (6H, s), 1.8-1.9 (2H, m), 2.1-2.2 (2H, m), 2.25 (3H, s), 2.3-2.45 (4H, m), 2.58 (2H, t, J=7.4Hz), 2.85-2.95 (1H, m), 3.52 (1H, dd, J=9.6Hz, 3.2Hz), 3.55-3.8 (10H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, J=7.4Hz), 7.0-7.15 (4H, m)

Example 62

3-(β-D-Galactopyranosyloxy)-5-isopropyl-4-([4-(3-{1-[(4-isopropylpiperazin-1-yl)carbonyl]-1-(methyl)ethyl-carbamoyl}propyl)phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 48 using 1-isopropylpiperazine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

1.03 (6H, d, J=6.6Hz), 1.05-1.15 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.1-2.2 (2H, m), 2.35-2.7 (7H, m), 2.8-2.95 (1H, m), 3.52 (1H, dd, J=9.8Hz, 3.4Hz), 3.55-3.8 (10H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, J=7.8Hz), 7.0-7.15 (4H, m)

20 Example 63

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-([4-[(1E)-2-{1-[2-(dimethylamino)ethylcarbonyl]-1-(methyl)ethylcarbonyl]-vinyl]phenyl)methyl]-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-([4-[(1E)-2-carboxyvinyl]phenyl)methyl)-5-isopropyl-1H-pyrazole (1.2 g) in *N,N*-dimethylformamide (15 mL) and dichloromethane (10 mL) was added triethylamine (15 mL).

To the mixture were added 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (0.56 g), 1-hydroxybenzotriazole (0.4 g), and a solution of 2-amino-2-methylpropionic acid (2.0 g) in water (15 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was neutralized by addition of 2 mol/L aqueous acetic acid solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: ethyl acetate - dichloromethane/methanol = 7/1 - 3/1) to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-[(1*E*)-2-[1-carboxy-1-(methyl)ethylcarbamoyl]vinyl]phenyl)methyl]-5-isopropyl-1*H*-pyrazole (0.44 g). This material was dissolved in *N,N*-dimethylformamide (0.3 mL). To the solution were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.18 g), 1-hydroxybenzotriazole (0.13 g) and *N,N*-dimethylethylenediamine (0.55 g), and the mixture was stirred at room temperature overnight. To the reaction mixture was added 5 mol/L aqueous sodium hydroxide solution (1.5 mL), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added acetic acid (1 mL), and the mixture was diluted with water (3 mL). The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å, 20 x 50 mm, flow rate 30 mL/minute linear gradient, water/

acetonitrile = 90/10 - 10/60) to give the title compound (71 mg).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.49 (6H, s), 2.27 (6H, s), 2.46 (2H, t, $J=6.7\text{Hz}$),
 5 2.8-2.95 (1H, m), 3.25-3.45 (6H, m), 3.6-3.9 (4H, m), 5.05-5.15
 (1H, m), 6.61 (1H, d, $J=15.7\text{Hz}$), 7.2-7.3 (2H, m), 7.35-7.5 (3H,
 m)

Example 64

10 3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-({4-[(1E)-2-{1-
 [(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}vinyl]-
 phenyl)methyl)-1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Example 63 using piperazine instead of
 15 *N,N*-dimethylethylenediamine.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.51 (6H, s), 2.65-2.8 (4H, m), 2.85-2.95
 (1H, m), 3.25-3.45 (4H, m), 3.5-3.9 (8H, m), 5.05-5.15 (1H, m),
 6.55 (1H, d, $J=15.8\text{Hz}$), 7.2-7.3 (2H, m), 7.4-7.55 (3H, m)

20

Example 65

3-(β -D-Glucopyranosyloxy)-4-[(4-[(1E)-2-[1-[[4-(2-hydroxy-
 ethyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]-
 vinyl)phenyl)methyl]-5-isopropyl-1H-pyrazole

25 The title compound was prepared in a similar manner to
 that described in Example 63 using 1-(2-hydroxyethyl)piperazine
 instead of *N,N*-dimethylethylenediamine.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.51 (6H, s), 2.35-2.65 (6H, m), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.55-3.9 (10H, m), 5.05-5.15 (1H, m), 6.55 (1H, d, J=15.8Hz), 7.2-7.3 (2H, m), 7.4-7.5 (3H, m)

5

Example 66

3-(β-D-Glucopyranosyloxy)-4-[(4-{3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

10 The title compound was prepared in a similar manner to that described in Example 1 using (S)-2-amino-1-propanol instead of glycineamide hydrochloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (9H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.7Hz), 2.57
15 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.25-3.5 (6H, m), 3.6-3.8 (3H, m), 3.83 (1H, d, J=11.9Hz), 3.85-4.0 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 67

20 3-(β-D-Galactopyranosyloxy)-4-[(4-{3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl}-5-isopropyl-1H-pyrazole and (S)-2-amino-1-propanol instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-gluco-

25

pyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl}-methyl)-5-isopropyl-1H-pyrazole and glycineamide hydrochloride, respectively.

¹H-NMR (CD₃OD) δ ppm:

5 1.05-1.2 (9H, m), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.6Hz), 2.57 (2H, t, J=7.6Hz), 2.85-2.95 (1H, m), 3.35-3.55 (3H, m), 3.55-3.65 (1H, m), 3.65-4.0 (7H, m), 5.0-5.15 (1H, m), 7.0-7.15 (4H, m)

Example 68

10 3-(β-D-Galactopyranosyloxy)-4-[(4-{3-[2-hydroxy-1,1-di-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methyl-1-propanol instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide
20 hydrochloride, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.25 (6H, s), 1.8-1.9 (2H, m), 2.15 (2H, t, J=7.6Hz), 2.56 (2H, t, J=7.5Hz), 2.8-2.95 (1H, m), 3.45-3.65 (4H, m), 3.65-3.8 (5H, m), 3.8-3.9 (1H, m), 5.0-5.1 (1H, m),
25 7.0-7.15 (4H, m)

Example 69

4-[(4-{3-[(S)-5-Amino-5-(carbamoyl)pentylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and (S)-2-benzyloxy-carbonylamino-6-aminohexanamide hydrochloride instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole and glycine hydrochloride, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.3-1.6 (5H, m), 1.6-1.75 (1H, m), 1.8-1.9 (2H, m), 2.15 (2H, t, $J=7.7\text{Hz}$), 2.56 (2H, t, $J=7.3\text{Hz}$), 2.8-2.95 (1H, m), 3.15 (2H, t, $J=7.0\text{Hz}$), 3.28 (1H, t, $J=6.4\text{Hz}$), 3.52 (1H, dd, $J=9.8\text{Hz}$, 3.1Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, $J=7.9\text{Hz}$), 7.0-7.15 (4H, m)

Example 70

4-[(4-{3-[(S)-2-Amino-1-(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl}-methyl)-5-isopropyl-1H-pyrazole (1.6 g) in methanol (20 mL) was added 10% palladium-carbon powder, and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours.

The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(3-carboxypropyl)phenyl]methyl)-5-isopropyl-1*H*-pyrazole (1.5 g).

5 This material was dissolved in *N,N*-dimethylformamide (15 mL). To the solution were added (*S*)-2-amino-1-propanol (0.89 g), 1-hydroxybenzotriazole (0.48 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.68 g), and the mixture was stirred at room temperature overnight. The reaction

10 mixture was poured into water, and the resulting mixture was extracted with dichloromethane twice. The extracts were washed with water and brine, and dried over anhydrous sodium sulfate.

The solvent was removed under reduced pressure to give

3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(3-
15 [(*S*)-2-hydroxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)-methyl]-5-isopropyl-1*H*-pyrazole (1.64 g). The obtained

3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(3-
[(*S*)-2-hydroxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)-methyl]-5-isopropyl-1*H*-pyrazole (0.19 g) was dissolved in

20 dichloromethane (2 mL). To the solution were added triethylamine (0.058 mL) and methanesulfonyl chloride (0.032 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and the resulting mixture was extracted with dichloromethane twice.

25 The extracts were washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. The residue was dissolved in *N,N*-dimethylformamide

(1 mL). To the solution was added sodium azide (0.18 g), and the mixture was stirred at 100°C overnight. The reaction mixture was cooled to room temperature. Five mol/L aqueous sodium hydroxide solution (1.5 mL) was added to the mixture, and the mixture was stirred for 1 hour. Acetic acid (1 mL) and water (2 mL) were added to the reaction mixture. The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ m, 120 Å, 20 x 50 mm, flow rate 30 mL/minute linear gradient, water/acetonitrile = 90/10 - 10/90) to give 4-[(4-{3-[(1S)-2-azido-1-(methyl)ethylcarbamoyl]-propyl}phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole (18 mg). This material was dissolved in methanol (1 mL). To the solution was added 10% palladium-carbon powder (0.01 g), and the mixture was stirred at room temperature under a hydrogen atmosphere for 4 hours. The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure to give the title compound (12 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (9H, m), 1.8-1.95 (2H, m), 2.1-2.25 (2H, m), 2.5-2.65 (4H, m), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.6-3.9 (5H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 71

4-[(4-{3-[2-Amino-1,1-di(methyl)ethylcarbamoyl]propyl}-phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and 2-amino-1-benzyloxycarbonylamino-2-(methyl)propane instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide hydrochloride, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.27 (6H, s), 1.8-1.9 (2H, m), 2.16 (2H, t, $J=7.7\text{Hz}$), 2.57 (2H, t, $J=7.6\text{Hz}$), 2.8-2.95 (3H, m), 3.51 (1H, dd, $J=9.8\text{Hz}$, 3.7Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, $J=7.7\text{Hz}$), 7.0-7.15 (4H, m)

Example 72

4-[(4-{3-[(R)-5-Amino-1-(hydroxymethyl)pentylcarbamoyl]-propyl}phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 1 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-phenyl)methyl)-5-isopropyl-1H-pyrazole and (R)-2-amino-6-benzyloxycarbonylamino-1-hexanol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl)methyl)-5-isopropyl-1H-pyrazole and glycineamide hydrochloride, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.2-1.7 (6H, m), 1.8-1.95 (2H, m), 2.2 (2H, t, J=7.5Hz), 2.57 (2H, t, J=7.6Hz), 2.65 (2H, t, J=7.3z), 2.8-3.0 (1H, m), 3.4-3.65 (4H, m), 3.65-3.95 (7H, m), 5.0-5.15 (1H, m), 7.0-7.15 (4H, m)

5

Example 73

3-(β-D-Glucopyranosyloxy)-4-[(4-((1E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl)phenyl)methyl]-5-isopropyl-1H-pyrazole

10 The title compound was prepared in a similar manner to that described in Example 26 using (S)-2-amino-1-propanol instead of ammonium chloride.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (9H, m), 2.8-2.95 (1H, m), 3.09 (2H, d, J=7.4Hz),
15 3.25-3.55 (6H, m), 3.6-3.9 (4H, m), 3.9-4.0 (1H, m), 5.05-5.15 (1H, m), 6.2-6.3 (1H, m), 6.47 (1H, d, J=15.9Hz), 7.1-7.2 (2H, m), 7.2-7.3 (2H, m)

Example 74

20 3-(β-D-Glucopyranosyloxy)-4-[[4-(3-((S)-1-[2-hydroxy-1-(hydroxymethyl)ethylcarbamoyl]ethylcarbamoyl)propyl)-phenyl]methyl]-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]phenyl}-methyl)-5-isopropyl-1H-pyrazole (7.13 g) in N,N-dimethyl-
25 formamide (30 mL) were added 1-hydroxybenzotriazole (2.31 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

(3.25 g) and benzyl (*S*)-2-aminopropionate (8.34 g), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate twice. The extracts were washed
5 with water and brine successively, and dried over sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/2) to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{(1*E*)-3-[(*S*)-1-
10 (benzyloxycarbonyl)ethylcarbamoyl]prop-1-enyl}phenyl)-methyl]-5-isopropyl-1*H*-pyrazole (3.25 g). This material was dissolved in methanol (40 mL). To the solution was added 10% palladium-carbon powder (1.0 g), and the mixture was stirred at room temperature under a hydrogen atmosphere overnight. The
15 insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[(*S*)-1-(carboxy)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole (2.25 g). To a solution of the obtained
20 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{3-[(*S*)-1-(carboxy)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole (0.09 g) in *N,N*-dimethylformamide (0.5 mL) were added 1-hydroxybenzotriazole (0.026 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.037 g) and
25 2-amino-1,3-propanediol (0.12 g), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 5 mol/L aqueous sodium hydroxide solution (0.5 mL), and

the mixture was stirred at room temperature for 1 hour. Acetic acid (0.3 mL) and water (1 mL) were added to the reaction mixture. The insoluble material was removed by filtration, and the filtrate was purified by preparative reverse phase column chromatography (Shiseido CAPCELL PAK UG120 ODS, 5 μ L, 120 Å, 20 x 50 mm, flow rate 30 mL/minute linear gradient, water/ acetonitrile = 90/10 - 10/90) to give the title compound (0.017 g).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

10 1.1-1.2 (6H, m), 1.32 (3H, d, $J=6.8\text{Hz}$), 1.8-1.95 (2H, m), 2.15-2.3 (2H, m), 2.58 (2H, t, $J=7.5\text{Hz}$), 2.85-2.95 (1H, m), 3.25-3.45 (4H, m), 3.5-3.95 (9H, m), 4.25-4.35 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

15 Example 75

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[(S)-1-(2-hydroxyethyl-carbamoyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 74 using 2-aminoethanol instead of 2-amino-1,3-propanediol.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.31 (3H, d, $J=7.0\text{Hz}$), 1.8-1.95 (2H, m), 2.15-2.25 (2H, m), 2.58 (2H, t, $J=7.6\text{Hz}$), 2.85-2.95 (1H, m), 25 3.25-3.45 (6H, m), 3.58 (2H, t, $J=5.7\text{Hz}$), 3.6-3.8 (3H, m), 3.83 (1H, d, $J=11.9\text{Hz}$), 4.25-4.35 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

Example 76

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{(S)-1-[(4-methylpiperazin-1-yl)carbonyl]ethylcarbamoyl}propyl)-phenyl]methyl}-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 74 using 1-methylpiperazine instead of 2-amino-1,3-propanediol.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.26 (3H, d, J=7.0Hz), 1.8-1.95 (2H, m), 2.2 (2H, t, J=7.4Hz), 2.25-2.55 (7H, m), 2.57 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.45-3.75 (6H, m), 3.77 (1H, d, J=16.0Hz), 3.83 (1H, d, J=11.7Hz), 4.75-4.9 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H, m)

15

Example 77

3-(β -D-Glucopyranosyloxy)-4-[(4-{3-[(S)-1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}ethylcarbamoyl]propyl}-phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 74 using 1-(2-hydroxyethyl)piperazine instead of 2-amino-1,3-propanediol.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.26 (3H, d, J=6.9Hz), 1.8-1.95 (2H, m), 2.2 (2H, t, J=7.4Hz), 2.4-2.65 (8H, m), 2.85-2.95 (1H, m), 3.2-3.45 (4H, m), 3.45-3.75 (8H, m), 3.77 (1H, d, J=16.4Hz), 3.83 (1H, d, J=11.9Hz), 4.75-4.9 (1H, m), 5.0-5.1 (1H, m), 7.0-7.15 (4H,

25

m)

Reference Example 22

(4-Benzyloxy-2-methylphenyl)methanol

5 To a solution of 4-bromo-3-methylphenol (10 g) in
N,N-dimethylformamide (50 mL) were added potassium carbonate
(8.87 g) and benzyl bromide (6.36 mL), and the mixture was stirred
at room temperature overnight. The reaction mixture was poured
into water, and the resulting mixture was extracted with diethyl
10 ether. The organic layer was washed with water and dried over
anhydrous magnesium sulfate. The solvent was removed under
reduced pressure to give 4-benzyloxy-1-bromo-2-methylbenzene
(14.6 g). This material was dissolved in tetrahydrofuran (200
mL). To the solution was added *n*-butyl lithium (2.66 mol/L
15 *n*-hexane solution, 21.7 mL) at -78°C under an argon atmosphere,
and the mixture was stirred for 10 minutes. To the reaction
mixture was added *N,N*-dimethylformamide (10.1 mL), and the
mixture was allowed to warm to 0°C and stirred for 30 minutes.
The reaction mixture was poured into water, and the resulting
20 mixture was extracted with diethyl ether. The organic layer
was washed with water and dried over anhydrous magnesium sulfate.
The solvent was removed under reduced pressure to give
4-benzyloxy-2-methylbenzaldehyde. This material was
dissolved in ethanol (100 mL). To the solution was added sodium
25 borohydride (1.99 g), and the mixture was stirred at room
temperature overnight. To the reaction mixture was added
methanol, and the resulting mixture was concentrated under

reduced pressure. To the residue was added a saturated aqueous sodiumhydrogen carbonate solution, and the mixture was extracted with diethylether. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution, water and brine successively, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethylacetate=6/1 - 3/1 - 1/1) to give the title compound (10.5 g).

10 $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.37 (1H, t, $J=5.8\text{Hz}$), 2.36 (3H, s), 4.64 (2H, d, $J=5.8\text{Hz}$), 5.06 (2H, s), 6.79 (1H, dd, $J=8.4\text{Hz}$, 2.4Hz), 6.84 (1H, d, $J=2.4\text{Hz}$), 7.23 (1H, d, $J=8.4\text{Hz}$), 7.25-7.45 (5H, m)

15 Reference Example 23

4-[(4-Benzyloxy-2-methylphenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

To a solution of (4-benzyloxy-2-methylphenyl)methanol (10.5 g) in tetrahydrofuran (80 mL) were added triethylamine (7.36 mL) and methanesulfonyl chloride (3.91 mL) under ice-cooling. After the mixture was stirred for 1 hour, the insoluble material was removed by filtration. The obtained solution of (4-benzyloxy-2-methylphenyl)methyl mesylate in tetrahydrofuran was added to a suspension of sodium hydride (60%, 2.11 g) and ethyl 4-methyl-3-oxopentanoate (7.99 g) in tetrahydrofuran (160 mL), and the mixture was refluxed for 15 hours. To the reaction mixture was added 1 mol/L hydrochloric

acid, and the resulting mixture was extracted with diethyl ether. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure. The residue was dissolved in toluene (30 mL).

5 Hydrazine monohydrate (6.68 mL) was added to the solution, and the mixture was stirred at 100°C overnight. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed under
10 reduced pressure, and the residue was treated with *n*-hexane. The precipitated crystals were collected by filtration, and dried under reduced pressure to give the title compound (12.3 g).

¹H-NMR (DMSO-d₆) δ ppm:

1.04 (6H, d, J=6.8Hz), 2.24 (3H, s), 2.65-2.8 (1H, m), 3.44 (2H,
15 s), 5.02 (2H, s), 6.69 (1H, dd, J=8.7Hz, 2.4Hz), 6.75-6.85 (2H, m), 7.25-7.45 (5H, m)

Reference Example 24

4-[(4-Benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-
20 (2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-
pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-[(4-benzyloxy-2-methylphenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-
25 one and 2,3,4,6-tetra-O-pivaloyl-α-D-glucopyranosyl bromide (Kunz, H.; Harreus, A. Liebigs Ann. Chem. 1982, 41-48 Velarde, S.; Urbina, J.; Pena, M.R. J.Org.Chem. 1996, 61, 9541-9545) instead

of 4-([4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]-methyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo- α -D-glucose, respectively.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

5 1.04 (9H, s), 1.05-1.2 (33H, m), 2.27 (3H, s), 2.7-2.85 (1H, m), 3.45-3.6 (2H, m), 3.8-3.9 (1H, m), 4.11 (1H, dd, $J=12.6\text{Hz}$, 4.8Hz), 4.17 (1H, dd, $J=12.6\text{Hz}$, 1.8Hz), 5.0 (2H, s), 5.15-5.3 (2H, m), 5.37 (1H, t, $J=9.5\text{Hz}$), 5.65 (1H, d, $J=7.8\text{Hz}$), 6.64 (1H, dd, $J=8.4\text{Hz}$, 2.8Hz), 6.77 (1H, d, $J=2.8\text{Hz}$), 6.83 (1H, d, $J=8.4\text{Hz}$),
10 7.25-7.45 (5H, m)

Reference Example 25

4-[(4-Hydroxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

4-[(4-Benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (5 g) was dissolved in tetrahydrofuran (18 mL). To the solution was added 10% palladium-carbon powder (500 mg),
20 and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (4.45 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

25 1.0-1.2 (42H, m), 2.24 (3H, s), 2.7-2.85 (1H, m), 3.52 (2H, s), 3.8-3.9 (1H, m), 4.09 (1H, dd, $J=12.4\text{Hz}$, 4.7Hz), 4.15 (1H, dd, $J=12.4\text{Hz}$, 1.9Hz), 4.6 (1H, s), 5.15-5.25 (2H, m), 5.36 (1H, t,

$J=9.2\text{Hz}$), 5.65 (1H, d, $J=8.0\text{Hz}$), 6.5 (1H, dd, $J=8.3\text{Hz}$, 2.9Hz), 6.61 (1H, d, $J=2.9\text{Hz}$), 6.78 (1H, d, $J=8.3\text{Hz}$)

Reference Example 26

5 Benzyl 4-bromobutyrate

To a mixture of 4-bromobutyric acid (1 g), benzyl alcohol (0.65 g) and triphenyl phosphine (1.57 g) in tetrahydrofuran (12 mL) was added diethyl azodicarboxylate (40% toluene solution, 2.88 mL), and the mixture was stirred at room temperature for 10 3 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with diethyl ether. The extract was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography 15 on silica gel (eluent: *n*-hexane/ethyl acetate = 20/1) to give the title compound (0.69 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

2.15-2.25 (2H, m), 2.56 (2H, t, $J=7.1\text{Hz}$), 3.46 (2H, t, $J=6.5\text{Hz}$), 5.13 (2H, s), 7.25-7.4 (5H, m)

20

Reference Example 27

4-({4-[3-(Benzyloxycarbonyl)propoxy]-2-methylphenyl}-methyl)-5-isopropyl-3-(2,3,4,6-tetra-*O*-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

25 To a solution of 4-[(4-hydroxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-*O*-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (0.2 g) in *N,N*-dimethylformamide (3 mL) were

added benzyl 4-bromobutyrate (0.1 g), cesium carbonate (0.18 g) and a catalytic amount of sodium iodide, and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 3/1 - 2/1) to give the title compound (0.16 g).

¹H-NMR (CDCl₃) δ ppm:

1.04 (9H, s), 1.05-1.2 (33H, m), 2.05-2.15 (2H, m), 2.25 (3H, s), 2.56 (2H, t, J=7.3Hz), 2.7-2.85 (1H, m), 3.53 (2H, s), 3.8-3.9 (1H, m), 3.94 (2H, t, J=6.2Hz), 4.1 (1H, dd, J=12.5Hz, 4.1Hz), 4.16 (1H, dd, J=12.5Hz, 2.0Hz), 5.13 (2H, s), 5.15-5.25 (2H, m), 5.36 (1H, t, J=9.6Hz), 5.65 (1H, d, J=8.1Hz), 6.54 (1H, dd, J=8.5Hz, 2.7Hz), 6.64 (1H, d, J=2.7Hz), 6.81 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 28

1,2-Dihydro-4-[(4-iodophenyl)methyl]-5-isopropyl-3H-pyrazol-3-one

The title compound was prepared in a similar manner to that described in Reference Example 23 using 4-iodobenzyl alcohol instead of (4-benzyloxy-2-methylphenyl)methanol.

¹H-NMR (CD₃OD) δ ppm:

1.12 (6H, d, J=7.3Hz), 2.8-2.95 (1H, m), 3.63 (2H, s), 6.9-7.0 (2H, m), 7.5-7.6 (2H, m)

Reference Example 29

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-iodophenyl)methyl]-5-isopropyl-1H-pyrazole

5 The title compound was prepared in a similar manner to that described in Reference Example 12 using 1,2-dihydro-4-[(4-iodophenyl)methyl]-5-isopropyl-3H-pyrazol-3-one and acetobromo- α -D-galactose instead of 4-[(4-(2-benzyloxy-carbonyl-2-methylpropoxy)phenyl)methyl]-1,2-dihydro-5-
10 isopropyl-3H-pyrazol-3-one and acetobromo- α -D-glucose, respectively.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.15-1.2 (6H, m), 1.88 (3H, s), 1.99 (3H, s), 2.03 (3H, s), 2.18 (3H, s), 2.8-2.95 (1H, m), 3.58 (1H, d, $J=16.0\text{Hz}$), 3.65 (1H,
15 d, $J=16.0\text{Hz}$), 4.0-4.1 (1H, m), 4.15-4.25 (2H, m), 5.09 (1H, dd, $J=10.7\text{Hz}$, 3.5Hz), 5.35-5.45 (2H, m), 5.56 (1H, d, $J=8.3\text{Hz}$), 6.85-6.95 (2H, m), 7.5-7.6 (2H, m)

Reference Example 30

20 {4-[2-(Benzyloxycarbonyl)ethoxy]phenyl}methanol

To a mixture of 3-[4-(hydroxymethyl)phenoxy]propionic acid (0.98 g) and potassium carbonate (0.9 g) in *N,N*-dimethyl-formamide (5 mL) was added benzyl bromide (0.65 mL), and the mixture was stirred at room temperature overnight. The reaction
25 mixture was poured into water, and the resulting mixture was extracted with diethyl ether. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent

was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 2/1 - 1/1) to give the title compound (1.1 g).

¹H-NMR (CDCl₃) δ ppm:

5 1.5-1.55 (1H, m), 2.85 (2H, t, J=6.4Hz), 4.28 (2H, t, J=6.4Hz),
4.62 (2H, d, J=5.9Hz), 5.18 (2H, s), 6.85-6.9 (2H, m), 7.25-7.4
(7H, m)

Reference Example 31

10 4-Hydroxy-2-methylbenzaldehyde

To a solution of 4-bromo-3-methylphenol (14 g) and *N,N*-diisopropylamine (39.1 mL) in dichloromethane (150 mL) was added chloromethyl methyl ether (11.4 mL) under ice-cooling, and the mixture was stirred at room temperature for 5 days. The
15 reaction mixture was poured into a saturated aqueous citric acid solution, and the resulting mixture was extracted with diethyl ether. The extract was washed with water, 1 mol/L aqueous sodium hydroxide solution, water and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced
20 pressure to give 4-bromo-3-methyl-1-(methoxymethoxy)benzene (16.7 g). This material was dissolved in tetrahydrofuran (250 mL). To the solution was added *n*-butyl lithium (2.64 mol/L *n*-hexane solution, 32.7 mL) at -78°C under an argon atmosphere, and the mixture was stirred at the same temperature for 15 minutes.
25 To the reaction mixture was added *N,N*-dimethylformamide (16.6 mL), and the mixture was stirred under ice-cooling for 1 hour. The reaction mixture was poured into a saturated aqueous ammonium

chloride solution, and the resulting mixture was extracted with diethyl ether. The extract was washed with a saturated aqueous sodium hydrogen carbonate solution and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give 2-methyl-4-(methoxymethoxy)benzaldehyde (12.9 g). This material was dissolved in tetrahydrofuran (70 mL)-methanol (10 mL). To the solution was added concentrated hydrochloric acid (6 mL), and the mixture was stirred at 50°C for 1.5 hours. The reaction mixture was poured into a saturated aqueous sodium hydrogen carbonate solution, and the resulting mixture was extracted with ethyl acetate. The extract was washed with brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) with heating at 60°C. *n*-Hexane (100 mL) was added to the solution gently, and the mixture was stirred at the same temperature for 10 minutes. The mixture was cooled to room temperature. *n*-Hexane (170 mL) was added to the mixture, and the resulting mixture was stirred overnight. The precipitated crystals were collected by filtration, and washed with *n*-hexane and dried under reduced pressure to give the title compound (5.6 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

2.63 (3H, s), 5.47 (1H, s), 6.7 (1H, d, $J=2.3\text{Hz}$), 6.79 (1H, dd, $J=8.4\text{Hz}$, 2.3Hz), 7.73 (1H, d, $J=8.4\text{Hz}$), 10.11 (1H, s)

25

Reference Example 32

4-(2-Carboxyethoxy)-2-methylbenzaldehyde

To a mixture of 4-hydroxy-2-methylbenzaldehyde (5 g) and potassium *tert*-butoxide (4.12 g) in tetrahydrofuran (60 mL) was added β -propiolactone (4.6 mL), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured
5 into 1 mol/L hydrochloric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. The residue was suspended in ethyl acetate (20 mL) - *n*-hexane (100 mL). The insoluble
10 material was collected by filtration, and washed with *n*-hexane and dried under reduced pressure to give the title compound (7.2 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

2.65 (3H, s), 2.89 (2H, t, $J=6.4\text{Hz}$), 4.32 (2H, t, $J=6.4\text{Hz}$), 6.76
15 (1H, d, $J=2.5\text{Hz}$), 6.85 (1H, dd, $J=8.7\text{Hz}$, 2.5Hz), 7.76 (1H, d, $J=8.7\text{Hz}$), 10.12 (1H, s)

Reference Example 33

4-[2-(Benzyloxycarbonyl)ethoxy]-2-methylbenzaldehyde

20 To a suspension of 4-(2-carboxyethoxy)-2-methylbenzaldehyde (7.2 g) and potassium carbonate (14.3 g) in *N,N*-dimethylformamide (70 mL) was added benzyl bromide (8.2 mL) at room temperature, and the mixture was stirred overnight. The reaction mixture was poured into water, and the resulting mixture
25 was extracted with diethyl ether. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was

purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 4/1 - 3/1) to give the title compound (6.47 g).

¹H-NMR (CDCl₃) δ ppm:

5 2.64 (3H, s), 2.88 (2H, t, J=6.3Hz), 4.34 (2H, t, J=6.3Hz), 5.19 (2H, s), 6.73 (1H, d, J=2.4Hz), 6.83 (1H, dd, J=8.5Hz, 2.4Hz), 7.3-7.4 (5H, m), 7.75 (1H, d, J=8.5Hz), 10.12 (1H, s)

Reference Example 34

10 {4-[2-(Benzyloxycarbonyl)ethoxy]-2-methylphenyl}methanol

The title compound was prepared in a similar manner to that described in Reference Example 10 using 4-[2-(benzyloxy-carbonyl)ethoxy]-2-methylbenzaldehyde instead of 4-(2-benzyl-oxycarbonyl-2-methylpropoxy)benzaldehyde.

15 ¹H-NMR (CDCl₃) δ ppm:

1.38 (1H, t, J=5.7Hz), 2.35 (3H, s), 2.84 (2H, t, J=6.4Hz), 4.26 (2H, t, J=6.4Hz), 4.63 (2H, d, J=5.7Hz), 5.18 (2H, s), 6.7-6.75 (2H, m), 7.22 (1H, d, J=8.2Hz), 7.3-7.4 (5H, m)

20 Reference Example 35

4-({4-[2-(Benzyloxycarbonyl)ethoxy]phenyl)methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

The title compound was prepared in a similar manner to that described in Reference Example 11 using {4-[2-(benzyloxy-carbonyl)ethoxy]phenyl}methanol instead of [4-(2-benzyloxy-carbonyl-2-methylpropoxy)phenyl]methanol.

25 ¹H-NMR (DMSO-d₆) δ ppm:

1.05-1.1 (6H, m), 2.75-2.85 (3H, m), 3.5 (2H, s), 4.16 (2H, t, J=5.9Hz), 5.14 (2H, s), 6.75-6.8 (2H, m), 7.0-7.05 (2H, m), 7.3-7.4 (5H, m)

5 Reference Example 36

4-({4-[2-(Benzyloxycarbonyl)ethoxy]-2-methylphenyl)methyl}-5-isopropyl-3H-pyrazol-3-one

The title compound was prepared in a similar manner to that described in Reference Example 11 using {4-[2-(benzyloxy-
10 carbonyl)ethoxy]-2-methylphenyl}methanol instead of [4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methanol.

¹H-NMR (CDCl₃) δ ppm:

1.12 (6H, d, J=6.8Hz), 2.3 (3H, s), 2.75-2.9 (3H, m), 3.6 (2H, s), 4.23 (2H, t, J=6.2Hz), 5.17 (2H, s), 6.62 (1H, dd, J=8.5Hz,
15 2.7Hz), 6.7 (1H, d, J=2.7Hz), 6.94 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 37

3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-({4-[2-(benzyloxycarbonyl)ethoxy]phenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-({4-[2-(benzyloxy-
25 carbonyl)ethoxy]phenyl)methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one instead of 4-{{4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl}methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one.

¹H-NMR (CDCl₃) δ ppm:

1.1-1.2 (6H, m), 1.87 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06
(3H, s), 2.82 (2H, t, J=6.4Hz), 2.85-2.95 (1H, m), 3.57 (1H,
d, J=15.9Hz), 3.63 (1H, d, J=15.9Hz), 3.8-3.9 (1H, m), 4.1-4.15
5 (1H, m), 4.22 (2H, t, J=6.4Hz), 4.31 (1H, dd, J=12.4Hz, 4.0Hz),
5.16 (2H, s), 5.2-5.3 (3H, m), 5.58 (1H, d, J=7.6Hz), 6.7-6.8
(2H, m), 7.0-7.05 (2H, m), 7.3-7.4 (5H, m)

Reference Example 38

10 3-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyloxy)-4-({4-[2-(benzyloxycarbonyl)ethoxy]phenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-({4-[2-(benzyloxy-
15 oxycarbonyl)ethoxy]phenyl)methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo-α-D-galactose instead of 4-{{4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl)methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo-α-D-glucose, respectively.

20 ¹H-NMR (CDCl₃) δ ppm:

1.1-1.2 (6H, m), 1.88 (3H, s), 1.99 (3H, s), 2.02 (3H, s), 2.17
(3H, s), 2.8-2.9 (3H, m), 3.58 (1H, d, J=16.1Hz), 3.65 (1H, d,
J=16.1Hz), 4.0-4.25 (5H, m), 5.09 (1H, dd, J=10.4Hz, 3.5Hz),
5.17 (2H, s), 5.4-5.45 (2H, m), 5.55 (1H, d, J=8.2Hz), 6.7-6.8
25 (2H, m), 7.0-7.05 (2H, m), 7.25-7.35 (5H, m)

Reference Example 39

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[2-(benzyloxycarbonyl)ethoxy]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-({4-[2-(benzyloxycarbonyl)ethoxy]-2-methylphenyl)methyl}-5-isopropyl-3H-pyrazol-3-one instead of 4-{[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one.

¹H-NMR (CDCl₃) δ ppm:

1.05-1.15 (6H, m), 1.8 (3H, s), 1.99 (3H, s), 2.02 (3H, s), 2.06 (3H, s), 2.25 (3H, s), 2.7-2.85 (3H, m), 3.49 (1H, d, J=16.2Hz), 3.59 (1H, d, J=16.2Hz), 3.8-3.9 (1H, m), 4.12 (1H, dd, J=12.4Hz, 2.3Hz), 4.21 (2H, t, J=6.6Hz), 4.3 (1H, dd, J=12.4Hz, 4.0Hz), 5.15-5.3 (5H, m), 5.56 (1H, d, J=8.0Hz), 6.57 (1H, dd, J=8.5Hz, 2.4Hz), 6.67 (1H, d, J=2.4Hz), 6.8 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 40

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 13 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-({4-[2-(benzyloxy-carbonyl)ethoxy]phenyl)methyl}-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl)methyl]-

5-isopropyl-1*H*-pyrazole.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.89 (3H, s), 1.97 (3H, s), 2.0 (3H, s), 2.02
(3H, s), 2.71 (2H, t, J=6.2Hz), 2.85-2.95 (1H, m), 3.6 (2H, s),
5 3.9-3.95 (1H, m), 4.1-4.15 (1H, m), 4.18 (2H, t, J=6.2Hz), 4.3
(1H, dd, J=12.4Hz, 4.0Hz), 5.05-5.15 (2H, m), 5.25-5.35 (1H,
m), 5.48 (1H, d, J=8.0Hz), 6.75-6.8 (2H, m), 7.0-7.05 (2H, m)

Reference Example 41

10 3-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyloxy)-4-([4-(2-carboxyethoxy)phenyl]methyl)-5-isopropyl-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 13 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-([4-(2-(benzyloxy-carbonyl)ethoxy]phenyl]methyl)-5-isopropyl-1*H*-pyrazole
15 instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-([4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methyl)-5-isopropyl-1*H*-pyrazole.

¹H-NMR (CD₃OD) δ ppm:

20 1.1-1.2 (6H, m), 1.9 (3H, s), 1.95 (3H, s), 1.99 (3H, s), 2.16
(3H, s), 2.71 (2H, t, J=6.1Hz), 2.85-2.95 (1H, m), 3.61 (2H, s), 4.05-4.2 (5H, m), 5.19 (1H, dd, J=10.4Hz, 3.5Hz), 5.25-5.35
(1H, m), 5.4-5.45 (1H, m), 5.46 (1H, d, J=8.1Hz), 6.75-6.8 (2H, m), 7.0-7.05 (2H, m)

25

Reference Example 42

3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-([4-(2-

carboxyethoxy)-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 13 using 3-(2,3,4,6-tetra-
 5 O-acetyl- β -D-glucopyranosyloxy)-4-({4-[2-(benzyloxy-carbonyl)ethoxy]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-([4-(2-benzyloxycarbonyl-2-methylpropoxy)-phenyl)methyl}-5-isopropyl-1H-pyrazole.

10 $^1\text{H-NMR}$ (CD_3OD) δ ppm:
 1.1-1.15 (6H, m), 1.82 (3H, s), 1.96 (3H, s), 2.0 (3H, s), 2.02 (3H, s), 2.26 (3H, s), 2.7 (2H, t, $J=6.2\text{Hz}$), 2.75-2.9 (1H, m), 3.53 (1H, d, $J=16.4\text{Hz}$), 3.58 (1H, d, $J=16.4\text{Hz}$), 3.85-3.95 (1H, m), 4.08 (1H, dd, $J=12.4\text{Hz}$, 2.4Hz), 4.17 (2H, t, $J=6.2\text{Hz}$), 4.28
 15 (1H, dd, $J=12.4\text{Hz}$, 4.1Hz), 5.0-5.15 (2H, m), 5.27 (1H, t, $J=9.6\text{Hz}$), 5.43 (1H, d, $J=7.9\text{Hz}$), 6.61 (1H, dd, $J=8.5\text{Hz}$, 2.5Hz), 6.71 (1H, d, $J=2.5\text{Hz}$), 6.77 (1H, d, $J=8.5\text{Hz}$)

Reference Example 43

20 4-([4-(3-Carboxypropoxy)-2-methylphenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 25 using 4-({4-[3-(benzyloxy-carbonyl)propoxy]-2-methylphenyl)methyl}-5-isopropyl-3-
 25 (2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-([4-benzyloxy-2-methylphenyl)methyl]-

5-isopropyl-3-(2,3,4,6-tetra-*O*-pivaloyl- β -D-glucopyranosyl-oxy)-1*H*-pyrazole.

¹H-NMR (CDCl₃) δ ppm:

1.04 (9H, s), 1.05-1.2 (33H, m), 2.05-2.15 (2H, m), 2.25 (3H,
5 s), 2.5-2.6 (2H, m), 2.7-2.8 (1H, m), 3.52 (2H, s), 3.8-3.9 (1H,
m), 3.95-4.0 (2H, m), 4.05-4.15 (1H, m), 4.17 (1H, dd, *J*=12.4Hz,
1.9Hz), 5.15-5.3 (2H, m), 5.36 (1H, t, *J*=9.4Hz), 5.53 (1H, d,
J=8.3Hz), 6.57 (1H, dd, *J*=8.4Hz, 2.7Hz), 6.67 (1H, d, *J*=2.7Hz),
6.81 (1H, d, *J*=8.4Hz)

10

Reference Example 44

Benzyl 2-amino-2-methylpropionate hydrochloride

To a solution of 2-(*tert*-butoxycarbonylamino)-2-methylpropionic acid (4.06 g) in *N,N*-dimethylformamide (40 mL) were
15 added potassium carbonate (4.15 g) and benzyl bromide (2.85 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate.
20 The solvent was removed under reduced pressure. The residue (solid) was treated with *n*-hexane and collected by filtration. The crystals were dried under reduced pressure to give benzyl 2-(*tert*-butoxycarbonylamino)-2-methylpropionate (4.44 g). Hydrochloric acid (4 mol/L 1,4-dioxane solution, 15 mL) was added
25 to the obtained benzyl 2-(*tert*-butoxycarbonylamino)-2-methylpropionate (4.44 g), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with

diethyl ether, and the resulting mixture was stirred for 1 hour. The insoluble material was collected by filtration, and washed with diethyl ether and dried under reduced pressure to give the title compound (3.4 g).

5 $^1\text{H-NMR}$ (DMSO-d_6) δ ppm:

1.49 (6H, s), 5.25 (2H, s), 7.3-7.45 (5H, m), 8.54 (3H, brs)

Reference Example 45

10 3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-(2-carboxyethoxy)-2-methylphenyl)-methyl]-5-isopropyl-1H-pyrazole (0.14 g) in *N,N*-dimethyl-
15 formamide (3 mL) were added benzyl 2-amino-2-methylpropionate hydrochloride (57 mg), 1-hydroxybenzotriazole (31 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (60 mg) and triethylamine (0.087 mL), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured
20 into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol
25 = 40/1 - 20/1) to give the title compound (0.15 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.1-1.15 (6H, m), 1.56 (6H, s), 1.81 (3H, s), 1.99 (3H, s), 2.02

(3H, s), 2.05 (3H, s), 2.25 (3H, s), 2.6 (2H, t, J=6.1Hz), 2.75-2.85 (1H, m), 3.5 (1H, d, J=16.7Hz), 3.59 (1H, d, J=16.7Hz), 3.8-3.9 (1H, m), 4.05-4.2 (3H, m), 4.29 (1H, dd, J=12.5Hz, 4.0Hz), 5.1-5.3 (5H, m), 5.56 (1H, d, J=8.1Hz), 6.53 (1H, brs), 6.57 (1H, dd, J=8.5Hz, 2.5Hz), 6.67 (1H, d, J=2.5Hz), 6.8 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 46

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(benzyloxycarbonyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 45 using benzyl (S)-2-amino-propionate *p*-toluenesulfonic acid salt instead of benzyl

2-amino-2-methylpropionate hydrochloride.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.38 (3H, d, J=7.3Hz), 1.82 (3H, s), 1.95 (3H, s), 2.0 (3H, s), 2.01 (3H, s), 2.25 (3H, s), 2.6-2.7 (2H, m), 2.75-2.9 (1H, m), 3.52 (1H, d, J=16.5Hz), 3.58 (1H, d, J=16.5Hz), 3.85-3.95 (1H, m), 4.07 (1H, dd, J=12.2Hz, 2.5Hz), 4.1-4.2 (2H, m), 4.27 (1H, dd, J=12.2Hz, 4.2Hz), 4.4-4.5 (1H, m), 5.0-5.2 (4H, m), 5.28 (1H, t, J=9.5Hz), 5.43 (1H, d, J=7.9Hz), 6.58 (1H, dd, J=8.5Hz, 2.2Hz), 6.69 (1H, d, J=2.2Hz), 6.76 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 47

4-[(4-{3-[1-Benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]-

propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 45 using 4-{[4-(3-carboxy-propoxy)-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole.

¹H-NMR (CDCl₃) δ ppm:

1.0-1.2 (42H, m), 1.52 (6H, s), 1.95-2.1 (2H, m), 2.25 (3H, s), 2.34 (2H, t, J=7.3Hz), 2.7-2.85 (1H, m), 3.52 (2H, s), 3.8-3.95 (3H, m), 4.05-4.2 (2H, m), 5.1-5.25 (4H, m), 5.36 (1H, t, J=9.1Hz), 5.65 (1H, d, J=8.3Hz), 6.05 (1H, brs), 6.53 (1H, dd, J=8.2Hz, 2.5Hz), 6.65 (1H, d, J=2.5Hz), 6.81 (1H, d, J=8.2Hz), 7.25-7.4 (5H, m)

Reference Example 48

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

3-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]-ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole (0.15 g) was dissolved in methanol (5 mL). To the solution was added 10% palladium-carbon powder (50 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere overnight.

The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (0.13 g).

¹H-NMR (CD₃OD) δ ppm:

- 5 1.05-1.15 (6H, m), 1.47 (6H, s), 1.82 (3H, s), 1.96 (3H, s),
2.0 (3H, s), 2.02 (3H, s), 2.26 (3H, s), 2.6 (2H, t, J=6.3Hz),
2.75-2.9 (1H, m), 3.52 (1H, d, J=16.4Hz), 3.58 (1H, d, J=16.4Hz),
3.85-3.95 (1H, m), 4.07 (1H, dd, J=12.4Hz, 2.2Hz), 4.16 (2H,
t, J=6.3Hz), 4.27 (1H, dd, J=12.4Hz, 4.0Hz), 5.0-5.15 (2H, m),
10 5.28 (1H, t, J=9.5Hz), 5.43 (1H, d, J=8.2Hz), 6.61 (1H, dd, J=8.5Hz,
2.6Hz), 6.71 (1H, d, J=2.6Hz), 6.77 (1H, d, J=8.5Hz)

Reference Example 49

- 15 3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-
[(S)-1-(carboxy)ethylcarbamoyl]ethoxy}-2-methylphenyl)-
methyl]-5-isopropyl-1H-pyrazole

- The title compound was prepared in a similar manner to that described in Reference Example 48 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(benzyloxy-
20 carbonyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole.

- 25 ¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.39 (3H, d, J=7.3Hz), 1.82 (3H, s), 1.96 (3H, s), 2.0 (3H, s), 2.02 (3H, s), 2.26 (3H, s), 2.6-2.7 (2H,

m), 2.75-2.9 (1H, m), 3.52 (1H, d, J=16.6Hz), 3.58 (1H, d, J=16.6Hz), 3.85-3.95 (1H, m), 4.07 (1H, dd, J=12.4Hz, 2.5Hz), 4.1-4.25 (2H, m), 4.27 (1H, dd, J=12.4Hz, 4.0Hz), 4.4 (1H, q, J=7.3Hz), 5.0-5.15 (2H, m), 5.28 (1H, t, J=9.4Hz), 5.43 (1H, d, J=8.0Hz), 6.62 (1H, dd, J=8.3Hz, 2.7Hz), 6.72 (1H, d, J=2.7Hz), 6.77 (1H, d, J=8.3Hz)

Reference Example 50

4-[(4-{3-[1-Carboxy-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 48 using 4-[(4-{3-[1-benzyl-oxycarbonyl-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-benzyl-oxycarbonyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (42H, m), 1.44 (6H, s), 1.95-2.05 (2H, m), 2.26 (3H, s), 2.35 (2H, t, J=7.4Hz), 2.75-2.85 (1H, m), 3.5-3.6 (2H, m), 3.9-4.0 (3H, m), 4.09 (1H, dd, J=12.4Hz, 1.8Hz), 4.17 (1H, dd, J=12.4Hz, 4.2Hz), 5.05-5.2 (2H, m), 5.39 (1H, t, J=9.5Hz), 5.58 (1H, d, J=7.9Hz), 6.58 (1H, dd, J=8.4Hz, 2.6Hz), 6.7 (1H, d, J=2.6Hz), 6.8 (1H, d, J=8.4Hz)

Reference Example 51

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{4-[1-carboxy-1-(methyl)ethylcarbamoyl]butyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole

- 5 A mixture of 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-iodophenyl)methyl]-5-isopropyl-1H-pyrazole (0.43 g), 4-pentynoic acid (94 mg), tetrakis-(triphenylphosphine)palladium(0) (37 mg), copper(I)iodide (12 mg) and triethylamine (0.45 mL) in tetrahydrofuran (5 mL) was
- 10 stirred at room temperature under an argon atmosphere overnight. The reaction mixture was poured into 0.5 mol/L hydrochloric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure,
- 15 and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/2 - ethyl acetate) to give 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[[4-(4-carboxybut-1-ynyl)phenyl]methyl]-5-isopropyl-1H-pyrazole (0.37 g). This material was dissolved in *N,N*-dimethyl-
- 20 formamide (6 mL). To the solution were added benzyl 2-amino-2-methylpropionate hydrochloride (0.15 g), 1-hydroxybenzotriazole (86 mg), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (0.22 g) and triethylamine (0.32 mL), and the mixture was stirred at room temperature overnight. The
- 25 reaction mixture was poured into 0.5 mol/L hydrochloric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water, a saturated aqueous sodium

hydrogen carbonate solution and brine successively, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 20/1) to give 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{4-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]but-1-ynyl}phenyl)methyl]-5-isopropyl-1H-pyrazole (0.36 g). This material was dissolved in methanol (5 mL). To the solution was added 10% palladium-carbon powder (50 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 2 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (0.31 g).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.44 (6H, s), 1.55-1.65 (4H, m), 1.88 (3H, s), 1.95 (3H, s), 1.99 (3H, s), 2.1-2.2 (5H, m), 2.5-2.6 (2H, m), 2.85-3.0 (1H, m), 3.55-3.7 (2H, m), 4.05-4.2 (3H, m), 5.19 (1H, dd, $J=10.4\text{Hz}$, 3.5Hz), 5.25-5.35 (1H, m), 5.4-5.45 (1H, m), 5.46 (1H, d, $J=8.1\text{Hz}$), 7.0-7.1 (4H, m)

Example 78

4-[(4-{2-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole (0.2 g) in *N,N*-dimethyl-

formamide (3 mL) were added 2-amino-2-methylpropionamide (47 mg), 1-hydroxybenzotriazole (50 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (118 mg) and triethylamine (0.13 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 20/1 - 10/1) to give 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carbamoyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole (0.12 g). This material was dissolved in methanol (3 mL). To the solution was added sodium methoxide (28% methanol solution, 0.06 mL), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added acetic acid (0.1 mL), and the resulting mixture was concentrated under reduced pressure. The residue was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: methanol) to give the title compound (80 mg).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.47 (6H, s), 2.29 (3H, s), 2.62 (2H, t, $J=6.1\text{Hz}$), 2.75-2.85 (1H, m), 3.25-3.4 (4H, m), 3.6-3.75 (3H, m), 3.81 (1H, d, $J=11.9\text{Hz}$), 4.18 (2H, t, $J=6.1\text{Hz}$), 4.95-5.05 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.4Hz), 6.72 (1H, d, $J=2.4\text{Hz}$), 6.86 (1H, d, $J=8.4\text{Hz}$)

Example 79

4-[(4-{2-[1-Carbamoyl-1-(methyl)ethylcarbamoyl]ethoxy}-
phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-
5 pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)phenyl]-methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-
10 O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.5-1.15 (6H, m), 1.47 (6H, s), 2.63 (2H, t, $J=6.2\text{Hz}$), 2.85-2.95
(1H, m), 3.3-3.4 (4H, m), 3.6-3.75 (3H, m), 3.8-3.85 (1H, m),
15 4.19 (2H, t, $J=6.2\text{Hz}$), 5.05-5.1 (1H, m), 6.8-6.85 (2H, m),
7.1-7.15 (2H, m)

Example 80

3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di-
20 (methyl)ethylcarbamoyl]ethoxy}phenyl)methyl]-5-isopropyl-
1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)phenyl]-
25 methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methyl-1-propanol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl]-

methyl}-5-isopropyl-1*H*-pyrazole and 2-amino-2-methyl-propionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.27 (6H, s), 2.59 (2H, t, J=6.2Hz), 2.85-2.95
 5 (1H, m), 3.3-3.4 (4H, m), 3.57 (2H, s), 3.6-3.85 (4H, m), 4.16
 (2H, t, J=6.2Hz), 5.05-5.1 (1H, m), 6.75-6.85 (2H, m), 7.05-7.15
 (2H, m)

Reference Example 52

10 1-(2-Amino-2-methylpropionyl)-4-methylpiperazine

To a solution of 2-benzyloxycarbonylamino-2-methyl-propionic acid (2.37 g) in tetrahydrofuran (20 mL) was added 1,1'-carbonylbis-1*H*-imidazole (1.78 g), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture
 15 was added 1-methylpiperazine (2.0 mL), and the mixture was stirred at 40°C for 3.5 days. To the reaction mixture was added methanol, and the resulting mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol
 20 = 20/1) to give 1-(2-benzyloxycarbonylamino-2-methyl-propionyl)-4-methylpiperazine (1.99 g). This material was dissolved in methanol (10 mL). To the solution was added 10% palladium-carbon powder (0.4 g), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours.
 25 The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (1.14 g).

¹H-NMR (CD₃OD) δ ppm:

1.39 (6H, s), 2.3 (3H, s), 2.44 (4H, t, J=5.1Hz), 3.77 (4H, brs)

Reference Example 53

5 2-(2-Amino-2-methylpropionylamino)ethanol

The title compound was prepared in a similar manner to that described in Reference Example 52 using 2-aminoethanol instead of 1-methylpiperazine.

¹H-NMR (CD₃OD) δ ppm:

10 1.31 (6H, s), 3.25-3.35 (2H, m), 3.6 (2H, t, J=5.8Hz)

Example 81

15 3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy)phenyl]methyl}-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)-phenyl]methyl}-5-isopropyl-1H-pyrazole and 1-(2-amino-2-methylpropionyl)-4-methylpiperazine instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)-2-methylphenyl]methyl}-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

25 1.05-1.2 (6H, m), 1.45 (6H, s), 2.2 (3H, s), 2.3-2.5 (4H, m), 2.6 (2H, t, J=5.7Hz), 2.85-2.95 (1H, m), 3.3-3.4 (4H, m), 3.6-3.9 (8H, m), 4.18 (2H, t, J=5.7Hz), 5.05-5.1 (1H, m), 6.75-6.85 (2H,

m), 7.1-7.15 (2H, m)

Example 82

3-(β -D-Galactopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy}phenyl)methyl]-1H-pyrazole}

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-{[4-(2-carboxyethoxy)phenyl]-methyl}-5-isopropyl-1H-pyrazole and 1-(2-amino-2-methylpropionyl)-4-methylpiperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.45 (6H, s), 2.17 (3H, s), 2.35 (4H, brs), 2.6 (2H, t, J=5.6Hz), 2.85-2.95 (1H, m), 3.52 (1H, dd, J=9.7Hz, 3.2Hz), 3.55-3.9 (11H, m), 4.18 (2H, t, J=5.6Hz), 5.08 (1H, d, J=7.6Hz), 6.75-6.85 (2H, m), 7.05-7.2 (2H, m)

Example 83

3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[1-(2-hydroxyethylcarbamoyl)-1-(methyl)ethylcarbamoyl]ethoxy}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-{[4-(2-carboxyethoxy)phenyl)methyl]-

5-isopropyl-1*H*-pyrazole and 2-(2-amino-2-methylpropionyl-amino)ethanol instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)-2-methylphenyl]-methyl)-5-isopropyl-1*H*-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (6H, m), 1.45 (6H, s), 2.63 (2H, t, *J*=6.2Hz), 2.85-2.95 (1H, m), 3.24 (2H, t, *J*=5.9Hz), 3.3-3.4 (4H, m), 3.51 (2H, t, *J*=5.9Hz), 3.6-3.85 (4H, m), 4.19 (2H, t, *J*=6.2Hz), 5.05-5.1 (1H, m), 6.8-6.85 (2H, m), 7.1-7.15 (2H, m)

Example 84

3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[(*S*)-2-hydroxy-1-(methyl)ethylcarbamoyl]ethoxy}phenyl)methyl]-5-isopropyl-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)phenyl]-methyl)-5-isopropyl-1*H*-pyrazole and (*S*)-2-amino-1-propanol instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)-2-methylphenyl]methyl)-5-isopropyl-1*H*-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.15 (9H, m), 2.55-2.65 (2H, m), 2.85-2.95 (1H, m), 3.3-3.4 (4H, m), 3.44 (1H, dd, *J*=10.9Hz, 5.7Hz), 3.49 (1H, dd, *J*=10.9Hz, 5.6Hz), 3.6-3.75 (3H, m), 3.8-3.85 (1H, m), 3.9-4.0 (1H, m),

4.15-4.25 (2H, m), 5.0-5.1 (1H, m), 6.75-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 85

5 3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -
10 D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-methylpiperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-
15 methylpropionamide, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.45 (6H, s), 2.18 (3H, s), 2.29 (3H, s), 2.36 (4H, brs), 2.6 (2H, t, $J=5.7\text{Hz}$), 2.75-2.85 (1H, m), 3.25-3.4 (4H, m), 3.55-3.75 (7H, m), 3.82 (1H, d, $J=11.8\text{Hz}$), 4.17 (2H,
20 t, $J=5.7\text{Hz}$), 5.0-5.15 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.5Hz), 6.71 (1H, d, $J=2.5\text{Hz}$), 6.87 (1H, d, $J=8.4\text{Hz}$)

Example 86

25 3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-bis-(hydroxymethyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Example 78 using tris(hydroxymethyl)-aminomethane instead of 2-amino-2-methylpropionamide.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 2.29 (3H, s), 2.68 (2H, t, J=6.1Hz), 2.75-2.85
5 (1H, m), 3.25-3.4 (4H, m), 3.6-3.75 (9H, m), 3.81 (1H, d, J=12.0Hz),
4.18 (2H, t, J=6.1Hz), 5.0-5.05 (1H, m), 6.65 (1H, dd, J=8.4Hz,
2.3Hz), 6.74 (1H, d, J=2.3Hz), 6.86 (1H, d, J=8.4Hz)

Example 87

10 3-(β-D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di-
(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-
isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 2-amino-2-methyl-1-propanol
15 instead of 2-amino-2-methylpropionamide.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.27 (6H, s), 2.29 (3H, s), 2.58 (2H, t, J=6.2Hz),
2.75-2.85 (1H, m), 3.2-3.4 (4H, m), 3.57 (2H, s), 3.6-3.75 (3H,
m), 3.82 (1H, d, J=11.9Hz), 4.16 (2H, t, J=6.2Hz), 4.95-5.05
20 (1H, m), 6.62 (1H, dd, J=8.4Hz, 2.0Hz), 6.72 (1H, d, J=2.0Hz),
6.86 (1H, d, J=8.4Hz)

Example 88

25 3-(β-D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1-hydroxy-
methyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)-
methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Example 78 using 2-amino-2-methyl-1,3-propanediol instead of 2-amino-2-methylpropionamide.

^1H -NMR (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.25 (3H, s), 2.29 (3H, s), 2.63 (2H, t, $J=6.2\text{Hz}$),
 5 2.75-2.85 (1H, m), 3.25-3.4 (4H, m), 3.6-3.7 (7H, m), 3.81 (1H, d, $J=11.8\text{Hz}$), 4.17 (2H, t, $J=6.2\text{Hz}$), 5.0-5.05 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.4Hz), 6.73 (1H, d, $J=2.4\text{Hz}$), 6.86 (1H, d, $J=8.4\text{Hz}$)

Example 89

10 3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[1-{[4-(2-hydroxyethyl)-piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -
 15 D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(2-hydroxyethyl)piperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-
 20 pyrazole and 2-amino-2-methylpropionamide, respectively.

^1H -NMR (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.45 (6H, s), 2.3 (3H, s), 2.35-2.55 (6H, m),
 2.6 (2H, t, $J=5.7\text{Hz}$), 2.75-2.9 (1H, m), 3.25-3.4 (4H, m), 3.57 (2H, t, $J=5.8\text{Hz}$), 3.6-3.8 (7H, m), 3.82 (1H, d, $J=11.9\text{Hz}$), 4.17
 25 (2H, t, $J=5.7\text{Hz}$), 5.0-5.05 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.4Hz), 6.71 (1H, d, $J=2.4\text{Hz}$), 6.87 (1H, d, $J=8.4\text{Hz}$)

Example 90

3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[1-(2-hydroxyethyl-carbamoyl)-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-phenyl)methyl]-5-isopropyl-1H-pyrazole

- 5 The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethyl-carbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-aminoethanol instead of 3-(2,3,4,6-tetra-O-
- 10 acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-(2-carboxyethoxy)-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

- 1.05-1.15 (6H, m), 1.45 (6H, s), 2.29 (3H, s), 2.63 (2H, t, J=6.2Hz),
- 15 2.75-2.85 (1H, m), 3.24 (2H, t, J=5.9Hz), 3.3-3.4 (4H, m), 3.51 (2H, t, J=5.9Hz), 3.6-3.7 (3H, m), 3.82 (1H, d, J=12.0Hz), 4.18 (2H, t, J=6.2Hz), 5.0-5.05 (1H, m), 6.64 (1H, dd, J=8.4Hz, 2.4Hz), 6.74 (1H, d, J=2.4Hz), 6.86 (1H, d, J=8.4Hz)

20 Example 91

3-(β -D-Glucopyranosyloxy)-4-[(4-{2-[1-(3-hydroxypropyl-carbamoyl)-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-phenyl)methyl]-5-isopropyl-1H-pyrazole

- The title compound was prepared in a similar manner to
- 25 that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethyl-carbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-

pyrazole and 3-amino-1-propanol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

5 ^1H -NMR (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.45 (6H, s), 1.55-1.65 (2H, m), 2.29 (3H, s), 2.62 (2H, t, $J=6.1\text{Hz}$), 2.75-2.85 (1H, m), 3.2 (2H, t, $J=6.6\text{Hz}$), 3.25-3.4 (4H, m), 3.51 (2H, t, $J=6.2\text{Hz}$), 3.6-3.7 (3H, m), 3.82 (1H, d, $J=12.0\text{Hz}$), 4.18 (2H, t, $J=6.1\text{Hz}$), 5.0-5.15 (1H, m), 6.64 (1H, dd, $J=8.4\text{Hz}$, 2.3Hz), 6.73 (1H, d, $J=2.3\text{Hz}$), 6.87 (1H, d, $J=8.4\text{Hz}$)

Example 92

15 4-[(4-{2-[(*S*)-1-(Carbamoyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using L-alanine amide hydrochloride instead of 2-amino-2-methylpropionamide.

20 ^1H -NMR (CD_3OD) δ ppm:

1.1-1.15 (6H, m), 1.36 (3H, d, $J=7.2\text{Hz}$), 2.29 (3H, s), 2.6-2.85 (3H, m), 3.3-3.4 (4H, m), 3.6-3.7 (3H, m), 3.81 (1H, d, $J=12.1\text{Hz}$), 4.15-4.25 (2H, m), 4.36 (1H, q, $J=7.2\text{Hz}$), 5.0-5.05 (1H, m), 6.62 (1H, dd, $J=8.4\text{Hz}$, 2.5Hz), 6.72 (1H, d, $J=2.5\text{Hz}$), 6.86 (1H, d, $J=8.4\text{Hz}$)

Example 93

3-(β -D-Glucopyranosyloxy)-4-[4-{2-[(S)-1-(2-hydroxyethyl-carbamoyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(carboxy)ethyl-carbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-aminoethanol instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.34 (3H, d, $J=7.2\text{Hz}$), 2.29 (3H, s), 2.67 (2H, t, $J=6.1\text{Hz}$), 2.75-2.85 (1H, m), 3.2-3.4 (6H, m), 3.55 (2H, t, $J=5.8\text{Hz}$), 3.6-3.7 (3H, m), 3.82 (1H, d, $J=12.0\text{Hz}$), 4.19 (2H, t, $J=6.1\text{Hz}$), 4.35 (1H, q, $J=7.2\text{Hz}$), 4.95-5.05 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.3Hz), 6.73 (1H, d, $J=2.3\text{Hz}$), 6.86 (1H, d, $J=8.4\text{Hz}$)

Example 94

4-[(4-{2-[(S)-1-Carbamoyl-2-hydroxyethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using L-serine amide hydrochloride instead of 2-amino-2-methylpropionamide.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 2.29 (3H, s), 2.65-2.9 (3H, m), 3.25-3.4 (4H,

m), 3.55-3.9 (6H, m), 4.21 (2H, t, J=6.0Hz), 4.4-4.5 (1H, m), 4.95-5.05 (1H, m), 6.64 (1H, dd, J=8.3Hz, 2.2Hz), 6.73 (1H, d, J=2.2Hz), 6.86 (1H, d, J=8.3Hz)

5 Example 95

3-(β-D-Glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1-(hydroxymethyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 2-amino-1,3-propanediol instead of 2-amino-2-methylpropionamide.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 2.29 (3H, s), 2.65 (2H, t, J=6.2Hz), 2.75-2.85 (1H, m), 3.3-3.4 (4H, m), 3.55-3.7 (7H, m), 3.86 (1H, d, J=11.6Hz), 3.9-4.0 (1H, m), 4.19 (2H, t, J=6.2Hz), 4.95-5.05 (1H, m), 6.63 (1H, dd, J=8.4Hz, 2.4Hz), 6.72 (1H, d, J=2.4Hz), 6.86 (1H, d, J=8.4Hz)

Example 96

20 3-(β-D-Glucopyranosyloxy)-4-[(4-{2-[(S)-1-(3-hydroxypropylcarbamoyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[(S)-1-(carboxy)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 3-amino-1-propanol instead of 3-(2,3,4,6-tetra-O-

acetyl- β -D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

5 1.05-1.15 (6H, m), 1.34 (3H, d, $J=7.2\text{Hz}$), 1.6-1.7 (2H, m), 2.29 (3H, s), 2.66 (2H, t, $J=6.2\text{Hz}$), 2.75-2.85 (1H, m), 3.2-3.4 (6H, m), 3.54 (2H, t, $J=6.2\text{Hz}$), 3.6-3.7 (3H, m), 3.82 (1H, d, $J=11.6\text{Hz}$), 4.19 (2H, t, $J=6.2\text{Hz}$), 4.32 (1H, q, $J=7.2\text{Hz}$), 5.0-5.05 (1H, m), 6.63 (1H, dd, $J=8.4\text{Hz}$, 2.5Hz), 6.72 (1H, d, $J=2.5\text{Hz}$), 6.86 (1H, d, $J=8.4\text{Hz}$)

Example 97

3-(β -D-Galactopyranosyloxy)-4-[(4-{4-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-butyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{4-[1-carboxy-1-(methyl)ethylcarbamoyl]butyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(2-hydroxyethyl)piperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

25 1.05-1.2 (6H, m), 1.42 (6H, s), 1.55-1.65 (4H, m), 2.18 (2H, t, $J=6.8\text{Hz}$), 2.4-2.65 (8H, m), 2.85-2.95 (1H, m), 3.5-3.8 (13H, m), 3.85-3.9 (1H, m), 5.08 (1H, d, $J=7.8\text{Hz}$), 7.04 (2H, d, $J=8.0\text{Hz}$),

7.1 (2H, d, J=8.0Hz)

Example 98

3-(β-D-Galactopyranosyloxy)-5-isopropyl-4-([4-(4-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-butyl)phenyl]methyl)-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-([4-{4-[1-carboxy-1-(methyl)ethylcarbamoyl]butyl}phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-methylpiperazine instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-([4-(2-carboxyethoxy)-2-methylphenyl]methyl)-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.41 (6H, s), 1.55-1.65 (4H, m), 2.18 (2H, t, J=6.9Hz), 2.24 (3H, s), 2.35 (4H, brs), 2.57 (2H, t, J=6.6Hz), 2.85-2.95 (1H, m), 3.45-3.8 (11H, m), 3.85-3.95 (1H, m), 5.08 (1H, d, J=7.7Hz), 7.04 (2H, d, J=7.9Hz), 7.1 (2H, d, J=7.9Hz)

Example 99

3-(β-D-Glucopyranosyloxy)-5-isopropyl-4-([4-(2-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy)-2-methylphenyl]methyl)-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-([4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-

pyrazole (40 mg) in *N,N*-dimethylformamide (1 mL) were added
 1-benzylpiperazine (12 mg), 1-hydroxybenzotriazole (8 mg),
 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
 (16 mg) and triethylamine (0.023 mL), and the mixture was stirred
 5 at room temperature overnight. The reaction mixture was poured
 into water, and the resulting mixture was extracted with ethyl
 acetate. The extract was washed with water and brine, and dried
 over anhydrous sodium sulfate. The solvent was removed under
 reduced pressure, and the residue was purified by column
 10 chromatography on silica gel (eluent: dichloromethane/methanol
 = 30/1 - 15/1) to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-{{[4-(2-{1-[(4-benzylpiperazin-1-yl)-
 carbonyl]-1-(methyl)ethylcarbamoyl}ethoxy)-2-methylphenyl]-
 methyl}-5-isopropyl-1*H*-pyrazole (31 mg). This material was
 15 dissolved in methanol (3 mL). To the solution was added sodium
 methoxide (28% methanol solution, 0.02 mL), and the mixture was
 stirred at room temperature for 1 hour. To the reaction mixture
 was added acetic acid (0.04 mL). The resulting mixture was
 concentrated under reduced pressure, and the residue was purified
 20 by solid phase extraction on ODS (washing solvent: distilled
 water, eluent: methanol) to give 4-{{[4-(2-{1-[(4-benzyl-
 piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}ethoxy)-
 2-methylphenyl]methyl}-3-(β -D-glucopyranosyloxy)-5-
 isopropyl-1*H*-pyrazole (24 mg). This material was dissolved in
 25 methanol (3 mL). To the solution was added 10% palladium-carbon
 powder (10 mg), and the mixture was stirred at room temperature
 under a hydrogen atmosphere overnight. The insoluble material

was removed under reduced pressure, and the solvent of the filtrate was removed under reduced pressure to give the title compound (20 mg).

¹H-NMR (CD₃OD) δ ppm:

- 5 1.05-1.15 (6H, m), 1.45 (6H, s), 2.3 (3H, s), 2.5-2.9 (7H, m), 3.25-3.4 (4H, m), 3.45-3.75 (7H, m), 3.81 (1H, d, J=11.5Hz), 4.17 (2H, t, J=5.7Hz), 4.95-5.05 (1H, m), 6.62 (1H, dd, J=8.4Hz, 2.5Hz), 6.71 (1H, d, J=2.5Hz), 6.86 (1H, d, J=8.4Hz)

10 Example 100

3-(β-D-Galactopyranosyloxy)-5-isopropyl-4-{[4-(4-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]butyl)-phenyl]methyl}-1H-pyrazole

- The title compound was prepared in a similar manner to that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-[(4-{4-[1-carboxy-1-(methyl)ethylcarbamoyl]butyl}phenyl)methyl]-5-isopropyl-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole.

¹H-NMR (CD₃OD) δ ppm:

- 1.05-1.15 (6H, m), 1.41 (6H, s), 1.5-1.65 (4H, m), 2.17 (2H, t, J=7.1Hz), 2.58 (2H, t, J=6.8Hz), 2.72 (4H, brs), 2.85-2.95 (1H, m), 3.45-3.8 (11H, m), 3.8-3.9 (1H, m), 5.08 (1H, d, J=7.7Hz), 7.04 (2H, d, J=8.0Hz), 7.1 (2H, d, J=8.0Hz)

Example 101

4-[(4-{2-[(S)-5-Amino-1-(carbamoyl)pentylcarbamoyl]ethoxy}-
2-methylphenyl)methyl]-3-(β-D-glucopyranosyloxy)-5-
isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 5 that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-β-
 D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methyl-
 phenyl)methyl]-5-isopropyl-1H-pyrazole and (S)-2-amino-6-
 (benzyloxycarbonylamino)hexanamide hydrochloride instead of
 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-
 10 [1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-
 phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzyl-
 piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.3-1.95 (6H, m), 2.3 (3H, s), 2.6-2.9 (5H,
 15 m), 3.3-3.4 (4H, m), 3.6-3.7 (3H, m), 3.82 (1H, d, J=11.8Hz),
 4.15-4.25 (2H, m), 4.38 (1H, dd, J=9.3Hz, 4.8Hz), 5.0-5.05 (1H,
 m), 6.62 (1H, dd, J=8.4Hz, 2.5Hz), 6.72 (1H, d, J=2.5Hz), 6.86
 (1H, d, J=8.4Hz)

20 Example 102

4-[(4-{2-[(S)-5-Amino-5-(carbamoyl)pentylcarbamoyl]ethoxy}-
2-methylphenyl)methyl]-3-(β-D-glucopyranosyloxy)-5-
isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 25 that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-β-
 D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methyl-
 phenyl)methyl]-5-isopropyl-1H-pyrazole and (S)-6-amino-2-

(benzyloxycarbonylamino)hexanamide hydrochloride instead of
 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-
 [1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-
 phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzyl-
 5 piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.3-1.8 (6H, m), 2.29 (3H, s), 2.59 (2H, t,
 J=6.1Hz), 2.75-2.85 (1H, m), 3.21 (2H, t, J=6.9Hz), 3.3-3.4 (5H,
 m), 3.6-3.7 (3H, m), 3.81 (1H, d, J=11.5Hz), 4.18 (2H, t, J=6.1Hz),
 10 5.0-5.05 (1H, m), 6.62 (1H, dd, J=8.4Hz, 2.4Hz), 6.71 (1H, d,
 J=2.4Hz), 6.86 (1H, d, J=8.4Hz)

Example 103

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-[(4-(3-{1-
 15 [(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
 propyl)-2-methylphenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl- β -
 D-glucopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-
 20 carbamoyl]propyl}-2-methylphenyl)methyl]-5-isopropyl-1H-
 pyrazole and 1-(benzyloxycarbonyl)piperazine instead of
 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-
 [1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-
 phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzyl-
 25 piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.16 (2H, t,

$J=7.2\text{Hz}$), 2.3 (3H, s), 2.55 (2H, t, $J=7.5\text{Hz}$), 2.65-2.9 (5H, m), 3.2-3.45 (4H, m), 3.5-3.9 (8H, m), 4.95-5.05 (1H, m), 6.8-6.9 (2H, m), 6.9-7.0 (1H, m)

5 Example 104

4-{\{4-(3-\{1-[(S)-5-Amino-5-(carbamoyl)pentylcarbamoyl]-1-(methyl)ethylcarbamoyl\}propyl)phenyl)methyl\}-3-(\beta-D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 10 that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-\beta-D-galactopyranosyloxy)-4-[(4-\{3-[1-carboxy-1-(methyl)ethyl-carbamoyl]propyl\}phenyl)methyl]-5-isopropyl-1H-pyrazole and
 (S)-6-amino-2-(benzyloxycarbonylamino)hexanamide hydro-
 chloride instead of 3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-4-[(4-\{2-[1-carboxy-1-(methyl)ethyl-
 15 carbamoyl]ethoxy\}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzylpiperazine, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.2-1.6 (11H, m), 1.6-1.75 (1H, m), 1.8-1.9
 20 (2H, m), 2.19 (2H, t, $J=7.8\text{Hz}$), 2.58 (2H, t, $J=7.7\text{Hz}$), 2.85-2.95 (1H, m), 3.1-3.25 (2H, m), 3.25-3.35 (1H, m), 3.52 (1H, dd, $J=9.7\text{Hz}$, 3.4Hz), 3.55-3.65 (1H, m), 3.65-3.8 (5H, m), 3.86 (1H, d, $J=3.1\text{Hz}$), 5.08 (1H, d, $J=8.0\text{Hz}$), 7.0-7.15 (4H, m)

25 Example 105

3-(\beta-D-Glucopyranosyloxy)-5-isopropyl-4-{\{4-(3-\{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl\}-

propoxy)-2-methylphenyl)methyl]-1H-pyrazole

To a solution of 4-[(4-{3-[1-carboxy-1-(methyl)ethyl-carbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (0.12 g) in *N,N*-dimethylformamide (3 mL) were added 1-(benzyloxycarbonyl)piperazine (43 mg), 1-hydroxybenzotriazole (19 mg), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (50 mg) and triethylamine (0.027 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water. The precipitated crystals were collected by filtration, and washed with water and dried under reduced pressure to give 4-[(4-{3-[1-[(4-(benzyloxycarbonyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (0.14 g). This material was dissolved in ethanol (4 mL). To the solution was added 10% palladium-carbon powder (30 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 1.5 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 10/1 - 5/1) to give 5-isopropyl-4-[(4-{3-[1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (89 mg). This material was dissolved in methanol (6 mL). To the solution was added sodium methoxide

(28% methanol solution, 0.087 mL), and the mixture was stirred at 50°C for 3 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: 5 methanol) to give the title compound (54 mg).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.29 (3H, s), 2.39 (2H, t, J=7.3Hz), 2.55-2.9 (5H, m), 3.25-3.4 (4H, m), 3.5-3.7 (7H, m), 3.75-3.85 (1H, m), 3.95 (2H, t, J=6.0Hz), 10 5.0-5.05 (1H, m), 6.61 (1H, dd, J=8.4Hz, 2.3Hz), 6.71 (1H, d, J=2.3Hz), 6.84 (1H, d, J=8.4Hz)

Example 106

15 3-(β-D-Glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

To a solution of 4-[(4-{3-[1-carboxy-1-(methyl)ethyl-carbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazole (40 mg) in *N,N*-dimethylformamide (2 mL) were added 20 1-(2-hydroxyethyl)piperazine (7 mg), 1-hydroxybenzotriazole (7 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (13 mg) and triethylamine (0.018 mL), and the mixture was stirred at room temperature overnight. The reaction 25 mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent

was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 15/1) to give 4-[[4-(3-[1-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]propoxy)-2-methylphenyl]methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole (27 mg). This material was dissolved in methanol (2 mL). To the solution was added sodium methoxide (28% methanol solution, 0.015 mL), and the mixture was stirred at 50°C overnight.

The reaction mixture was concentrated under reduced pressure, and the residue was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: methanol) to give the title compound (12 mg).

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.29 (3H, s), 2.35-2.5 (8H, m), 2.75-2.85 (1H, m), 3.25-3.4 (4H, m), 3.55-3.75 (9H, m), 3.75-3.85 (1H, m), 3.94 (2H, t, $J=6.1\text{Hz}$), 5.0-5.05 (1H, m), 6.61 (1H, dd, $J=8.4\text{Hz}$, 2.4Hz), 6.7 (1H, d, $J=2.4\text{Hz}$), 6.85 (1H, d, $J=8.4\text{Hz}$)

20

Example 107

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-[[4-(3-[1-[[4-methylpiperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]propoxy)-2-methylphenyl]methyl]-1H-pyrazole

25

The title compound was prepared in a similar manner to that described in Example 106 using 1-methylpiperazine instead of 1-(2-hydroxyethyl)piperazine.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.22 (3H, s), 2.25-2.45 (9H, m), 2.75-2.85 (1H, m), 3.25-3.4 (4H, m), 3.55-3.75 (7H, m), 3.75-3.85 (1H, m), 3.95 (2H, t, J=6.0Hz),
 5 5.03 (1H, d, J=7.5Hz), 6.61 (1H, dd, J=8.3Hz, 2.6Hz), 6.7 (1H, d, J=2.6Hz), 6.85 (1H, d, J=8.3Hz)

Example 108

3-(β-D-Glucopyranosyloxy)-4-[(4-{3-[1-(2-hydroxyethyl-carbamoyl)-1-(methyl)ethylcarbamoyl]propoxy}-2-methyl-phenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 106 using 2-aminoethanol instead of 1-(2-hydroxyethyl)piperazine.

15 ¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.28 (3H, s), 2.39 (2H, t, J=7.4Hz), 2.75-2.85 (1H, m), 3.2-3.4 (6H, m), 3.56 (2H, t, J=5.9Hz), 3.6-3.7 (3H, m), 3.75-3.85 (1H, m), 3.94 (2H, t, J=6.1Hz), 4.95-5.05 (1H, m), 6.61 (1H, dd, J=8.4Hz, 2.3Hz),
 20 6.71 (1H, d, J=2.3Hz), 6.85 (1H, d, J=8.4Hz)

Reference Example 54

1-(3-Benzoyloxypropyl)-1,2-dihydro-4-[(4-iodophenyl)-methyl]-5-isopropyl-3H-pyrazol-3-one

25 To a solution of 1,2-dihydro-4-[(4-iodophenyl)-methyl]-5-isopropyl-3H-pyrazol-3-one (5 g) and imidazole (1.19 g) in *N,N*-dimethylformamide (20 mL) was added triisopropylsilyl

chloride (3.1 g) at room temperature, and the mixture was stirred for 3 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give 4-[(4-iodophenyl)methyl]-5-isopropyl-3-triisopropylsilyloxy-1*H*-pyrazole (7.27 g). To a solution of obtained 4-[(4-iodophenyl)methyl]-5-isopropyl-3-triisopropylsilyloxy-1*H*-pyrazole (3 g) in *N,N*-dimethylformamide (10 mL) was added sodium hydride (55%, 0.33 g) under ice-cooling, and the mixture was stirred for 20 minutes. To the reaction mixture were added a solution of 1-benzoyloxy-3-chloropropane (3.0 g) in *N,N*-dimethylformamide (10 mL) and potassium iodide (0.25 g) at the same temperature, and the resulting mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 20/1 - 10/1) to give 1-(3-benzoyloxypropyl)-4-[(4-iodophenyl)methyl]-5-isopropyl-3-triisopropylsilyloxy-1*H*-pyrazole (2.55 g). This material was dissolved in tetrahydrofuran (3 mL). To the solution was added 4 mol/L hydrochloric acid (1,4-dioxane solution, 10 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, and the resulting mixture was poured into water. The organic

layer was separated, and the organic layer was washed with brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. To the residue was added a mixed solvent of *n*-hexane and ethyl acetate (20/1) (10 mL), and the mixture
 5 was stirred at room temperature for 1 hour. The precipitated crystals were collected by filtration, and washed with a mixed solvent of *n*-hexane and ethyl acetate (20/1) and dried under reduced pressure to give the title compound (0.85 g).

¹H-NMR (DMSO-d₆) δ ppm:

10 1.06 (6H, d, J=7.3Hz), 2.1-2.2 (2H, m), 2.95-3.1 (1H, m), 3.6 (2H, s), 4.02 (2H, t, J=6.9Hz), 4.27 (2H, t, J=6.1Hz), 6.94 (2H, d, J=8.3Hz), 7.5-7.7 (5H, m), 7.9-8.0 (2H, m), 9.51 (1H, s)

Reference Example 55

15 Benzyl 2-amino-2-methylpropionate

Benzyl 2-amino-2-methylpropionate hydrochloride (1.48 g) was dissolved in ethyl acetate (60 mL) and a saturated aqueous sodium hydrogen carbonate solution (20 mL), and the organic layer was separated. The organic layer was washed with brine, and
 20 dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure to give the title compound (1.2 g).

¹H-NMR (CDCl₃) δ ppm:

1.37 (6H, s), 5.14 (2H, s), 7.3-7.45 (5H, m)

25 Reference Example 56

3-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyloxy)-1-(3-benzoyloxypropyl)-4-[(4-{3-[1-carboxy-1-(methyl)ethyl-

carbamoyl}propyl}phenyl)methyl]-5-isopropyl-1H-pyrazole

To a mixture of 1-(3-benzoyloxypropyl)-1,2-dihydro-4-
[(4-iodophenyl)methyl]-5-isopropyl-3H-pyrazol-3-one (0.85 g),
acetobromo- α -D-galactose (0.91 g) and benzyltri(*n*-butyl)-
5 ammonium chloride (0.53 g) in dichloromethane (2.55 mL) was added
5 mol/L aqueous sodium hydroxide solution (0.85 mL), and the
mixture was stirred at room temperature for 6 hours. The reaction
mixture was diluted with dichloromethane, and the mixture was
poured into water. The organic layer was separated, and washed
10 with brine and dried over anhydrous sodium sulfate. The solvent
was removed under reduced pressure. To a solution of the residue
in acetonitrile (2.5 mL) were added 3-butenic acid (0.36 g),
triethylamine (1.71 g), palladium acetate (II) (38 mg) and
tris(2-methylphenyl)phosphine (0.1 g), and the mixture was
15 refluxed for 3 hours. The solvent was removed under reduced
pressure, and the residue was dissolved in ethyl acetate. The
solution was washed with water. The aqueous layer was extracted
with ethyl acetate. The combined organic layers were washed
with water and brine, and dried over anhydrous sodium sulfate.
20 The solvent was removed under reduced pressure, and the residue
was dissolved in tetrahydrofuran (5 mL). To the solution were
added benzyl 2-amino-2-methylpropionate (1.63 g),
1-hydroxybenzotriazole (0.46 g) and 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide hydrochloride (0.65 g), and the
25 mixture was stirred at room temperature for 2 days. The reaction
mixture was poured into water, and the resulting mixture was
extracted with ethyl acetate. The extract was washed with water

and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/1) to give 3-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyloxy)-1-(3-benzoyloxypropyl)-4-[(4-((1*E*)-3-[1-carboxy-1-(methyl)ethylcarbamoyl]prop-1-enyl)phenyl)-methyl]-5-isopropyl-1*H*-pyrazole (0.55 g). This material was dissolved in methanol (5 mL). To the solution was added 10% palladium-carbon powder (0.15 g), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The insoluble material was removed by filtration, and the solvent of the filtrate was removed under reduced pressure to give the title compound (0.48 g).

¹H-NMR (CDCl₃) δ ppm:

1.1-1.2 (6H, m), 1.53 (3H, s), 1.54 (3H, s), 1.85-2.2 (16H, m), 2.25-2.35 (2H, m), 2.61 (2H, t, *J*=7.1Hz), 2.95-3.05 (1H, m), 3.67 (1H, d, *J*=16.7Hz), 3.71 (1H, d, *J*=16.7Hz), 3.95-4.05 (1H, m), 4.05-4.2 (4H, m), 4.36 (2H, t, *J*=5.7Hz), 5.0-5.1 (1H, m), 5.3-5.45 (2H, m), 5.51 (1H, d, *J*=8.2Hz), 6.19 (1H, s), 6.95-7.05 (4H, m), 7.4-7.5 (2H, m), 7.5-7.6 (1H, m), 8.0-8.1 (2H, m)

Example 109

3-(β -D-Galactopyranosyloxy)-1-(3-hydroxypropyl)-5-isopropyl-4-[[4-(3-[1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propyl)phenyl]methyl]-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Example 99 using 3-(2,3,4,6-tetra-*O*-acetyl- β -

D-galactopyranosyloxy)-1-(3-benzoyloxypropyl)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole and 1-(benzyloxycarbonyl)piperazine instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-
 5 4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole and 1-benzylpiperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.42 (6H, s), 1.8-2.0 (4H, m), 2.17 (2H, t,
 10 J=7.7Hz), 2.58 (2H, t, J=7.4Hz), 2.65-2.8 (4H, m), 3.05-3.2 (1H, m), 3.45-3.9 (14H, m), 4.08 (2H, t, J=7.0Hz), 5.11 (1H, d, J=7.8Hz), 7.0-7.15 (4H, m)

Example 110

15 3-(2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(benzyloxycarbonyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-5-isopropyl-1*H*-pyrazole

3-(2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyloxy)-4-
 20 [(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propyl}phenyl)-methyl]-5-isopropyl-1*H*-pyrazole (37 g) was dissolved in *N,N*-dimethylformamide (180 mL). To the solution were added 1-(benzyloxycarbonyl)piperazine (28.4 g), 1-hydroxybenzotriazole (10.5 g) and 1-ethyl-3-(3-dimethylaminopropyl)-
 25 carbodiimide hydrochloride (14.8 g), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl

acetate twice. The extracts were washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 1/2 - ethyl acetate) to give the title compound (40.5 g).

¹H-NMR (CDCl₃) δ ppm:

1.1-1.2 (6H, m), 1.56 (6H, s), 1.85-1.95 (5H, m), 1.98 (3H, s), 2.02 (3H, s), 2.12 (2H, t, J=7.5Hz), 2.16 (3H, s), 2.58 (2H, t, J=7.5Hz), 2.85-2.95 (1H, m), 3.4-3.55 (4H, m), 3.55-3.75 (6H, m), 4.0-4.1 (1H, m), 4.1-4.2 (2H, m), 5.09 (1H, dd, J=10.6Hz, 3.3Hz), 5.14 (2H, s), 5.35-5.45 (2H, m), 5.56 (1H, d, J=7.8Hz), 6.39 (1H, s), 6.95-7.1 (4H, m), 7.3-7.4 (5H, m)

Example 111

15 4-[(4-{3-[1-{[4-(Benzyloxycarbonyl)piperazin-1-yl]-carbonyl}-1-(methyl)ethylcarbamoyl]propyl}phenyl)methyl]-3-(β-D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole

To a solution of 3-(2,3,4,6-tetra-*O*-acetyl-β-D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(benzyloxycarbonyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propyl}phenyl)-methyl]-5-isopropyl-1H-pyrazole (39.5 g) in methanol (160 mL) was added sodium methoxide (28% methanol solution, 8.24 mL), and the mixture was stirred at room temperature overnight. To the reaction mixture was added acetic acid (2.7 mL), and the resulting mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 10/1) to give the title

compound (21.3 g).

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.8-1.9 (2H, m), 2.16 (2H, t, J=7.8Hz), 2.57 (2H, t, J=7.6Hz), 2.8-2.95 (1H, m), 3.35-3.8 (15H, m), 3.85-3.9 (1H, m), 5.07 (1H, d, J=7.9Hz), 5.12 (2H, s), 7.04 (2H, d, J=8.2Hz), 7.11 (2H, d, J=8.2Hz), 7.25-7.4 (5H, m)

Reference Example 57

[4-Benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methanol

10 To a solution of tetrahydro-4H-pyran-4-ol (3.62 g) and triethylamine (5.6 mL) in tetrahydrofuran (35 mL) was added methanesulfonyl chloride (2.93 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. The insoluble material was removed by filtration. To the filtrate were added

15 *N,N*-dimethylformamide (70 mL), 4-benzyloxy-2-hydroxybenzaldehyde (5.39 g) and cesium carbonate (23 g), and the mixture was stirred at 80°C for 12 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with diethyl ether. The extract was washed with water and brine, and dried

20 over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 4/1 - 2/1) to give 4-benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)benzaldehyde (4.58 g). This material was dissolved in

25 ethanol (70 mL). To the solution was added sodium borohydride (0.28 g) under ice-cooling, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added

methanol, and the resulting mixture was concentrated under reduced pressure. A saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted with diethyl ether. The extract was washed with
 5 a saturated aqueous sodium hydrogen carbonate solution, water and brine successively, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: *n*-hexane/ethyl acetate = 3/1 - 1/1) to give the title
 10 compound (4.45 g).

¹H-NMR (CDCl₃) δ ppm:

1.75-1.85 (2H, m), 1.95-2.05 (2H, m), 2.11 (1H, t, J=6.3Hz),
 3.5-3.65 (2H, m), 3.9-4.0 (2H, m), 4.45-4.55 (1H, m), 4.63 (2H,
 d, J=6.3Hz), 5.05 (2H, s), 6.5-6.6 (2H, m), 7.19 (1H, d, J=7.7Hz),
 15 7.3-7.45 (5H, m)

Reference Example 58

4-([4-Benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]-methyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

20 To a solution of [4-benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methanol (4.45 g) in tetrahydrofuran (28 mL) were added triethylamine (2.27 mL) and methanesulfonyl chloride (1.21 mL) under ice-cooling, and the mixture was stirred for 1 hour. The insoluble material was removed by filtration. The obtained
 25 solution of [4-benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)-phenyl]methyl mesylate in tetrahydrofuran was added to a suspension of sodium hydride (55%, 710 mg) and methyl

4-methyl-3-oxopentanoate (2.25 g) in tetrahydrofuran (56 mL), and the mixture was heated for reflux for 8 hours. To the reaction mixture was added 1 mol/L hydrochloric acid, and the resulting mixture was extracted with diethyl ether. The organic layer
 5 was washed with water, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure. To a solution of the residue in toluene (8 mL) was added hydrazine monohydrate (3.43 mL), and the mixture was stirred at 100°C for 8 hours. The reaction mixture was purified by column chromatography on
 10 silica gel (eluent: dichloromethane/methanol = 20/1 - 10/1) to give the title compound (1.69 g).

¹H-NMR (CDCl₃) δ ppm:

1.16 (6H, d, J=7.1Hz), 1.75-1.9 (2H, m), 1.95-2.1 (2H, m),
 2.9-3.05 (1H, m), 3.5-3.6 (2H, m), 3.64 (2H, s), 3.9-4.05 (2H,
 15 m), 4.4-4.5 (1H, m), 5.0 (2H, s), 6.45-6.55 (2H, m), 7.0 (1H,
 d, J=8.4Hz), 7.25-7.45 (5H, m)

Reference example 59

3-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyloxy)-4-[(4-benzyloxy-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole
 20

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-[(4-benzyloxy-2-methylphenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo-α-D-galactose instead of 4-[[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo-α-D-glucose, respectively.
 25

¹H-NMR (CDCl₃) δ ppm:

1.05-1.2 (6H, m), 1.78 (3H, s), 1.98 (3H, s), 2.03 (3H, s), 2.16
(3H, s), 2.28 (3H, s), 2.75-2.85 (1H, m), 3.51 (1H, d, J=16.4Hz),
3.62 (1H, d, J=16.4Hz), 4.0-4.1 (1H, m), 4.1-4.2 (2H, m), 5.02
5 (2H, s), 5.07 (1H, dd, J=10.4Hz, 3.5Hz), 5.35-5.45 (2H, m), 5.51
(1H, d, J=7.9Hz), 6.66 (1H, dd, J=8.3Hz, 2.8Hz), 6.75-6.85 (2H,
m), 7.2-7.45 (5H, m)

Reference Example 60

10 · 4-{[4-Benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]-
methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-
glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to
that described in Reference Example 12 using 4-{[4-benzyloxy-
15 2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methyl}-1,2-dihydro-
5-isopropyl-3H-pyrazol-3-one and 2,3,4,6-tetra-O-pivaloyl-α-
D-glucopyranosyl bromide instead of 4-{[4-(2-benzyloxy-
carbonyl-2-methylpropoxy)phenyl]methyl}-1,2-dihydro-5-
isopropyl-3H-pyrazol-3-one and acetobromo-α-D-glucose,
20 respectively.

¹H-NMR (CDCl₃) δ ppm:

1.0-1.2 (42H, m), 1.7-1.85 (2H, m), 1.95-2.05 (2H, m), 2.85-2.95
(1H, m), 3.5-3.65 (4H, m), 3.8-3.9 (1H, m), 3.9-4.0 (2H, m),
4.12 (1H, dd, J=12.4Hz, 5.1Hz), 4.19 (1H, dd, J=12.4Hz, 1.8Hz),
25 4.4-4.5 (1H, m), 4.99 (2H, s), 5.15-5.3 (2H, m), 5.36 (1H, t,
J=9.4Hz), 5.66 (1H, d, J=8.0Hz), 6.42 (1H, dd, J=8.3Hz, 2.3Hz),
6.47 (1H, d, J=2.3Hz), 6.86 (1H, d, J=8.3Hz), 7.25-7.45 (5H,

m)

Reference Example 61

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-
5 hydroxy-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 25 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-benzyloxy-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole instead of 4-[(4-
10 benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.1-1.2 (6H, m), 1.83 (3H, s), 1.98 (3H, s), 2.03 (3H, s), 2.16
(3H, s), 2.25 (3H, s), 2.75-2.9 (1H, m), 3.5 (1H, d, $J=16.6\text{Hz}$),
15 3.6 (1H, d, $J=16.6\text{Hz}$), 4.0-4.05 (1H, m), 4.1-4.2 (2H, m), 4.78
(1H, brs), 5.06 (1H, dd, $J=10.4\text{Hz}$, 3.5Hz), 5.35-5.45 (2H, m),
5.5 (1H, d, $J=8.2\text{Hz}$), 6.52 (1H, dd, $J=8.1\text{Hz}$, 2.6Hz), 6.62 (1H,
d, $J=2.6\text{Hz}$), 6.76 (1H, d, $J=8.1\text{Hz}$)

20 Reference Example 62

4-[[4-Hydroxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]-
methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to
25 that described in Reference Example 25 using 4-[[4-benzyloxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-

pyrazole instead of 4-[(4-benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

^1H -NMR (CDCl_3) δ ppm:

5 1.0-1.2 (42H, m), 1.75-1.9 (2H, m), 1.95-2.1 (2H, m), 2.8-2.95 (1H, m), 3.52 (1H, d, $J=16.5\text{Hz}$), 3.55-3.65 (3H, m), 3.8-3.9 (1H, m), 3.9-4.05 (2H, m), 4.05-4.2 (2H, m), 4.4-4.5 (1H, m), 5.14 (1H, brs), 5.15-5.3 (2H, m), 5.3-5.4 (1H, m), 5.65 (1H, d, $J=8.1\text{Hz}$), 6.22 (1H, dd, $J=8.2\text{Hz}$, 2.3Hz), 6.37 (1H, d, $J=2.3\text{Hz}$), 6.78 (1H, d, $J=8.2\text{Hz}$)

Reference Example 63

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[3-(benzyloxycarbonyl)propoxy]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 27 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-hydroxy-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole instead of 4-[(4-hydroxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

^1H -NMR (CDCl_3) δ ppm:

1.05-1.15 (6H, m), 1.81 (3H, s), 1.98 (3H, s), 2.02 (3H, s), 2.05-2.15 (2H, m), 2.16 (3H, s), 2.26 (3H, s), 2.56 (2H, t, $J=7.1\text{Hz}$), 2.7-2.85 (1H, m), 3.5 (1H, d, $J=16.5\text{Hz}$), 3.6 (1H, d, $J=16.5\text{Hz}$), 3.9-4.0 (2H, m), 4.0-4.1 (1H, m), 4.1-4.2 (2H, m), 5.07 (1H,

dd, $J=10.6\text{Hz}$, 3.6Hz), 5.13 (2H, s), 5.35-5.45 (2H, m), 5.52 (1H, d, $J=8.2\text{Hz}$), 6.55 (1H, dd, $J=8.6\text{Hz}$, 2.5Hz), 6.66 (1H, d, $J=2.5\text{Hz}$), 6.79 (1H, d, $J=8.6\text{Hz}$), 7.25-7.4 (5H, m)

5 Reference Example 64

4-([4-[3-(Benzyloxycarbonyl)propoxy]-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methyl)-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to
 10 that described in Reference Example 27 using 4-([4-hydroxy-2-(tetrahydro-4H-pyran-4-yloxy)phenyl]methyl)-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-([4-hydroxy-2-methylphenyl]methyl)-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyl-
 15 oxy)-1H-pyrazole.

^1H -NMR (CDCl_3) δ ppm:

1.0-1.2 (42H, m), 1.75-1.85 (2H, m), 1.95-2.15 (4H, m), 2.56 (2H, t, $J=7.3\text{Hz}$), 2.8-2.95 (1H, m), 3.5-3.65 (4H, m), 3.8-3.9 (1H, m), 3.9-4.05 (4H, m), 4.05-4.25 (2H, m), 4.4-4.5 (1H, m),
 20 5.13 (2H, s), 5.15-5.3 (2H, m), 5.36 (1H, t, $J=9.5\text{Hz}$), 5.66 (1H, d, $J=8.1\text{Hz}$), 6.3 (1H, dd, $J=8.4\text{Hz}$, 2.5Hz), 6.38 (1H, d, $J=2.5\text{Hz}$), 6.84 (1H, d, $J=8.4\text{Hz}$), 7.25-7.4 (5H, m)

Reference Example 65

25 3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-([4-(3-carboxypropoxy)-2-methylphenyl]methyl)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 25 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[3-(benzyloxy-carbonyl)propoxy]-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole instead of 4-[(4-benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.05-1.15 (6H, m), 1.78 (3H, s), 1.98 (3H, s), 2.02 (3H, s),
 2.05-2.15 (2H, m), 2.16 (3H, s), 2.27 (3H, s), 2.45-2.6 (2H, m),
 2.75-2.85 (1H, m), 3.49 (1H, d, $J=16.8\text{Hz}$), 3.6 (1H, d, $J=16.8\text{Hz}$),
 3.98 (2H, t, $J=6.3\text{Hz}$), 4.0-4.1 (1H, m), 4.1-4.25 (2H, m),
 5.06 (1H, dd, $J=10.3\text{Hz}$, 3.4Hz), 5.3-5.45 (3H, m), 6.58 (1H, dd, $J=8.6\text{Hz}$, 2.4Hz),
 6.68 (1H, d, $J=2.4\text{Hz}$), 6.78 (1H, d, $J=8.6\text{Hz}$)

Reference Example 66

4-{{4-(3-Carboxypropoxy)-2-(tetrahydro-4H-pyran-4-yloxy)-phenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 25 using 4-({4-[3-(benzyloxy-carbonyl)propoxy]-2-(tetrahydro-4H-pyran-4-yloxy)-phenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-[(4-benzyloxy-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.0-1.2 (42H, m), 1.75-1.9 (2H, m), 1.95-2.15 (4H, m), 2.5-2.6
 (2H, m), 2.8-2.95 (1H, m), 3.45-3.65 (4H, m), 3.8-3.9 (1H, m),
 3.9-4.05 (4H, m), 4.1-4.25 (2H, m), 4.4-4.55 (1H, m), 5.2-5.3
 (2H, m), 5.36 (1H, t, J=9.2Hz), 5.52 (1H, d, J=7.7Hz), 6.33 (1H,
 5 dd, J=8.1Hz, 2.1Hz), 6.41 (1H, d, J=2.1Hz), 6.84 (1H, d, J=8.1Hz)

Reference Example 67

3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-
{3-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]propoxy}-
 10 2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to
 that described in Reference Example 45 using 3-(2,3,4,6-tetra-O-
 acetyl- β -D-galactopyranosyloxy)-4-[[4-(3-carboxypropoxy)-2-
 methylphenyl)methyl]-5-isopropyl-1H-pyrazole instead of
 15 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-
 carboxyethoxy)-2-methylphenyl)methyl]-5-isopropyl-1H-
 pyrazole.

¹H-NMR (CDCl₃) δ ppm:

1.05-1.15 (6H, m), 1.53 (6H, s), 1.83 (3H, s), 1.95-2.1 (8H,
 20 m), 2.15 (3H, s), 2.26 (3H, s), 2.34 (2H, t, J=7.2Hz), 2.7-2.85
 (1H, m), 3.5 (1H, d, J=16.6Hz), 3.6 (1H, d, J=16.6Hz), 3.85-3.95
 (2H, m), 4.0-4.1 (1H, m), 4.1-4.2 (2H, m), 5.07 (1H, dd, J=10.4Hz,
 3.5Hz), 5.15 (2H, s), 5.35-5.45 (2H, m), 5.52 (1H, d, J=8.1Hz),
 6.06 (1H, s), 6.55 (1H, dd, J=8.5Hz, 2.6Hz), 6.66 (1H, d, J=2.6Hz),
 25 6.79 (1H, d, J=8.5Hz), 7.25-7.4 (5H, m)

Reference Example 68

4-{{4-{{3-{{1-Benzylloxycarbonyl-1-(methyl)ethylcarbamoyl}}-propoxy}}-2-(tetrahydro-4H-pyran-4-yloxy)phenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazole

- 5 The title compound was prepared in a similar manner to that described in Reference Example 45 using 4-{{4-{{3-carboxypropoxy}}-2-(tetrahydro-4H-pyran-4-yloxy)phenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-{{4-{{2-carboxyethoxy}}-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole.

¹H-NMR (CDCl₃) δ ppm:

- 1.0-1.2 (42H, m), 1.54 (6H, s), 1.75-1.85 (2H, m), 2.0-2.1 (4H, m), 2.34 (2H, t, J=7.2Hz), 2.8-2.95 (1H, m), 3.5-3.65 (4H, m),
15 3.8-4.05 (5H, m), 4.05-4.25 (2H, m), 4.4-4.5 (1H, m), 5.1-5.3 (4H, m), 5.36 (1H, t, J=9.5Hz), 5.65 (1H, d, J=7.5Hz), 6.09 (1H, brs), 6.29 (1H, dd, J=8.3Hz, 2.2Hz), 6.4 (1H, d, J=2.2Hz), 6.83 (1H, d, J=8.3Hz), 7.25-7.4 (5H, m)

- 20 Reference Example 69

3-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyloxy)-4-{{4-{{3-{{1-carboxy-1-(methyl)ethylcarbamoyl}}propoxy}}-2-methylphenyl)methyl}-5-isopropyl-1H-pyrazole

- 25 The title compound was prepared in a similar manner to that described in Reference Example 48 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-{{4-{{3-{{1-benzylloxycarbonyl-1-(methyl)ethylcarbamoyl}}propoxy}}-2-methylphenyl)-

methyl]-5-isopropyl-1*H*-pyrazole instead of 3-(2,3,4,6-tetra-
O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxy-
 carbonyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)-
 methyl]-5-isopropyl-1*H*-pyrazole.

5 $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.05-1.15 (6H, m), 1.55 (3H, s), 1.56 (3H, s), 1.79 (3H, s),
 1.98 (3H, s), 2.0-2.2 (8H, m), 2.26 (3H, s), 2.4 (2H, t, $J=6.9\text{Hz}$),
 2.7-2.85 (1H, m), 3.49 (1H, d, $J=16.6\text{Hz}$), 3.59 (1H, d, $J=16.6\text{Hz}$),
 3.98 (2H, t, $J=6.1\text{Hz}$), 4.0-4.2 (2H, m), 4.22 (1H, dd, $J=10.9\text{Hz}$,
 10 5.7Hz), 5.0-5.1 (1H, m), 5.3-5.45 (3H, m), 6.24 (1H, s), 6.59
 (1H, dd, $J=8.2\text{Hz}$, 2.7Hz), 6.69 (1H, d, $J=2.7\text{Hz}$), 6.75 (1H, d,
 $J=8.2\text{Hz}$)

Reference Example 70

15 4-[[4-{3-[1-Carboxy-1-(methyl)ethylcarbamoyl]propoxy}-2-
(tetrahydro-4*H*-pyran-4-yloxy)phenyl]methyl]-5-isopropyl-3-
(2,3,4,6-tetra-*O*-pivaloyl- β -D-glucopyranosyloxy)-1*H*-
pyrazole

The title compound was prepared in a similar manner to
 20 that described in Reference Example 48 using 4-[[4-{3-[1-benzyl-
 oxycarbonyl-1-(methyl)ethylcarbamoyl]propoxy}-2-(tetra-
 hydro-4*H*-pyran-4-yloxy)phenyl]methyl]-5-isopropyl-3-
 (2,3,4,6-tetra-*O*-pivaloyl- β -D-glucopyranosyloxy)-1*H*-
 pyrazole instead of 3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxycarbonyl-1-(methyl)-
 25 ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-
 1*H*-pyrazole.

¹H-NMR (CDCl₃) δ ppm:

1.0-1.2 (42H, m), 1.54 (6H, s), 1.7-1.9 (2H, m), 1.95-2.15 (4H, m), 2.35-2.45 (2H, m), 2.8-2.95 (1H, m), 3.45-3.65 (4H, m), 3.8-3.9 (1H, m), 3.9-4.05 (4H, m), 4.05-4.25 (2H, m), 4.4-4.55
5 (1H, m), 5.15-5.3 (2H, m), 5.36 (1H, t, J=9.4Hz), 5.56 (1H, d, J=8.4Hz), 6.17 (1H, brs), 6.32 (1H, d, J=8.1Hz), 6.41 (1H, s), 6.82 (1H, d, J=8.1Hz)

Example 112

10 3-(β-D-Galactopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}-propoxy)-2-methylphenyl)methyl}-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)-ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(benzyloxycarbonyl)piperazine instead of
15 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methyl-phenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzyl-
20 piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.29 (3H, s), 2.39 (2H, t, J=7.4Hz), 2.55-2.9 (5H, m), 3.45-3.8 (11H, m),
25 3.85 (1H, d, J=3.2Hz), 3.95 (2H, t, J=6.1Hz), 5.04 (1H, d, J=7.5Hz), 6.61 (1H, dd, J=8.2Hz, 2.4Hz), 6.71 (1H, d, J=2.4Hz), 6.84 (1H, d, J=8.2Hz)

Example 113

3-(β -D-Galactopyranosyloxy)-5-isopropyl-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethyl-carbamoyl]propoxy}-2-methylphenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 78 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-(2-hydroxyethyl)piperazine instead of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[[4-(2-carboxyethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole and 2-amino-2-methylpropionamide, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.05-1.15 (6H, m), 1.42 (6H, s), 1.95-2.05 (2H, m), 2.28 (3H, s), 2.3-2.55 (8H, m), 2.7-2.85 (1H, m), 3.45-3.8 (13H, m), 3.85 (1H, d, J=2.9Hz), 3.94 (2H, t, J=6.0Hz), 5.04 (1H, d, J=7.6Hz), 6.6 (1H, d, J=8.5Hz), 6.7 (1H, s), 6.85 (1H, d, J=8.5Hz)

Example 114

3-(β -D-Glucopyranosyloxy)-5-isopropyl-4-[[4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propoxy}-2-(tetrahydro-4H-pyran-4-yloxy)phenyl)methyl]-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 105 using 4-[[4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propoxy}-2-(tetrahydro-4H-pyran-4-

yloxy)phenyl)methyl}-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-[(4-{3-[1-carboxy-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-pyrazole.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.05-1.2 (6H, m), 1.42 (6H, s), 1.7-1.85 (2H, m), 1.95-2.1 (4H, m), 2.38 (2H, t, $J=7.4\text{Hz}$), 2.6-2.8 (4H, m), 2.8-2.95 (1H, m), 3.25-3.45 (4H, m), 3.5-3.75 (9H, m), 3.83 (1H, d, $J=12.1\text{Hz}$), 3.9-4.0 (4H, m), 4.5-4.65 (1H, m), 5.07 (1H, d, $J=7.1\text{Hz}$), 6.4 (1H, dd, $J=8.3\text{Hz}$, 2.5Hz), 6.54 (1H, d, $J=2.5\text{Hz}$), 6.89 (1H, d, $J=8.3\text{Hz}$)

Reference Example 71

15 4-[(4-Bromo-2-fluorophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

The title compound was prepared in a similar manner to that described in Reference Example 2 using 4-bromo-2-fluorobenzyl bromide instead of 4-bromobenzyl bromide.

20 $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.17 (6H, d, $J=7.1\text{Hz}$), 2.85-3.05 (1H, m), 3.67 (2H, s), 7.0-7.3 (3H, m)

Reference Example 72

25 3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-[(4-bromo-2-fluorophenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to

that described in Reference Example 12 using 4-[(4-bromo-2-fluorophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo- α -D-galactose instead of 4-{[4-(2-benzyloxycarbonyl-2-methylpropoxy)phenyl]methyl}-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one and acetobromo- α -D-glucose, respectively.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.15-1.25 (6H, m), 1.92 (3H, s), 1.99 (3H, s), 2.02 (3H, s),
2.18 (3H, s), 2.9-3.0 (1H, m), 3.59 (1H, d, $J=16.1\text{Hz}$), 3.67 (1H,
10 d, $J=16.1\text{Hz}$), 4.05-4.25 (3H, m), 5.1 (1H, dd, $J=10.4\text{Hz}$, 3.4Hz),
5.35-5.45 (2H, m), 5.58 (1H, d, $J=8.1\text{Hz}$), 6.95-7.05 (1H, m),
7.1-7.2 (2H, m)

Reference Example 73

15 3-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-
[(1E)-3-carboxyprop-1-enyl]-2-fluorophenyl}methyl)-5-
isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using 3-(2,3,4,6-tetra-
20 O-acetyl- β -D-galactopyranosyloxy)-4-[(4-bromo-2-fluorophenyl)methyl]-5-isopropyl-1H-pyrazole instead of
3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-bromophenyl)methyl]-5-isopropyl-1H-pyrazole.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

25 1.1-1.2 (6H, m), 1.89 (3H, s), 1.99 (3H, s), 2.01 (3H, s), 2.17
(3H, s), 2.85-3.0 (1H, m), 3.27 (2H, d, $J=6.9\text{Hz}$), 3.59 (1H, d,
 $J=16.2\text{Hz}$), 3.7 (1H, d, $J=16.2\text{Hz}$), 4.05-4.3 (3H, m), 5.1 (1H,

dd, $J=10.2\text{Hz}$, 3.5Hz), 5.3-5.5 (3H, m), 6.2-6.35 (1H, m), 6.43 (1H, d, $J=16.2\text{Hz}$), 6.9-7.15 (3H, m)

Reference Example 74

5 1-(2-Amino-2-methylpropionyl)-4-(benzyloxycarbonyl)-piperazine

To a solution of 2-(*tert*-butoxycarbonylamino)-2-methylpropionic acid (10 g) in tetrahydrofuran (20 mL) were added 1-(benzyloxycarbonyl)piperazine (16.3 g), 1-hydroxybenzo-
 10 triazole (8.02 g) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (11.4 g), and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted with ethyl acetate. The extract was washed with water and brine, and dried
 15 over anhydrous sodium sulfate. The solvent was removed under reduced pressure. The residue was dissolved in a mixed solvent of *n*-hexane and ethyl acetate (1/1) (40 mL) at 60°C with heating, and the solution was stirred at room temperature overnight. To the mixture was added the same solvent (30 mL), and the mixture
 20 was further stirred overnight. The precipitated crystals were collected by filtration, and washed with the same solvent and dried under reduced pressure to give 4-benzyloxycarbonyl-1-[2-(*tert*-butoxycarbonylamino)-2-methylpropionyl]piperazine (13.5 g). To a solution of the obtained 4-benzyloxycarbonyl-
 25 1-[2-(*tert*-butoxycarbonylamino)-2-methylpropionyl]-piperazine (5 g) in tetrahydrofuran (30 mL) was added hydrochloric acid (4 mol/L 1,4-dioxane solution, 40 mL), and

the mixture was stirred at room temperature overnight. The precipitated crystals were collected by filtration. The obtained crystals were dissolved in ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution. The organic layer
 5 was separated, and the organic layer was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the title compound (3.65 g).

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.41 (6H, s), 3.45-3.55 (4H, m), 3.7-3.95 (4H, br), 5.15 (2H,
 10 s), 7.25-7.4 (5H, m)

Example 115

4-([2-Fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-ethylcarbamoyl}propyl)phenyl)methyl}-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole
 15

The title compound was prepared in a similar manner to that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-2-fluorophenyl)methyl}-5-isopropyl-1H-pyrazole and 1-(2-amino-2-methylpropionyl)-4-(benzyloxycarbonyl)piperazine instead
 20 of 3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzylpiperazine, respectively.

$^1\text{H-NMR}$ (CD_3OD) δ ppm:

1.1-1.2 (6H, m), 1.42 (6H, s), 1.8-1.95 (2H, m), 2.17 (2H, t, $J=7.6\text{Hz}$), 2.6 (2H, t, $J=7.6\text{Hz}$), 2.7-2.85 (4H, m), 2.85-3.0 (1H,

m), 3.45-3.85 (11H, m), 3.85-3.9 (1H, m), 5.09 (1H, d, J=7.8Hz), 6.8-6.9 (2H, m), 7.0-7.15 (1H, m)

Reference Example 75

5 4-Bromo-2-chlorobenzyl alcohol

The title compound was prepared in a similar manner to that described in Reference Example 14 using 4-bromo-2-chlorobenzoic acid instead of 4-bromo-2-methylbenzoic acid.

¹H-NMR (CDCl₃) δ ppm:

10 1.9-2.0 (1H, m), 4.73 (2H, d, J=5.5Hz), 7.3-7.45 (2H, m), 7.45-7.55 (1H, m)

Reference Example 76

15 4-[(4-Bromo-2-chlorophenyl)methyl]-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one

The title compound was prepared in a similar manner to that described in Reference Example 15 using 4-bromo-2-chlorobenzyl alcohol instead of 4-bromo-2-methylbenzyl alcohol.

¹H-NMR (DMSO-d₆) δ ppm:

20 1.07 (6H, d, J=6.9Hz), 2.7-2.85 (1H, m), 3.61 (2H, s), 6.97 (1H, d, J=8.5Hz), 7.46 (1H, dd, J=8.5Hz, 2.0Hz), 7.66 (1H, d, J=2.0Hz)

Reference Example 77

25 3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-bromo-2-chlorophenyl)methyl]-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 12 using 4-[(4-bromo-2-

chlorophenyl)methyl]-1,2-dihydro-5-isopropyl-3*H*-pyrazol-3-one instead of 4-([4-(2-benzyloxycarbonyl-2-methylpropoxy)-phenyl)methyl]-1,2-dihydro-5-isopropyl-3*H*-pyrazol-3-one.

¹H-NMR (CDCl₃) δ ppm:

- 5 1.17 (6H, d, J=7.0Hz), 1.9 (3H, s), 2.01 (3H, s), 2.03 (3H, s),
2.07 (3H, s), 2.85-3.0 (1H, m), 3.65 (1H, d, J=16.7Hz), 3.74
(1H, d, J=16.7Hz), 3.8-3.9 (1H, m), 4.05-4.2 (1H, m), 4.31 (1H,
dd, J=12.8Hz, 4.3Hz), 5.1-5.35 (3H, m), 5.6 (1H, d, J=8.1Hz),
6.93 (1H, d, J=8.2Hz), 7.24 (1H, dd, J=8.2Hz, 1.8Hz), 7.49 (1H,
10 d, J=1.8Hz)

Reference Example 78

3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-({4-
[(1*E*)-3-carboxyprop-1-enyl]-2-chlorophenyl)methyl)-5-
15 isopropyl-1*H*-pyrazole

The title compound was prepared in a similar manner to that described in Reference Example 4 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-bromo-2-chlorophenyl)methyl]-5-isopropyl-1*H*-pyrazole instead of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-bromophenyl)-
20 methyl]-5-isopropyl-1*H*-pyrazole.

¹H-NMR (CDCl₃) δ ppm:

- 1.1-1.2 (6H, m), 1.85 (3H, s), 2.0 (3H, s), 2.02 (3H, s), 2.05
(3H, s), 2.85-3.0 (1H, m), 3.27 (2H, d, J=6.4Hz), 3.68 (1H, d,
25 J=16.7Hz), 3.78 (1H, d, J=16.7Hz), 3.8-3.9 (1H, m), 4.1-4.2 (1H,
m), 4.32 (1H, dd, J=12.6Hz, 3.8Hz), 5.15-5.3 (3H, m), 5.43 (1H,
d, J=7.8Hz), 6.2-6.35 (1H, m), 6.42 (1H, d, J=16.1Hz), 6.96 (1H,

d, J=1.6Hz), 7.13 (1H, dd, J=8.2Hz, 1.6Hz), 7.36 (1H, d, J=1.6Hz)

Example 116

4-{[2-Chloro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-
 5 ethylcarbamoyl}propyl)phenyl)methyl}-3-(8-D-glucopyranosyl-
oxy)-5-isopropyl-1H-pyrazole

The title compound was prepared in a similar manner to that described in Example 99 using 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-({4-[(1E)-3-carboxyprop-1-enyl]-2-chlorophenyl)methyl)-5-isopropyl-1H-pyrazole and 1-(2-amino-2-methylpropionyl)-4-(benzyloxycarbonyl)piperazine instead
 10 of 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-carboxy-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole and 1-benzyl-
 15 piperazine, respectively.

¹H-NMR (CD₃OD) δ ppm:

1.1-1.2 (6H, m), 1.43 (6H, s), 1.8-1.95 (2H, m), 2.17 (2H, t, J=7.7Hz), 2.59 (2H, t, J=7.6Hz), 2.65-2.95 (5H, m), 3.25-3.45 (4H, m), 3.5-3.9 (8H, m), 5.09 (1H, d, J=7.1Hz), 6.95-7.1 (2H,
 20 m), 7.2 (1H, d, J=1.3Hz)

Test Example 1

Assay for inhibitory effects on human SGLT1 activity

1) Cloning and construction of the vector expressing human SGLT1

25 The cDNA library was prepared for PCR amplification by reverse transcription from total RNA deprived from human small intestine (Ori gene) using oligo-dT as a primer. Using this

cdNA library as a template, the DNA fragment coding 1 to 2005 bp of human SGLT1 (ACCESSION: M24847), which was reported by Hediger et al., was amplified by PCR method and inserted into the multi-cloning site of pcDNA3.1(-) (Invitrogen). The DNA
5 sequence inserted was perfectly matched to the previously reported sequence.

2) Establishment of cell line stably expressing human SGLT1

The expression vector of human SGLT1 was digested by Sca I into a linear DNA. The linear DNA was transfected into CHO-K1
10 cells by means of lipofection (Effectene Transfection Reagent: QIAGEN). Neomycin resistant cell lines were selected by culture in the medium containing G418 (1 mg/mL, LIFE TECHNOLOGIES), and then the activity against the uptake of methyl- α -D-glucopyranoside was measured by the method described below. The cell
15 line, which showed the greatest uptake activity, was selected and designated as CS1-5-11D. CS1-5-11D cells were cultured in the presence of G418 at 200 μ g/mL.

3) Measurement of the inhibitory activity against the uptake of methyl- α -D-glucopyranoside (α -MG)

20 CS1-5-11D cells were seeded into a 96-well culture plate at a density of 3×10^4 cells/well and cultured for 2 days, and were used in the uptake assay. A mixture of non-labeled (Sigma) and 14 C-labeled α -MG (Amersham Pharmcia Biotec) was added to the uptake buffer (pH 7.4; containing 140 mM sodium chloride,
25 2 mM potassium chloride, 1 mM calcium chloride, 1 mM magnesium chloride, 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane sulfonic acid, and 5 mM tris(hydroxymethyl)aminomethane) at the

final concentration of 1 mM. A test compound was dissolved in dimethyl sulfoxide, and then appropriately diluted with distilled water. The test compound solution was added to the uptake buffer containing 1 mM α -MG, and designated as a measurement buffer. For the control group, the measurement buffer without any test compound was prepared. For measuring the basal uptake, a basal uptake measurement buffer which contains 140 mM choline chloride instead of sodium chloride was prepared. After removing the culture medium of CS1-5-11D cells, 180 μ L of the pre-treatment buffer (the basal uptake buffer without α -MG) was added to each well and incubated at 37°C for 10 minutes. After repeating the same treatment, the pre-treatment buffer was removed. To each well was added 75 μ L of the measurement buffer or the basal uptake buffer was added and incubated at 37°C for 1 hour. After removing the measurement buffer, cells were washed twice with 180 μ L per well of the washing buffer (the basal uptake buffer containing 10 mM non-labeled α -MG). The cells were solubilized by 75 μ L per well of 0.2 mol/L sodium hydroxide. The cell lysates were transferred into PicoPlates (Packard), and then added 150 μ L of MicroScint-40 (Packard) and mixed. Radioactivity was measured by means of micro-scintillation counter TopCount (Packard). One hundred % was set to the difference between the uptake in the control group and the basal uptake, and the uptake of methyl α -D-glucopyranoside at each drug concentration were calculated. The drug concentration, at which 50% uptake of methyl α -D-glucopyranoside was inhibited (IC_{50} value), was calculated using logit plot.

The results are shown in Table 1.

[Table 1]

Test compound	IC ₅₀ value (nM)
Example 15	113
Example 18	181
Example 21	12
Example 24	24
Example 27	237
Example 28	267
Example 29	431
Example 30	52
Example 31	96
Example 32	220
Example 33	174
Example 34	245
Example 35	115
Example 48	31
Example 57	39
Example 61	18

Test Example 2

5 Assay for inhibitory effects on blood glucose level increase in rats

1) Preparation of diabetic rat model

Male wistar rats (Japan Charles River), aged 8 weeks old,

were injected nicotinamide (230 mg/kg) intraperitoneally. Fifteen minutes after injection, they were injected streptozotocin (85 mg/kg) intravenously from tail vein under anesthesia with ether. After a week, rats were fasted overnight and then glucose tolerance test (2 g/kg) was done. The rats which showed plasma glucose concentration at 1 hour after glucose load was over 300 mg/dL were selected to use liquid meal tolerance test.

2) Liquid meal tolerance test

After overnight fasted, the diabetic rats were orally administered a test compound (1 mg/kg), which was dissolved in distilled water, in the drug-treating group, or distilled water alone in a control group. Immediately after the compound administration, 17.25 kcal/kg of liquid meal (No. 038, Control diet, assorted with dextrin and maltose; Oriental Yeast Co., Ltd.) was loaded orally. The blood was collected from tail artery immediately before and after administration with the time course, and treated with heparin immediately. The blood was centrifuged, and the plasma was collected to quantify the plasma glucose concentration by glucose oxidase method. Plasma glucose concentrations at pretreatment (0h), 0.5 and 1 hour after the drug administration are shown in Table 2. The values in the table are presented as the mean $\pm$ S.E.

[Table 2]

Test compound	Plasmaglucoase concentration (mg/dL)		
	0h	0.5h	1h
Control	117 ± 8	326 ± 46	297 ± 35
Example 21	118 ± 9	156 ± 15	178 ± 19
Control	121 ± 7	313 ± 33	303 ± 63
Example 30	121 ± 6	163 ± 8	187 ± 9
Control	140 ± 11	280 ± 22	287 ± 23
Example 32	125 ± 8	223 ± 20	278 ± 32
Example 33	127 ± 11	207 ± 8	251 ± 21
Control	116 ± 11	241 ± 15	237 ± 10
Example 48	112 ± 5	139 ± 4	132 ± 4
Control	133 ± 9	236 ± 9	210 ± 11
Example 57	126 ± 6	149 ± 7	158 ± 10
Control	122 ± 6	277 ± 16	272 ± 21
Example 61	116 ± 6	136 ± 6	172 ± 37

Test Example 3

Acute toxicity test

- 5 Male ICR mice (CLEA Japan, Inc.; 32-37 g, n = 5), aged 6 weeks old, were fasted for 4 hours. A test compound, which was dissolved in distilled water, was administered orally at a dose of 1 g/kg, and then mice were observed for 24 hours. The results are shown in the following Table 3.

10 [Table 3]


Test compound	Number of death
Example 57	0/5

Industrial Applicability

The pyrazole derivatives represented by the above general formula (I) of the present invention, pharmaceutically acceptable salts thereof and prodrugs thereof exert an inhibitory activity in human SGLT1 and can suppress increase of blood glucose level by inhibiting absorption of carbohydrate such as glucose at the small intestine, and particularly, can normalize postprandial hyperglycemia by delaying carbohydrate absorption based on the mechanism. Therefore, the present invention can provide excellent agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, diabetic complications, obesity or the like. In addition, since the pyrazole derivatives represented by the above general formula (II) of the present invention and salts thereof are important as intermediates in the production of the pyrazole derivatives represented by the above general formula (I), the compounds represented by the above general formula (I) of the present invention can be readily prepared via such compounds.

CLAIMS


1. A pyrazole derivative represented by the general formula:




- 5 wherein

R^1 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group, an aryl group which may have the same or different 1 to 3 substituents
 10 selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group, or an aryl(C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C_{1-6} alkyl group and
 15 a C_{1-6} alkoxy group on the ring;

one of Q and T represents a group represented by the formula:



or a group represented by the formula:



while the other represents a C₁₋₆ alkyl group, a halo(C₁₋₆ alkyl) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkyl) group or a C₃₋₇ cycloalkyl group;

5 R² represents a hydrogen atom, a halogen atom, a hydroxy group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a halo(C₁₋₆ alkyl) group, a halo(C₁₋₆ alkoxy) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkoxy) group, a C₃₋₇ cycloalkyl-substituted (C₂₋₆ alkoxy) group or a group of the general formula:
 10 -A-R⁸ in which A represents a single bond, an oxygen atom, a methylene group, an ethylene group, -OCH₂- or -CH₂O-; and R⁸ represents a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen
 15 atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₂₋₆ alkenyloxy group, a halo(C₁₋₆ alkyl) group, a hydroxy(C₁₋₆ alkyl) group, a carboxy group, a C₂₋₇ alkoxycarbonyl group, a cyano group and a nitro group, or a heteroaryl group which may have a substituent selected from the
 20 group consisting of a halogen atom and a C₁₋₆ alkyl group;

X represents a single bond, an oxygen atom or a sulfur atom;

Y represents a single bond, a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group with the proviso that X is a single bond
 25 when Y is a single bond;

Z represents a carbonyl group or a sulfonyl group;

R⁴ and R⁵ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (i), or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group;

R³, R⁶ and R⁷ are the same or different, and each represents a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

substituent group (i) consists of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group, a group of the general formula: -CON(R⁹)R¹⁰ in which R⁹ and R¹⁰ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group

consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group,
 a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl
 group which may have the same or different 1 to 3 substituents
 selected from the group consisting of a halogen atom, a hydroxy
 5 group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group,
 a heteroaryl group which may have a substituent selected from
 the group consisting of a halogen atom and a C₁₋₆ alkyl group,
 a C₂₋₆ cyclic amino group which may have a substituent selected
 from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆
 10 alkyl) group, and a C₁₋₄ aromatic cyclic amino group which may
 have a C₁₋₆ alkyl group as a substituent,
 or a pharmaceutically acceptable salt thereof.

2. A pyrazole derivative as claimed in claim 1, wherein Y
 15 represents a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group;
 one of R⁴ and R⁵ represents a C₁₋₆ alkyl group which has the
 same or different 1 to 3 groups selected from the following
 substituent group (i), the other represents a hydrogen atom or
 a C₁₋₆ alkyl group which may have the same or different 1 to
 20 3 groups selected from the following substituent group (i); and
 substituent group (i) consists of a hydroxy group, an amino group,
 a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆
 alkyl)]amino group, an ureido group, a sulfamide group, a mono
 or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide
 25 group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group,
 a group of the general formula: -CON(R⁹)R¹⁰ in which R⁹ and R¹⁰
 are the same or different, and each represents a hydrogen atom

or a C₁₋₆ alkyl group which may have the same or different 1
 to 3 substituents selected from the group consisting of a hydroxy
 group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a
 mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group,
 5 a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group,
 a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they
 bind together with the neighboring nitrogen atom to form a C₂₋₆
 cyclic amino group which may have a substituent selected from
 the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆
 10 alkyl) group, a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl
 group, an aryl group which may have the same or different 1 to
 3 substituents selected from the group consisting of a halogen
 atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and
 a C₁₋₆ alkoxy group, a heteroaryl group which may have a
 15 substituent selected from the group consisting of a halogen atom
 and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have
 a substituent selected from the group consisting of a C₁₋₆ alkyl
 group and a hydroxy(C₁₋₆ alkyl) group, and a C₁₋₄ aromatic cyclic
 amino group which may have a C₁₋₆ alkyl group as a substituent,
 20 or a pharmaceutically acceptable salt thereof.

3. A pyrazole derivative as claimed in claim 2, wherein one
 of R⁴ and R⁵ represents a C₁₋₆ alkyl group which has a group
 selected from the following substituent group (iA), the other
 25 represents a hydrogen atom; and substituent group (iA) is a group
 of the general formula: -CON(R^{9A})R^{10A} in which R^{9A} and R^{10A} bind
 together with the neighboring nitrogen atom to form a C₂₋₆ cyclic

amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, or a pharmaceutically acceptable salt thereof.

5 4. A pyrazole derivative as claimed in any one of claims 1-3, wherein X represents a single bond; and Y represents a trimethylene group or a 1-propenylene group, or a pharmaceutically acceptable salt thereof.


10 5. A pyrazole derivative as claimed in any one of claims 1-3, wherein X represents an oxygen atom; and Y represents an ethylene group or a trimethylene group, or a pharmaceutically acceptable salt thereof.

15 6. A pyrazole derivative as claimed in claim 1, wherein X represents a single bond; Y represents a single bond; one of R⁴ and R⁵ represents a C₁₋₆ alkyl group which has the same or different 1 to 3 groups selected from the following substituent group (iB), the other represents a hydrogen atom or a C₁₋₆ alkyl
20 group which may have the same or different 1 to 3 groups selected from the following substituent group (iB); and substituent group (iB) consists of an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₁₋₆ alkylsulfonylamino group, a group of the general
25 formula: -CON(R^{9B})R^{10B} in which one of R^{9B} and R^{10B} represents a C₁₋₆ alkyl group which has the same or different 1 to 3 substituents selected from the group consisting of a hydroxy


group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, the other
5 represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C₁₋₆ alkyl)amino group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇
10 acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, a C₃₋₇ cycloalkyl group, a C₂₋₆
15 heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting
20 of a halogen atom and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group, and a C₁₋₄ aromatic cyclic amino group which may have a C₁₋₆ alkyl group as a substituent, or a pharmaceutically acceptable
25 salt thereof.

7. A pyrazole derivative as claimed in any one of claims 1-6,

wherein R^1 represents a hydrogen atom or a hydroxy(C_{2-6} alkyl) group; T represents a group represented by the formula:




or a group represented by the formula:



5


Q represents a C_{1-6} alkyl group or a halo(C_{1-6} alkyl) group; and R^3 , R^6 and R^7 represent a hydrogen atom, or a pharmaceutically acceptable salt thereof.

10 8. A pyrazole derivative as claimed in any one of claims 1-6, wherein one of Q and T represents a group represented by the formula:



the other represents a C_{1-6} alkyl group, a halo(C_{1-6} alkyl) group,
15 a C_{1-6} alkoxy-substituted (C_{1-6} alkyl) group or a C_{3-7} cycloalkyl group, or a pharmaceutically acceptable salt thereof.

9. A pyrazole derivative as claimed in claim 7 or 8, wherein T represents a group represented by the formula:




or a pharmaceutically acceptable salt thereof.

10. A pyrazole derivative as claimed in claim 7 or 9, wherein
 5 Q represents an isopropyl group, or a pharmaceutically acceptable salt thereof.


11. A prodrug of a pyrazole derivative as claimed in any one of claims 1-10 or a pharmaceutically acceptable salt thereof.

10

12. A prodrug as claimed in claim 11, wherein T represents a group represented by the formula:



or a group represented by the formula:



15

in which the hydroxy group at the 4-position is substituted by a glucopyranosyl group or a galactopyranosyl group, or the hydroxy group at the 6-position is substituted by a glucopyranosyl group, a galactopyranosyl group, a C₂₋₇ acyl group,

a C₁₋₆ alkoxy-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxy-carbonyl-substituted (C₂₋₇ acyl) group, a C₂₋₇ alkoxycarbonyl group, an aryl(C₂₋₇ alkoxycarbonyl) group or a C₁₋₆ alkoxy-substituted (C₂₋₇ alkoxycarbonyl) group.

5

13. A pyrazole derivative as claimed in claim 1, which is a compound selected from the following group:

4-[(4-{3-[1-carbamoyl-1-(methyl)ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-(β-D-glucopyranosyloxy)-5-isopropyl-
10 1H-pyrazole;

3-(β-D-galactopyranosyloxy)-4-[(4-{3-[1-[(4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl)methyl]-5-isopropyl-1H-pyrazole;

3-(β-D-galactopyranosyloxy)-5-isopropyl-4-[(4-(3-{1-[2-(dimethylamino)ethylcarbamoyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl)methyl]-1H-pyrazole;

4-[(4-{3-[1-(2-aminoethylcarbamoyl)-1-(methyl)ethylcarbamoyl]propyl]phenyl)methyl]-3-(β-D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole;

20 3-(β-D-galactopyranosyloxy)-5-isopropyl-4-[(4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-propyl]phenyl)methyl]-1H-pyrazole;

3-(β-D-glucopyranosyloxy)-4-[(4-{3-[1-[(4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]-

25 propyl]-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole;

3-(β-D-galactopyranosyloxy)-5-isopropyl-4-[(4-(3-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

propyl)phenyl)methyl}-1*H*-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-[(4-isopropylpiperazin-1-yl)carbonyl]-1-(methyl)ethyl-carbamoyl}propyl)phenyl)methyl}-1*H*-pyrazole;

5 3-(β -D-glucopyranosyloxy)-4-[(4-{3-[(*S*)-2-hydroxy-1-(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-5-isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{(1*E*)-3-[(*S*)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl)phenyl)methyl]-5-

10 isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(2-{1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}-ethoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{2-[2-hydroxy-1,1-di-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-
15 isopropyl-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{2-[1-[[4-(2-hydroxyethyl)-piperazin-1-yl]carbonyl]-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;

20 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(2-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-ethoxy)-2-methylphenyl)methyl}-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

25 propyl)-2-methylphenyl)methyl}-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{{4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

- propoxy)-2-methylphenyl)methyl]-1H-pyrazole;
- 3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole;
- 5 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-[(4-{3-[1-[(4-methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propoxy)-2-methylphenyl)methyl]-1H-pyrazole;
- 3-(β -D-galactopyranosyloxy)-1-(3-hydroxypropyl)-5-isopropyl-4-[(4-{3-[1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-1H-pyrazole;
- 10 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-[(4-{3-[1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propoxy)-2-methylphenyl)methyl]-1H-pyrazole;
- 4-[[2-fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-3-(β -D-galactopyranosyloxy)-5-isopropyl-1H-pyrazole;
- 15 4-[[2-chloro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole, and
- 20 pharmaceutically acceptable salts thereof.

14. A pyrazole derivative as claimed in claim 13, which is a compound selected from the following group:

- 3-(β -D-galactopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]propyl)phenyl)methyl]-5-isopropyl-1H-pyrazole;
- 25 3-(β -D-galactopyranosyloxy)-5-isopropyl-4-[(4-{3-[1-

[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl}-
propyl)phenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{3-[1-{[4-(2-hydroxyethyl)-
piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]-

5 propyl)-2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-[(4-
methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propyl)phenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-[(4-
10 methylpiperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
ethoxy)-2-methylphenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-4-[(4-{2-[1-{[4-(2-hydroxyethyl)-
piperazin-1-yl]carbonyl}-1-(methyl)ethylcarbamoyl]ethoxy}-
2-methylphenyl)methyl]-5-isopropyl-1*H*-pyrazole;

15 3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(2-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
ethoxy)-2-methylphenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-

20 propyl)-2-methylphenyl)methyl]-1*H*-pyrazole;

3-(β -D-glucopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-
[(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propoxy)-2-methylphenyl)methyl]-1*H*-pyrazole;

3-(β -D-galactopyranosyloxy)-5-isopropyl-4-{[4-(3-{1-
25 [(piperazin-1-yl)carbonyl]-1-(methyl)ethylcarbamoyl]-
propoxy)-2-methylphenyl)methyl]-1*H*-pyrazole;

4-{[2-fluoro-4-(3-{1-[(piperazin-1-yl)carbonyl]-1-(methyl)-

ethylcarbamoyl}propyl)phenyl)methyl}-3-(β -D-galacto-
pyranosyloxy)-5-isopropyl-1H-pyrazole, and
pharmaceutically acceptable salts thereof.

5 15. A pharmaceutical composition comprising as an active
ingredient a pyrazole derivative as claimed in any one of claims
1-14, a pharmaceutically acceptable salt thereof or a prodrug
thereof.

10 16. A human SGLT1 inhibitor comprising as an active ingredient
a pyrazole derivative as claimed in any one of claims 1-14, a
pharmaceutically acceptable salt thereof or a prodrug thereof.

17. An agent for inhibiting postprandial hyperglycemia
15 comprising as an active ingredient a pyrazole derivative as
claimed in any one of claims 1-14, a pharmaceutically acceptable
salt thereof or a prodrug thereof.

18. An agent for the prevention or treatment of a disease
20 associated with hyperglycemia, which comprises as an active
ingredient a pyrazole derivative as claimed in any one of claims
1-14, a pharmaceutically acceptable salt thereof or a prodrug
thereof.

25 19. An agent for the prevention or treatment as claimed in
claim 18, wherein the disease associated with hyperglycemia is
a disease selected from the group consisting of diabetes,

impaired glucose tolerance, diabetic complications, obesity,
hyperinsulinemia, hyperlipidemia, hypercholesterolemia,
hypertriglyceridemia, lipid metabolism disorder,
atherosclerosis, hypertension, congestive heart failure, edema,
5 hyperuricemia and gout.

20. An agent for the inhibition of advancing impaired glucose
tolerance or impaired fasting glycemia into diabetes in a subject,
which comprises as an active ingredient a pyrazole derivative
10 as claimed in any one of claims 1-14, a pharmaceutically
acceptable salt thereof or a prodrug thereof.

21. An agent for the prevention or treatment of a disease
associated with the increase of blood galactose level, which
15 comprises as an active ingredient a pyrazole derivative as
claimed in any one of claims 1-14, a pharmaceutically acceptable
salt thereof or a prodrug thereof.

22. An agent for the prevention or treatment as claimed in
20 claim 21, wherein the disease associated with the increase of
blood galactose level is galactosemia.

23. A pharmaceutical composition as claimed in claim 15,
wherein the dosage form is sustained release formulation.

25

24. An agent as claimed in any one of claims 16-22, wherein
the dosage form is sustained release formulation.

25. A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof
5 or a prodrug thereof.

26. A method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject, which comprises
10 administering an effective amount of a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof.

27. A use of a pyrazole derivative as claimed in any one of
15 claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia.

20 28. A use of a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a pharmaceutical composition for the inhibition of advancing impaired glucose tolerance into diabetes in a subject.

25

29. A pharmaceutical combination which comprises (A) a pyrazole derivative as claimed in any one of claims 1-14, a

pharmaceutically acceptable salt thereof or a prodrug thereof,
and (B) at least one member selected from the group consisting
of an insulin sensitivity enhancer, a glucose absorption
inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2
5 inhibitor, an insulin or insulin analogue, a glucagon receptor
antagonist, an insulin receptor kinase stimulant, a tripeptidyl
peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor,
a protein tyrosine phosphatase-1B inhibitor, a glycogen
phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a
10 fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase
inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol,
a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1,
a glucagon-like peptide-1 analogue, a glucagon-like peptide-1
agonist, amylin, an amylin analogue, an amylin agonist, an aldose
15 reductase inhibitor, an advanced glycation endproducts
formation inhibitor, a protein kinase C inhibitor, a
 γ -aminobutyric acid receptor antagonist, a sodium channel
antagonist, a transcript factor NF- κ B inhibitor, a lipid
peroxidase inhibitor, an *N*-acetylated- α -linked-acid-
20 dipeptidase inhibitor, insulin-like growth factor-I,
platelet-derived growth factor, a platelet-derived growth
factor analogue, epidermal growth factor, nerve growth factor,
a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin,
EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics,
25 cathartics, a hydroxymethylglutaryl coenzyme A reductase
inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist,
an acyl-coenzyme A cholesterol acyltransferase inhibitor,

probcol, a thyroid hormone receptor agonist, a cholesterol
 absorption inhibitor, a lipase inhibitor, a microsomal
 triglyceride transfer protein inhibitor, a lipoxygenase
 inhibitor, a carnitine palmitoyl-transferase inhibitor, a
 5 squalene synthase inhibitor, a low-density lipoprotein receptor
 enhancer, a nicotinic acid derivative, a bile acid sequestrant,
 a sodium/bile acid cotransporter inhibitor, a cholesterol ester
 transfer protein inhibitor, an appetite suppressant, an
 angiotensin-converting enzyme inhibitor, a neutral
 10 endopeptidase inhibitor, an angiotensin II receptor antagonist,
 an endothelin-converting enzyme inhibitor, an endothelin
 receptor antagonist, a diuretic agent, a calcium antagonist,
 a vasodilating antihypertensive agent, a sympathetic blocking
 agent, a centrally acting antihypertensive agent, an
 15 α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid
 synthesis inhibitor, a uricosuric agent and a urinary
 alkalizer.

30. A method for the prevention or treatment of a disease
 20 associated with hyperglycemia, which comprises administering
 an effective amount of (A) a pyrazole derivative as claimed in
 any one of claims 1-14, a pharmaceutically acceptable salt
 thereof or a prodrug thereof, and (B) at least one member selected
 from the group consisting of an insulin sensitivity enhancer,
 25 a glucose absorption inhibitor, a biguanide, an insulin secretion
 enhancer, a SGLT2 inhibitor, an insulin or insulin analogue,
 a glucagon receptor antagonist, an insulin receptor kinase

stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl
 peptidase IV inhibitor, a protein tyrosine phosphatase-1B
 inhibitor, a glycogen phosphorylase inhibitor, a
 glucose-6-phosphatase inhibitor, a fructose-bisphosphatase
 5 inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic
 gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase
 kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like
 peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin,
 an amylin analogue, an amylin agonist, an aldose reductase
 10 inhibitor, an advanced glycation endproducts formation
 inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid
 receptor antagonist, a sodium channel antagonist, a transcript
 factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an
 N-acetylated- α -linked-acid-dipeptidase inhibitor,
 15 insulin-like growth factor-I, platelet-derived growth factor,
 a platelet-derived growth factor analogue, epidermal growth
 factor, nerve growth factor, a carnitine derivative, uridine,
 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide,
 Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl
 20 coenzyme A reductase inhibitor, a fibric acid derivative, a
 β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol
 acyltransferase inhibitor, probcol, a thyroid hormone receptor
 agonist, a cholesterol absorption inhibitor, a lipase inhibitor,
 a microsomal triglyceride transfer protein inhibitor, a
 25 lipoxxygenase inhibitor, a carnitine palmitoyl-transferase
 inhibitor, a squalene synthase inhibitor, a low-density
 lipoprotein receptor enhancer, a nicotinic acid derivative, a

bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin
5 II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an
10 antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

31. A method for the inhibition of advancing impaired glucose tolerance into diabetes in a subject, which comprises
15 administering an effective amount of (A) a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof, and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a
20 biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase
25 inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol,

a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin

receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

32. A use of (A) a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof, and (B) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an N-acetylated- α -linked-acid-

dipeptidase inhibitor, insulin-like growth factor-I,
 platelet-derived growth factor, a platelet-derived growth
 factor analogue, epidermal growth factor, nerve growth factor,
 a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin,
 5 EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics,
 cathartics, a hydroxymethylglutaryl coenzyme A reductase
 inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist,
 an acyl-coenzyme A cholesterol acyltransferase inhibitor,
 probcol, a thyroid hormone receptor agonist, a cholesterol
 10 absorption inhibitor, a lipase inhibitor, a microsomal
 triglyceride transfer protein inhibitor, a lipoxxygenase
 inhibitor, a carnitine palmitoyl-transferase inhibitor, a
 squalene synthase inhibitor, a low-density lipoprotein receptor
 enhancer, a nicotinic acid derivative, a bile acid sequestrant,
 15 a sodium/bile acid cotransporter inhibitor, a cholesterol ester
 transfer protein inhibitor, an appetite suppressant, an
 angiotensin-converting enzyme inhibitor, a neutral
 endopeptidase inhibitor, an angiotensin II receptor antagonist,
 an endothelin-converting enzyme inhibitor, an endothelin
 20 receptor antagonist, a diuretic agent, a calcium antagonist,
 a vasodilating antihypertensive agent, a sympathetic blocking
 agent, a centrally acting antihypertensive agent, an
 α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid
 synthesis inhibitor, a uricosuric agent and a urinary alkalinizer,
 25 for the manufacture of a pharmaceutical composition for the
 prevention or treatment of a disease associated with
 hyperglycemia.

33. A use of (A) a pyrazole derivative as claimed in any one of claims 1-14, a pharmaceutically acceptable salt thereof or a prodrug thereof, and (B) at least one member selected from
5 the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl
10 peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3
15 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist,
20 a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor,
25 a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, antidiarrhoics, cathartics, a hydroxymethylglutaryl coenzyme A reductase

inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probocol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal


5 triglyceride transfer protein inhibitor, a lipoxxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester

10 transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist,

15 a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer, for the manufacture of a pharmaceutical composition for the

20 inhibition of advancing impaired glucose tolerance into diabetes in a subject.

34. A pyrazole derivative represented by the general formula:



wherein

R^{11} represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a hydroxy(C_{2-6} alkyl) group which may have a protective group, a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyl-substituted (C_{1-6} alkyl) group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group, or an aryl(C_{1-6} alkyl) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino group which may have a protective group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group on the ring;

one of Q^2 and T^2 represents a 2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy group or a 2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyloxy group, while the other represents a C_{1-6} alkyl group, a halo(C_{1-6} alkyl) group, a C_{1-6} alkoxy-substituted (C_{1-6} alkyl) group or a C_{3-7} cycloalkyl group;

R^{12} represents a hydrogen atom, a halogen atom, a hydroxy group which may have a protective group, a C_{1-6} alkyl group,

a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a halo(C₁₋₆ alkyl) group, a halo(C₁₋₆ alkoxy) group, a C₁₋₆ alkoxy-substituted (C₁₋₆ alkoxy) group, a C₃₋₇ cycloalkyl-substituted (C₂₋₆ alkoxy) group or a group of the general formula: -A-R¹⁸ in which A represents
 5 a single bond, an oxygen atom, a methylene group, an ethylene group, -OCH₂- or -CH₂O-; and R¹⁸ represents a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which
 10 may have a protective group, an amino group which may have a protective group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₂₋₆ alkenyloxy group, a halo(C₁₋₆ alkyl) group, a hydroxy(C₁₋₆ alkyl) group which may have a protective group, a carboxy group which may have a protective group, a C₂₋₇ alkoxycarbonyl group,
 15 a cyano group and a nitro group, or a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group;

X represents a single bond, an oxygen atom or a sulfur atom;

20 Y represents a single bond, a C₁₋₆ alkylene group or a C₂₋₆ alkenylene group with the proviso that X is a single bond when Y is a single bond;

Z represents a carbonyl group or a sulfonyl group;

R¹⁴ and R¹⁵ are the same or different, and each represents
 25 a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (ii), or they bind together with the neighboring nitrogen

atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group which may have a protective group;

R³, R⁶ and R⁷ are the same or different, and each represents
 5 a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group; and

substituent group (ii) consists of a hydroxy group which may have a protective group, an amino group which may have a protective group, a mono or di(C₁₋₆ alkyl)amino group which may
 10 have a protective group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group which may have a protective group, an ureido group, a sulfamide group, a mono or di(C₁₋₆ alkyl)ureido group, a mono or di(C₁₋₆ alkyl)sulfamide group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group, a group of the general formula:
 15 -CON(R¹⁹)R²⁰ in which R¹⁹ and R²⁰ are the same or different, and each represents a hydrogen atom or a C₁₋₆ alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group which may have a protective group, an amino group which may have a protective group, a mono
 20 or di(C₁₋₆ alkyl)amino group which may have a protective group, a mono or di[hydroxy(C₁₋₆ alkyl)]amino group which may have a protective group, an ureido group, a mono or di(C₁₋₆ alkyl)ureido group, a C₂₋₇ acylamino group, a C₁₋₆ alkylsulfonylamino group and a carbamoyl group, or they bind together with the neighboring
 25 nitrogen atom to form a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl group and a hydroxy(C₁₋₆ alkyl) group which may have a protective

group, a C₃₋₇ cycloalkyl group, a C₂₋₆ heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group which may have a protective group, an amino
5 group which may have a protective group, a C₁₋₆ alkyl group and a C₁₋₆ alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C₁₋₆ alkyl group, a C₂₋₆ cyclic amino group which may have a substituent selected from the group consisting of a C₁₋₆ alkyl
10 group and a hydroxy(C₁₋₆ alkyl) group which may have a protective group, and a C₁₋₄ aromatic cyclic amino group which may have a C₁₋₆ alkyl group as a substituent, or a salt thereof.